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Abstract 
Normal cellular proliferation is controlled by two major pathways, the pRB and the p53 
pathways. It is be1ieved that one or both of these two pathways is disrupted in all tumour cells. 
The functions of pRB are disrupted by viral oncoproteins, which displace important cellular 
components from a highly conserved region known as the "pocket". The first cellular "pocket"-
binding protein identified is the retinoblastoma binding protein 1 (RBPI). RBPI and the RBPI-
like protein BCAA are inherent subunits of the chromatin modifying transcription repression 
complex mSIN3A1HDAC. By linking the pRB protein to this repression complex, RBPI is 
believed to mediate repression of E2F -dependent transcription, thereby regulating cellular 
proliferation. 
RBPI and BCAA repress transcription in both HDAC-independent (RI) and HDAC-
dependent (R2) manners. l show in this work that, as with RBPI, BCAA can associate with the 
mSIN3A/HDAC complex via a direct interaction with the SAP30 subunit. The region 
responsible for this interaction (R2) mediates HDAC-dependent transcriptional repression. The 
latter is regulated by the NAD+ -dependent enzymatic activity of the class III histone deacetylase 
longevity factor SIRTI, which is recruited to the mSIN3A/HDAC complex via the tumour 
suppressors INGlb/ING2 and probably acts by deacetylating HDACl. 
The HDAC-independent repression activity ofboth RBPI and BCAA is regulated by post-
translational modifications. The RI repression activity can be further dissected into a domain that 
targets basal transcription (RIa) and one that represses both basal and activated transcription 
(RIa) SUMOylation of the RIa region is essential for its repression activities. SUMOylation of 
RIa is itself regulated by the overall local amino acids charge. In agreement with published 
results demonstrating that a negative charge in the vicinity of the tpKxE site allows interaction 
with a positively charged patch on the SUMO E2 ligase enzyme UBC9, neutralization of lysine 
positive charge by acetylation of RIa allows SUMOylation whereas mutation of lysines to 
arginines conserves the positive charge and hinders SUMOylation. 
The biological relevance of RBPI and BCAA transcriptional repreSSlOn activities is 
highlighted by their requirement for induction of cell growth arrest and terminal cell cycle 
withdrawal or cellular senescence. 
v 
Résumé 
La prolifération cellulaire est nonnalement controllé par deux principaux sentiers; le sentier 
de pRB et celui de p53. Il est largement accepté que l'un ou ces deux sentiers est rendu 
disfunctionnel dans les cellules tumorales. Les functions de pRB sont altérées par des 
oncoprotéines virales, qui délogent d'important composants cellulaire d'une région hautement 
conservée et connue sous le tenne "pocket". Retinoblastoma binding protein 1 (RBP 1) fût la 
première protéine cellulaire identifiée se liant au "pocket" de pRB. RBP 1 ainsi que la protéine 
RBPI-like, BCAA, sont des sous-unités inherentes au complexe de modification des histones et 
de répression de la transcription mSIN3A/HDAC. En joignant pRB à ce complexe de répression, 
RBP 1 médie la répression de la transcription dépendante de E2F, ainsi régulant la prolifération 
cellulaire. 
RBPI et BCAA répressent la transcription de façon indépendante de HDAC (RI) ainsi que 
de mannière dépendante de HDAC (R2). Je démontre par mon travail présenté ici que 
similairement à RBPI, BCAA est associé au complexe mSIN3A/HDAC via une interaction 
direct avec la sous-unité SAP30. La région responsable de cette interaction (R2) médie la 
répression de la transcription de façon dépendante de HDAC. Cette dernière est régulée par le 
facteur de longévité SIRTI qui est une déacétylase de histone de classe III requérant le co-
facteur NAD+, qui est recruité au complexe mSIN3NHDAC via les suppresseurs de tumeur 
INOIb/IN02 et agit probablement par déacétylation de HDACl. 
L'activité de répression de la transcription indépendante de HDAC inhérente à RBPI et 
BCAA est régulatée par des modifications post-traductionnel. Les activités de répression de RI 
peut être dissectée en un domaine qui cible la transcription basale (RIa) et un second qui 
represse la transcription basale et activée (RIo). La SUMOylation de la région RIO' est 
essentielle pour la répression. La SUMOylation de RIO' est elle-même régulé par la charge des 
acides aminées entourant le site. En accord avec une récente publication démontrant qu'une 
charge négative dans la vicinité d'un site \f'KxE pennet une interaction avec la région 
positivement chargé de la SUMO ligase UBC9, la neutralization de la charge positive des lysines 
par acetylation de RIO' pennet la SUMOylation tandis que la mutation de lysine à arginine 
,/" conserve la charge positive et entrave la SUMOylation. 
Vl 
La pertinence biologique des activités de répression de la transcription par RBPI et BCAA 
est mise en évidence par leur nécessité pour réprimer la croissance cellulaire et induire le retrait 
permanent du cycle cellulaire qu'est la sénescence. 
vu 
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Chapter One: Introduction 
1.1 Cell Cycle Regulation 
Cellular division is highly regulated at all stages of the cell cycle. Upon stimulation by 
growth factors, signalling pathways trigger the exit from the gap 1 (G l ) phase and the beginning 
ofDNA replication (S phase). Following successful completion ofDNA synthesis, the cell goes 
through the gap 2 (G2) checkpoint prior to mitosis (M phase) and separates its genetic material in 
two before cell division and finally retuming in Gl. The progression through this cell cycle is 
orchestrated by the cyclins, which are required for the activity of cyclin-dependent kinases. CDK 
activity is also negatively regulated by CDK inhibitors (CDKi). A major substrate ofthe CDKs is 
pRB whose potential to keep the cell in G l by b10cking the transcription of genes required for 
cell cycle progression is regu1ated by phosphorylation. 
In the following pages 1 will describe in depth the CUITent understanding of how pRB 
functions are regulated in normal cells and dysregulated in tumour cells as well as how pRB 
orchestrates proper cell cycle progression. In order to achieve this 1 will start with a brief 
overview of the discovery of pRB and then expand from there as pRB-binding proteins were 
identified. 
1.1.1 Viral Oncoproteins 
The study of viral proteins is important from an academic standpoint as it elucidates virus-
specific phenomena related to infection and repli cation in the host cell and this information can 
be used for the design of antiviral drugs. But it has also been a to01 of unparalleled value to 
identify and characterize key pathways that regulate cell cycle progression, cellular 
immortalization and transformation, all of which are at sorne point disrupted during 
tumourigenesis and are targeted by viral oncoproteins. The importance of this field of study, 
which merges virology and cellular biology, can be underlined by the breakthroughs it 
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facilitated, for example, the discovery in the late seventies and mid-eighties of the two major 
tumour suppressors namely, p53 and pRB. 
1.1.1.1 Ad5 ElA 
As early as 1962, the human adenovirus was shown to be oncogenic in animaIs (Trentin et al. 
1962). Analysis of DNA extracts from cell lines transformed by adenovirus demonstrated that 
the minimal region required for transformation includes 14% of the viral genome at its left-hand 
end (Gallimore et al. 1974). Calcium phosphate-mediated transfection of adenoviral DNA 
confirmed this observation and allowed further mapping of the minimal region required for 
cellular transformation (Graham et al. 1974). Mutant viruses of early region 1 (El) as weIl as 
tranfection of DNA encoding individual El products demonstrated that transformation by ElA 
requires E1B (Houweling et al. 1980; Bernards et al. 1983; Ruley 1983; Gallimore et al. 1985; 
Byrd et al. 1988). 
The peptides coded from the early region lA of Ad5 have an essential function in cellular 
transformation and in viral repli cation (reviewed in (Branton et al. 1984)). Ad5 mutants for ElA 
are incapable of replication. This phenotype can be rescued in HEK293 cells, which are 
transformed with adenoviral DNA and express ElA. These mutants also fail to induce oncogenic 
transformation. In order to identify cellular targets required for ElA functions, an E1A-specific 
anti-peptide serum was used to immunoprecipitate five cellular peptides that were E1A-specific, 
with apparent molecular masses of 65kDa, 68kDa, 105kDa (doublet), and ~250kDa (Yee and 
Branton 1985). The 105kDa doublet was later identified as the tumour suppressor pRB (Whyte et 
al. 1988; Egan et al. 1989) and the ~250kDa peptide to be the histone acetyltransferase p300 
(Eckner et al. 1994). Furthermore, the regions of ElA essential for cellular transformation are 
also required for the association with the cellular proteins described ab ove, strongly suggesting 
that interactions with cellular components are necessary for the transforming activity of ElA 
(Egan et al. 1988; Whyte et al. 1989). 
In parallel, other ElA properties led to the identification of yet another seminal cell cycle 
regulator, the E2 factor (E2F). ElA trans-activates a number of viral promoters (Berk et al. 
1979) as weIl as cellular promoters. In particular, the adenovirus E2 promoter is induced by ElA 
(Elkaim et al. 1983), which requires a cellular factor associated with the E2 promoter (Kovesdi 
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et al. 1986a; Kovesdi et al. 1986b). A purified fraction from nuclear extracts containing this E2 
factor was shown to stimu1ate transcription from an E2F consensus containing promoter in vitro 
(Yee et al. 1989). This E2F transcription factor was subsequent1y cloned on the basis of its pRB-
binding properties (Bandara and La Thangue 1991; Chellappan et al. 1991; Chittenden et al. 
1991; Helin et al. 1992; Kaelin et al. 1992; Shan et al. 1992). The biological function of the 
interaction ofpRB with E2F will be discussed in more detail in section 1.1.2.1 pRE. 
Interestingly, the ElA amino terminal region that binds to pRB (Egan et al. 1988; Barbeau et 
al. 1992) and CBP/p300 (Arany et al. 1995; Lundb1ad et al. 1995) is a transactivation domain 
(Bondesson et al. 1994), which shares extensive sequence homology and functionality with the 
transcription factor E2F1 (Trouche and Kouzarides 1996). Like E2F1, the ElA transactivation 
domain is regu1ated positively by CBP/p300 and negatively by pRB. This idea goes somewhat 
against the broadly-accepted view that it is ElA that regulates these cellular factors to induce 
cellular transformation as opposed to cellular factors being used for tight regulation of viral 
transcription and replication. 
The E1A-associated p400 protein (Barbeau et al. 1994) is required for E1A-mediated cellular 
transformation (Fuchs et al. 2001) and induction of apoptosis (Samuelson et al. 2005) as well as 
UV-induced apoptosis (Tyteca et al. 2006). Acute depletion of p400 leads to premature 
senescence (Chan et al. 2005). This phenotype can be rescued by concomitant depletion of either 
p53 or one of its transcriptiona1 targets, p21, but not by depletion of pRB, suggesting an 
involvement of the p53 pathway specifically (Chan et al. 2005), although the pRB-related p130 
protein could compensate for pRB loss. Consistant with these results, p400 is found in 
association with p53, and its depletion results in increased leve1 ofp21 (Chan et al. 2005; Tyteca 
et al. 2006) and p400 is found with p53 at p21 promoter (Chan et al. 2005). In conclusion, p400 
acts as a key regulator of the p53 pathway through repression of p21 expression, thus its 
requirement for normal progression through cell cycle. 
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Figure 1.1: Retinoblastoma-dependent cell cycle regulatory pathway. 
This figure depicts a simplified representation of how growth inhibitory signaIs Iead to 
repression by pRB of E2F-dependent transcription and induction of cell cycle arrest in G1• 
Growth inhibitory signaIs trigger activation of CDKi (GSK3p, pI6, p2I, p27), which in tum 
deactivate CDK activity. In the absence of CDK activity, pRB is found in its 
hypophosphorylated state, which associates with E2F, masks its transactivition domain and 
recruits histone deacetylase activity (HDAC) to repress transcription of genes required for DNA 
synthesis and cell cycle progression. AIso, the adenoviral oncoprotein ElA can dissociates the 
pRBlE2F compIex. 
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1.1.1.2 SV40 Large T Antigen 
The early region of simian virus 40 (SV 40) encodes two splice variants sharing common 
amino termini (Berk and Sharp 1978), termed the large T and small t antigens (T Ag and tAg, 
respectively). TAg by itse1f transforms cells (Kriegler et al. 1984; Brown et al. 1986). The 
sequence homology between a small region of TAg required for cell transformation (residues 
106 to 114) (Kalderon and Smith 1984; Cherington et al. 1988; Chen and Paucha 1990) and the 
conserved region 2 of ElA, which mediates the association with pRB, led to the hypothesis that 
the function of these viral sequences may be similar (Figge et al. 1988). In fact, SV 40 TAg 
residues 101 to 118 can functionally substitute for ElA CR2 (Moran 1988). Furthermore, TAg 
forms a complex with pRB (DeCaprio et al. 1988), underlining conserved strategies used by 
viruses to target key pathways and take over the control of cellular machinery for their 
replication. 
Both E1A-associated proteins p300 and p400 are also found in association with SV40 large T 
antigen (Lill et al. 1997). 
1.1.1.3 HPV E7 
The hurnan papillomavirus (HPV) causes cervical carcinoma in humans. HPV encodes two 
proteins, E6 and E7, which, respective1y, target and inactivate the tumour suppressors p53 
(Scheffner et al. 1990; Wemess et al. 1990) and pRB (Dyson et al. 1989). 
Clearly, oncoproteins encoded by these small DNA tumour viruses, Ad5 ElA, SV40 TAg 
and HPV E7 viral proteins, carry out similar functions and thus may induce oncogenic 
transformation by similar mechanisms. Very interesting experiments were recently conducted in 
the HPV -positive E61E7 -expressing HeLa cellline. The HPV E2 protein was expressed to inhibit 
expression of E6 and E7 from HeLa cells (Goodwin and DiMaio 2000; Wells et al. 2000). This 
effect led to post-transcriptional induction of p53, pRB, p107, and p130 and concomitant 
expression ofp53-regulated genes MDM2, p21, and repression of several E2F-dependent targets 
followed by growth inhibition and senescence (Goodwin and DiMaio 2000; DeFilippis et al. 
2003; Psyrri et al. 2004). Re-introduction ofE61E7 reverted these effects (Goodwin and DiMaio 
2000; Wells et al. 2000). Repression of E7 sole1y was sufficient to activate pRB and induce 
senescence, whereas repression of E6 resulted in p53 activation and induction of both apoptosis 
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and senescence (DeFilippis et al. 2003). Thus, the expression of both E6 and E7 proteins is 
essential for proliferation of cervical carcinoma cells and these data show that these two viral 
proteins exert distinct effects on cell survival and proliferation (DeFilippis et al. 2003). 
Accordingly, failure of pRB-binding-deficient E7 mutants to prevent senescence (Psyrri et al. 
2004) provides strong evidence that the pRB pathway is essential for senescence induction when 
E7 is removed and that E7 stimulates cellular proliferation by disrupting the pRB pathway. 
1.1.2 Retinoblastoma Family ofPoeket Pro teins 
The retinoblastoma family of pocket proteins includes three members, namely pRB, p107 
and p130, whose principal function is to orchestrate the progression through the cell cycle by 
negatively regulating E2F-dependent transcription. The pRB family functional domains are 
illustrated in Figure 1.2. The principal feature of this family of proteins is a structure generally 
referred to as the "pocket", which is a large domain organized in two sub-domains, "pocket A" 
and "pocket B". The structure of "pocket A" is somewhat related to the structure of the cyclin 
foid (cyclin box-like) whereas the "pocket B" is more closely related to the cyclin box (Gibson et 
r'. al. 1994; Noble et al. 1997). All three pocket pro teins contain these two domains, which are 
required and self sufficient to induce cell cycle arrest. Furthermore, they also contain a third 
region at the amino terminus that is related to the cyclin structure. Both pRB and pl 07 have a 
cyclin box-like domain at the amino terminus whereas p130 contains a cyclin box. Surprisingly, 
there are no reports in the literature describing the function of this third cyclin box domain. 
A lot of effort has been focused on understanding the functions and regulation of this family 
ofproteins mostly, to comprehend how the pathways they control are disrupted in cancer. 
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Figure 1.2: The retinoblastoma family of pocket proteins. 
This diagram represents the members of the pRB family of "pocket" proteins, pRB, pl 07, and 
p130. The "pocket" domain, which is the minimal region required for cell cycle regulation, 
extends from the "pocket" A to the "pocket" B and comprises a poorly conserved "spacer" 
region of variable length between the A and B "pockets". These "pocket" domains share 
structural similarity with the cyclin fold. 
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1.1.2.1 pRB 
pRB is the prototypical tumour suppressor. It is at the ongm of the Knudson two-hit 
hypothesis, which states that two distinct genetic changes have to occur leading to 10ss of both 
alleles of a tumour suppressor gene resulting in tumour fonnation (Knudson 1971). 
Retinoblastoma is a rare fonn of eye cancer afflicting mostly children, who usually survive 
following surgi cal removal of the tumours, but often succumb to other fonns of cancer at a 
relatively early age. This condition led to the discovery of the RB gene (Friend et al. 1986). 
Although a large amount of data is available on pRB (over 13655 references in PubMed as of 
J anuary 2007) and over 110 other cellular proteins have been reported to functionally associate 
with pRB (Morris and Dyson 2001), its functions still remain elusive. While it is generally 
accepted that pRB negatively regulates the cell cycle by blocking the transactivation domain of 
E2F and recruiting co-repressors, there are still gray areas about how pRB is regulated and how 
it recruits co-repressors and how these influence development and tumour suppression. 
The pRB family of proteins is characterized by a common structure illustrated in Figure 1.2. 
AlI three members of the family have a region tenned the "pocket", which is further divided into 
the A and B regions that are separated by a "spacer" region. Naturally occuring mutations in the 
pRB "pocket" region account for about seventy percent of the mutations identified in RB from 
both hereditary and sporadic retinoblastoma (Goodrich 2003), demonstrating the importance of 
this region for tumour suppression. 
Reintroduction of a nonnal RB allele can delay and even suppress tumourigenicity of 
retinoblastoma, osteosarcoma and human prostate carcinoma cell hnes lacking functional pRB 
(Huang et al. 1988; Bookstein et al. 1990; Sumegi et al. 1990). Furthennore, either 
microinjection of pRB or transfection of cDNA encoding pRB leads to arrest in the G1 phase of 
the cell cycle (Goodrich et al. 1991; Hinds et al. 1992), demonstrating the importance of pRB in 
cell cycle progression and its role as a tumour suppressor. 
The E2F transcription factor associates with pRB (Bandara and La Thangue 1991 ; 
Chellappan et al. 1991; Chittenden et al. 1991). The E2F-pRB association is restricted to the 
underphosphorylated fonn ofpRB (Chellappan et al. 1991), a fonn ofpRB predominantly found 
in the Go and G1 phases of the cell cycle (Buchkovich et al. 1989; Chen et al. 1989; DeCaprio et 
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al. 1989; Mihara et al. 1989) and preceding growth arrest (Chen et al. 1989). This association 
results in the inhibition ofE2F-dependent transcriptional activity (Hiebert et al. 1992). 
In G}, pRB is found in an hypophosphorylated fonn, which can efficiently bind to the E2F 
transcription factors and repress their activity by masking the transactivation domain (Weintraub 
et al. 1995; Ross et al. 1999) and also by recruiting histone deacetylases (Brehm et al. 1998; Luo 
et al. 1998; Magnaghi-Jaulin et al. 1998; Lai et al. 1999a; Lai et al. 2001) and possibly histone 
methylases2 (Nielsen et al. 2001). During this phase of the cell cycle, CDKj (pI6, p21, and p27) 
prevent CDKs (CDK2, 4, and 6) from phosphorylating pRB. As cells exit the Gl phase, cyclin 
D/CDK4/6 and cyclin E/CDK2 phosphorylate pRB. This hyperphosphorylated fonn of pRB no 
longer associates with E2F, which is relieved from repression and drives the expression of genes 
required for cell cycle progression and DNA synthesis. 
To better understand pRB functions in tumourigenesis and deve1opment, animal models were 
engineered. A great deal of insight into pRB in vivo functions were revealed from transgenic 
work in murine mode1s (Clarke et al. 1992; Jacks et al. 1992; Lee et al. 1992). The RB-1-
genotype leads to early embryonic lethality at day E13.5, which is accompanied by ectopie S 
phase entry, neuronal apoptosis, and defective erythrocyte and muscle cell tenninal 
differentiation. Although viable, RB +1- mice have a decreased life expectancy and deve10p 
pituitary tumours. Interestingly, concomitant de1etion of RB and E2F l (RB+1- E2F rl- (Yamasaki 
et al. 1998) and RB-1- E2Frl- (Tsai et al. 1998)), E2F3 (Re-I- E2F3+/) (Ziebold et al. 2001; 
Ziebold et al. 2003), or ld2 (RB-1- Id2-1-) (Lasorella et al. 2000) leads to increased life span or 
delayed embryonic lethality, suppression of pituitary tumour deve10pment (RB-1- E2F3+1-) and a 
reversaI of neurogenesis and haematopoiesis defects (RB-1- IdT1-). These phenotypes suggest that 
sorne E2F factors and the pRB inhibitor protein Id2 may have opposite roles during deve10pment 
and their ablation compensates for the loss of RB. Deletion of the other RB family members, 
pl07 (Lee et al. 1996) or pl30 (Cobrinik et al. 1996), have surprisingly no obvious phenotype in 
neither 129/Sv nor C57BL/6 backgrounds, suggesting not only that the remaining RB family 
2 This was the only occurrence in the literature of an association between pRB, HPl, and SUV39Hl. Other 
laboratories faited to reproduce this data (Dynlacht, BD. Personal communication). 
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members can compensate for the loss ofpI07 or p130 but also functional redund~mcy amongst 
these factors. 
Interestingly, null mutation ofpI07 or pI30 in the Balb/cl mouse genetic background led to 
embryonic lethality between embryonic days Il and 13 for p 130-1- (LeCouter et al. 1998b), while 
piOrl - mice were viable, but displayed impaired growth and accelerated cell cycle progression 
(LeCouter et al. 1998a). Interestingly, both piOrl- and p130-1- mutant mice reverted to a wild-
type phenotype following a single backcross with C57BL/6J mice, suggesting the existence of 
genes in this mice strain that have potentially epistatic relationships with pI07 and p130 
(LeCouter et al. 1998a; LeCouter et al. 1998b). Loss ofheterozygosity on chromosome Il, at the 
RB locus, has been reported in Balb/cl (Herzog et al. 1996) and this could possibly account for 
the strain-dependent phenotype discrepancies. 
Concomitant deletion of all three RB family members leads to severe cell cycle regulation 
defects. In one case (C57BL/61129/Sv background), cellular growth could not be arrested in the 
0 1 phase by cell-cell contact inhibition, growth factor deprivation, or induction of DNA damage, 
although the latter led to an accumulation in 02, the p53 pathway being presumably intact (Sage 
et al. 2003). When conducted in a 12901a background, triple knockout of the RB genes also led 
to unresponsiveness of the cells to normally growth inhibitory cues (contact inhibition and 
growth factor deprivation) (Dannenberg et al. 2000). These cells had apparently uncontrolled 
proliferation properties. Therefore, their immortalization and transformation potential was 
further investigated. Triple knockout cells grow in an anchorage-dependent manner and therefore 
are not transformed, but retain long-term proliferation capacity, and thus are immortalized. 
The functions of pRB are evolutionarily conserved in Drosophila and allowed genetic studies 
to dissect the contribution of each component of the RBF/ dE2F/ dDP pathway to the regulation of 
E2F-dependent transcription and cell cycle progression (Dimova et al. 2003). 
The above section demonstrates the importance of "pocket" proteins in adequate regulation 
of cell cycle progression, and subsequently their essential role in keeping in check 
tumourigenicity. 
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1.1.2.2 p107 
The pRB-related protein pl 07 is a potent inhibitor of E2F -mediated trans-activation and 
cellular proliferation, inducing an arrest in G1 (Zhu et al. 1993). However, in the pRB-deficient 
cervical carcinoma cell line C33A, ectopic expression pl 07 could inhibit growth while pRB 
could not (Zhu et al. 1993). Unlike the other "pocket" proteins, p107 is prominently expressed 
from late G1 to G2/M and is virtually absent in quiescent and differentiated cells but accumulates 
as cells enter the cell cycle. 
Surprisingly, in transgenic mouse models, targeted disruption of either p107 (Lee et al. 1996) 
or p130 (Cobrinik et al. 1996) does not lead to any discernable developmental defects. However, 
simultaneous ablation of both RB-related genes led to developmental defects such as the 
ab normal proliferation of chondrocytes leading to defective endochondral ossification and bone 
development, as weIl as shortened limbs and neonatal lethality. These results suggest 
overlapping roles for p107 and p130 in limb development that are not compensated by pRB 
(Cobrinik et al. 1996). 
The p107 and p130 proteins also share a common feature that is not evident in pRB. They 
both associate with and inhibit cyclin A/CHEU and cyclin E/CDK2 kinases, thereby acting as 
CDKis that are as potent as p21 (Woo et al. 1997; Castaiio et al. 1998). This association relies on 
a highly homologous region between the "pockets" A and B ofp107 and p130 (Zhu et al. 1995; 
Adams et al. 1996; Lacy and Whyte 1997) termed the "spacer", which is dissimilar in pRB 
(Classon and Dyson 2001). 
Regulation of cell cycle by pl 07 does not end with E2F, indeed, pl 07 can also associate with 
and inhibit the transactivation domain of Myc (Beijersbergen et al. 1994; Gu et al. 1994). Thus 
there appear to be divergent and non-overlapping functions amongst the three "pocket" proteins. 
1.1.2.3 p130 
Contrasting from p107, the expression of the "pocket" protein p130 is a hallmark of Go 
arrested, quiescent cells. The p130 protein with pRB were shown recently to be associated with 
the establishment and maintenance of senescence by the laboratory of Scott Lowe at Cold Spring 
;' Harbor (Narita et al. 2003). The occupancy of the E2F-responsive promoters cyclin A and PCNA 
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by "pocket" proteins at the onset of senescence was quite different from qui es cent cells. pl 07 
was displaced from those promoters and pRB seemed to replace it, whereas occupancy by p 130 
remained e1evated, suggesting that p130 is important for both Go arrest and senescence, whereas 
pRB may play an accessory role only in senescent cells. Furtherrnore, suppression of either 
INK4A or RB by shRNA prevented the appearance of senescence-associated heterochromatic 
foci, therefore suggesting that the establishment of senescence necessitates an intact pRB 
pathway. 
In a more general context, in contrast to the other "pocket" proteins, p130 leve1s are tightly 
regulated throughout the cell cycle. It is the most abundant "pocket" protein found in the Go 
phase (Kiess et al. 1995) and its leve1 rapidly drops as cells exit the Gj phase and enter the S 
phase (Baldi et al. 1995; Mayol et al. 1995; Tedesco et al. 2002). Unlike pRB, the 
hypophosphorylated forrn of p130 associates with the "repressor" class of the E2F farnily, i.e. 
E2F4 and E2F5, and this complex, along with HDACs, mediates repression of E2F-responsive 
promoters (Smith et al. 1996; Ferreira et al. 1998; Takahashi et al. 2000; Rayrnan et al. 2002). 
1.1.3 E2F Family of Transcription Factors 
As mentioned in a previous section (l.l.l.l Ad5 ElA), E2F was originally identified as a 
cellular factor required for the efficient transcription of the adenovirus E2 gene (Kovesdi et al. 
1986a; Kovesdi et al. 1986b) and then as a pRB associated protein (Bandara and La Thangue 
1991; Chellappan et al. 1991; Chittenden et al. 1991). It was subsequently demonstrated to be an 
essential positive regulator for transcription of genes required for cell cycle progression, DNA 
synthesis, and apoptosis. 
E2Fs are DNA-binding transcription factors that heterodimerize with the small DP proteins 
to cooperative1y associate with DNA (Bandara et al. 1993; Helin et al. 1993; Huber et al. 1993) 
elements (TTTCGCGC) (Yee et al. 1987) at specific promoters. This E2F consensus is found in 
the promo ter of numerous cell cycle-regulated genes with functions ranging from DNA synthesis 
(DHFR (Blake and Azizkhan 1989), DNA polyrnerase a (Pearson et al. 1991), and PCNA 
(Tommasi and Pfeifer 1999; Li et al. 2003)), and transcription (B-myb (Larn and Watson 1993)), 
to apoptosis (Apafl (Moroni et al. 2001a; Furukawa et al. 2002),p73 (Pediconi et al. 2003), and 
casp-7 (Nahle et al. 2002)), that are essential for cell cycle progression. The transactivation 
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domain (TAD) ofE2F elicits strong transcriptional activity (Helin et al. 1992; Kaelin et al. 1992) 
through interactions with basal transcription machinery subunits TBP and TFIIH (Pearson and 
Greenblatt 1997; Fry et al. 1999) as well as with p300/CBP HAT (Trouche and Kouzarides 
1996; Fry et al. 1999). The TAD of E2F is negatively regulated by pRB (Flemington et al. 
1993). The latter passively inhibits E2F-mediated transcription by binding and masking the TAD 
(Ross et al. 1999), preventing further association with general transcription factors (GTFs) and 
transcriptional activation but also by recruiting histone deacetylase (Luo et al. 1998), histone 
methylation (Nielsen et al. 2001), and DNA methylation (Robertson et al. 2000; Pradhan and 
Kim 2002) activities to actively repress transcription. 
Over the last decade, numerous studies have established the E2F family proteins as critical 
regulators of cell cycle progression. These proteins (depicted in Figure 1.3) can be divided into 
three subclasses: transcriptional "activators" (E2Fl, E2F2, and E2F3); transcriptional 
"repressors" (E2F4 and E2F5) (the latter two subclasses being negatively regulated by the pRB 
"pocket" proteins); and the third subclass comprising "repressor" E2Fs (E2F6, E2F7, and E2F8) 
lacking the carboxy terminal transactivation domain as well as the pRB-binding domain, 
therefore thought to act in a pRB-independent manner. For their part, the E2F-related factors 
DPI (Girling et al. 1993) and DP2 (Zhang and Chellappan 1995) contain a DNA-binding domain 
and a dimerization domain allowing association with the E2Fs. 
Regulation of E2F functions is partially achieved via cellular localization. E2Fl, E2F2, and 
E2F3 contain nuc1ear localization signais whereas E2F4 and E2F5 are actively exc1uded from the 
nucleus via their nuclear export signaIs. Association with "pocket" proteins is a pre-requisite for 
E2F4 and E2F5 nuclear localization (Müller et al. 1997; Verona et al. 1997). Furthermore, the 
"pocket" proteins differentially regulate E2Fs. Specifically, pRB associates with and inhibits the 
"activator" E2Fs, E2Fl, E2F2, and E2F3 whereas pl07 and p130 association with E2Fs is 
restricted to the "repressor" E2Fs, E2F4 and E2F5 (Cobrinik 2005). 
The E2F6 protein lacks the "pocket"-binding and transactivation domains found in the E2Fl-
5 but has a repression domain at its carboxy terminal end (Morkel et al. 1997; Gaubatz et al. 
1998; Trimarchi et al. 1998). The E2F7 (de Bruin et al. 2003; Di Stefano et al. 2003; Logan et 
al. 2004) and E2F8 (Christensen et al. 2005; Logan et al. 2005; Maiti et al. 2005) factors are 
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divergent from the other E2F family members in many aspects. They have two separate DNA-
binding domains, which confer DP-independent DNA-binding of E2F consensus sites, but lack 
DP-dimerization, "pocket" -binding, and transcriptional activation domains. 
The view that E2F transcriptional activation leads to cell cycle progression cornes from the 
observation that expression of E2Fl in growth arrested cells can activate DNA synthesis and 
induce entry into S phase (Johnson et al. 1993). However, lack of E2f1 (Field et al. 1996; 
Yamasaki et al. 1996), E2j2 (Murga et al. 2001), E2f1 and E2j2 (Zhu et al. 2001), E2f4 
(Humbert et al. 2000a; Rempel et al. 2000), E2f5 (Lindeman et al. 1998), or E2f6 (Storre et al. 
2002), does not impair cellular proliferation but actually results in increased proliferation of 
thymic and haematopoietic cells in the case of E2frl- and E2j2-I-, respectively, due to apoptotic 
defects, whereas loss of E2j3 (Humbert et al. 2000b) results in slow growth via derepression of 
pI9ARF, activation of p53 and induction of p21 expression (Aslanian et al. 2004). Loss of aIl 
three "activator" E2Fs (E2fr l-; E2j2-I-; E2j3-I-) leads to the incapacity of the cells to proliferate 
(Wu et al. 2006). Likewise, the expression of a dominant negative fonn of DPI, which 
sequesters DP-dependent E2Fs (E2Fl to E2F6), induces cell cycle arrest in the G1 phase (Wu et 
al. 1996). Furthennore, shRNA-mediated depletion of DPI causes severe proliferation defects 
and senescence in HeLa cells (Maehara et al. 2005) in which both pRB and p53 are rendered 
non-functional by the E7 and E6 proteins. 
Interestingly, expression ofE2Fl (Zhang et al. 1999a; Rowland et al. 2002) or E2F2 (Bargou 
et al. 1996) mutants, which lack the transactivation domain, occupy E2F-dependent promoters 
and displace endogenous E2Fs, actually generated cells that had increased proliferation, were 
transfonned, and were refractory to antiproliferative signalling. Furthennore, several E2F-
dependent genes were switched "ON" in those cells. These observations suggest that 
transcriptional activation by E2F of genes required for cell proliferation is not necessary. The 
function of "activator" E2Fs may in fact therefore be to occupy E2F sites and interfere with the 
action of "repressor" E2Fs. In agreement with the latter hypothesis, the growth arrest phenotype 
observed in E2j3-I- cells was found not to results from failure to activate transcription but rather 
from failure to repress transcription ofp19ARF (Aslanian et al. 2004). 
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1.1.4 Cyclins, Cyclin-dependent Kinases and CDK lnhibitors 
The existence of cyclins was first observed in the early 1980's. Cyclins were identified as 
proteins whose level oscillates following sea urchin egg fertilization, resulting in new protein 
synthesis in quiescent eggs and cells that undergo many cell cycle divisions (Evans et al. 1983). 
There are two types of cyclins relevant to the G1 phase of the cell cycle, the D-type cyclins 
(Dl, D2, and D3), which regulate the kinase activity ofCDK4 and CDK6 and the E-type cyclins 
(El and E2), which regulate CDK2 (reviewed in (Morgan 1997)). The catalytic CDK subunits 
are positively regulated by the cyclin subunits. 
CDK activity is regulated by the associated cyclins, the levels of which are regulated 
transcriptionally. The D-type cyclins are regulated by transcription factors such as c-Myc 
(Bouchard et al. 1999; Perez-Roger et al. 1999), AP-1 (Herber et al. 1994; Bakiri et al. 2000), 
SPI and E2F (Watanabe et al. 1998). Cyc1in E is negatively regulated by E2F4 (Le Cam et al. 
1999) and an HDAC/SWI/SNF-containing pRB complex, which loses HDAC activity upon pRB 
phosphorylation by cyc1in D/CDK4, leading to expression of cyc1in E and G1 arrest while 
repression of cyc1in A by the remaining pRB/SWIISNF complex is maintained (Zhang et al. 
2000). Therefore, pRB-associated repressors dictate the sequence in which cyc1ins are expressed, 
thus allowing tight regulation of cell cycle progression. 
CDK activity is also regulated by phosphorylation-dependent ubiquitination and subsequent 
proteasome degradation of the Gl cyc1ins (Tyers and Jorgensen 2000). More specificaIly, the 
CDKi GSK3j3 mediates phosphorylation of cyclin Dl, triggering its rapid proteasomal 
degradation (Diehl et al. 1998). Cyclin E degradation is mediated via autophosphorylation of 
cyclin E itselfby cyclin E/CDK2 (Clurman et al. 1996; Won and Reed 1996). 
Finally, CDK activity can be regulated by three types of CDK inhibitors, the CIP/KIP family 
(p21WAFI/CIPl (El-Deiry et al. 1993; Harper et al. 1993), p27KIP1 (Polyak et al. 1994; Toyoshima 
and Hunter 1994), p57KIP2 (Lee et al. 1995; Matsuoka et al. 1995)), the INK4 family (p15 INK4B 
(Hannon and Beach 1994), p 16INK4A (Ebralidze et al. 1989; Serrano et al. 1993), p 18INK4C (Guan 
et al. 1994), p19INK4D (Hirai et al. 1995)), and GSK3j3 (Dieh1 et al. 1998; Welcker et al. 2003). 
The CIP/KIP family CDKi p27 inhibits CDK2 activity by binding the amino terminal inhibitory 
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domain to cyclin A, extending across the amino-lobe of the CDK and by mimicking ATP it 
inserts into the catalytic cleft causing confonnational changes (Russo et al. 1996). Extensive 
sequence similarity between the members of the CIP/KIP family suggest similar CDK inhibitory 
mechanisms. The INK4 family inhibits CDK activity by binding across the non-catalytic side of 
the CDK inducing a confonnational change that does not support catalysis nor cyclin binding 
(Brotherton et al. 1998; Russo et al. 1998). 
The pRB "pocket" proteins are the principal target of the G1 cyclinlCDK activity (Lundberg 
and Weinberg 1998; Harbour et al. 1999) resulting in relief of repression and expression of genes 
necessary for cell cycle progression. 
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Figure 1.3: The E2F family of transcription factors. 
This figure shows the eight know members of the E2F family as well as the two E2F-like factors 
DPI and DP2, which associate with DNA as heterodimers with E2F. Association of DP with 
E2F is mediated by the dimerization domain (yellow). E2F transcription activity is mediated by 
the transactivation domain (purple), which associates with the GTF TFIID and the HAT p300. 
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1.1.5 The p53 Tumour Suppressor 
RB is indeed very important, as discussed in the previous section, but it is not the only gene 
with tumour suppression functions. Another such gene that is almost systematically mutated in 
cancer cells was discovered even earlier then RB, but was categorized initially as an oncoprotein 
because of a mutation in the cDNA that was cloned. Interestingly, the function of both of these 
tumour suppressors, and others such as the inhibitor of growth ING, have been attributed to the 
permanent cell cycle exit phenotype, senescence, suggesting a recurrent anti-tumoural 
mechanism amongst these genes. 
In the late 1970s, a 54kDa cellular protein was detected in association with 
immunoprecipitates of the SV 40 large-T antigen from SV 40-transformed cells (Lane and 
Crawford 1979; Linzer and Levine 1979). A few years later, the same protein was also found to 
associate with the adenovirus E1B protein (Sarnow et al. 1982), which cooperates with ElA in 
cell transformation. These results suggested that these viral oncoproteins were targeting the same 
cellular protein to induce transformation. It was originally shown that overexpression of p53 
combined with activated ras induced cellular transformation (Eliyahu et al. 1984; Jenkins et al. 
1984; Parada et al. 1984). Furthermore, p53 could also induce immortalization on its own 
(Jenkins et al. 1984). Ironically, p53 was therefore classified as an oncogene. Work from the 
Levine laboratory challenged the literature. A cDNA isolated from embryonic carcinoma murine 
cells failed to complement ras-induced transformation (Finlay et al. 1988). The publication of 
Xenopus laevis p53 cDNA sequence (Soussi et al. 1987) allowed the detection of five highly 
conserved regions. Sequence comparison with the previously re1eased sequences allowed the 
identification of an alanine to valine point mutation at amino acid 135 (Eliyahu et al. 1988; 
Hinds et al. 1989) within the second conserved region. This mutation within the DNA-binding 
domain (Bargonetti et al. 1993 ; Wang et al. 1993; Wang et al. 1995) resulted in a form of p53 
with dominant negative activity (Lavigueur et al. 1989) and decreased DNA-binding activity 
(Kem et al. 1991a). 
p53 was ultimately shown to prevent transformation by ElA and ras (Finlay et al. 1989), to 
bind DNA in a sequence specifie manner (Kem et al. 1991b; EI-Deiry et al. 1992), and to 
potently activate transcription (Fields and Jang 1990; O'Rourke et al. 1990; Raycroft et al. 1990), 
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suggesting that it could drive transcription of genes required for growth inhibition. As a matter of 
fact, p53 drives transcription of p21 (amongst other genes of interest), a potent CDK inhibitor, 
resulting in inhibition of cyc1in E/CDK2 and accumulation of the pRB hypophosphorylated form 
(see Figure 1.1). The p53 gene or components of the p53 pathway are believed to be mutated in a 
majority of tumours (Vogelstein et al. 2000). Indeed, p53-1- mi ce are predisposed to tumour 
development (Donehower et al. 1992). 
The negative regulation of cell growth by p53 takes form in either apoptosis or growth arrest. 
Upon DNA damage, p53 induces either an arrest in G1 (Lin et al. 1992) or in G2/M (Stewart et 
al. 1995) depending on the stage of cell replication. The arrest in Gl is mediated via the CDKi 
p21 (Brugarolas et al. 1995; Deng et al. 1995). The arrest in G2 is also mediated via p21 but 
through inhibition of the cyclin B lIcdc2 complex activity (Bunz et al. 1998) instead of cyclin 
AlCDK2 and cyclin E/CDK2 (Harper et al. 1993). DNA damaging events leading to G2 arrest 
activate the ATM/ ATR kinases (Ismail et al. 2005), which phosphorylate p53 (Siliciano et al. 
1997; Banin et al. 1998; Canman et al. 1998; Tibbetts et al. 1999). Although how ATM/ATR 
regulates p53 activity remains elusive, p53 phosphorylation is essential for the DNA damage 
response (Chao et al. 2000) and may prevent interaction ofp53 with MDM2 (Shieh et al. 1997), 
which is also a substrate of ATM (Khosravi et al. 1999). 
The transcription factor E2F1 can transactivate p14ARF (Bates et al. 1998), which interacts 
with the MDM2 E3 ubiquitin ligase, and inhibits the ability of MDM2 to target p53 for 
ubiquitination and subsequent degradation rvveber et al. 1999). E2Fl can also regulate apoptosis 
via transcriptional activation of p73 (Irwin et al. 2000; Stiewe and Putzer 2000) and Apaf-l 
(Moroni et al. 2001 b; Furukawa et al. 2002). Apoptosis mediated by p53 results from the 
accumulation of p53 and a concomitant increased expression of the p53-dependent pro-apoptotic 
genes bax (Miyashita and Reed 1995), Noxa (Oda et al. 2000a), PUMA (Nakano and Vousden 
2001), BID (Sax et al. 2002), Apaf-l (Moroni et al. 2001b), andp53AIPl (Oda et al. 2000b). 
1.2 Senescence 
In living organisms, a cell requires two major events to occur in order to become 
tumourigenic. A first barrier the cell needs to overcome is senescence. In the 1960s, Hayflick 
(' observed that cells could be kept in culture for a limited number of passages or cell divisions. 
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After about 30 to 40 divisions, the ceUs stop dividing and become irreversibly growth arrested 
(Haytlick 1965). This permanent withdrawal from the ceU cycle is termed senescence. Certain 
insults to the cell can cause them to become immortal. That is the case of most cell lines used in 
the laboratory as they can be kept in culture and dividing virtuaUy forever. But in order to 
become tumourigenic, the cell also must become unresponsive to growth factor signalling. This 
state is known as transformation. 
Two major pathways, the pRB and the p53 pathways, are responsible for restraining the cell 
from becoming immortalized. The p53 pathway appears to function upstream of the pRB 
pathway. The transcriptional activity of p53 drives the expression of the CDKj p21, which 
inactivates cyclin E/CDK2, thereby resulting in the accumulation of hypophosphorylated 
"pocket" proteins and ceU cycle arrest (see Figure 1.1). 
1.2.1 The p53 Pathway RaIe in Senescence 
As a transcriptional activator ofkey regulators of ceU cycle progression, p53 can, upon DNA 
damage in particular, induce the expression of p21, a CDKj, which leads to accumulation of the 
hypophosphorylated form of pRB and ceU cycle arrest. Genetic insults can emerge from outside 
the ceU, such as UV irradiation, or from within by metabolic by-products such as singlet oxygen 
species, or as a result of te10mere shortening. 
Telomeres are chromatin structures found at the end of chromosomes. The length of 
te10meres is proportional to the age of the ceU. After a number of divisions, the te10meres 
become too short and internaI chromosomal DNA starts to be degraded, which leads to a DNA 
damage response. The latter involves activation of the ATM/ATR kinases, which turn on p53. 
Telomere attrition leads to replicative senescence via transcriptional events mediated by p53 and 
to expression of the CDKj p21 and cell cycle arrest. 
The p53 pathway is also involved in stress-induced cellular senescence, a form of permanent 
cell cycle exit undistinguishable from replicative senescence. Most studies make use of activated 
Ras, which keeps mitogenic signalling "ON". 
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1.2.2 The Raie of the pRB Pathway in Senescence 
The adenoviral oncoprotein ElA has been known since the 1970s to be involved in cellular 
immortalization. The mechanism of ElA immortalization was investigated by identifying 
interacting cellular proteins. Three major ElA interacting proteins are the pRB family members, 
suggesting a central role for these proteins in the regulation of immortalization. Indeed the 
ablation of all three pocket proteins leads to cellular immortalization (Dannenberg et al. 2000; 
Sage et al. 2003). Furthermore, loss of Rb following the onset of replicative senescence leads to 
a reversaI of cell cycle arrest, highlighting the absolute requirement of pRB for the maintenance 
of senescence (Sage et al. 2003). 
A number of observations have already been discussed conceming pRB functions, but the 
important point here is that in response to proper upstream signaIs, pRB, and mainly p130, are 
recruited to senescence-associated heterochromatic foci (SAHF) where they actively participate 
in the establishment and maintenance of senescence through recruitment of histone deacetylase 
and methylase activities to silence the expression of genes required for cell cycle progression and 
DNA synthesis, resulting in a permanent and irreversible exit from the cell cycle (Narita et al. 
2003). 
1.2.3 Biological markers of senescence 
Cells that undergo permanent cell cycle exit harbour distinctive features such as enlarged 
morphology and expression of certain specific genes. The most widely used biomarker of 
senescence is SA-p-Gal activity (Dimri et al. 1995), which may reflect an increase in lysosomal 
mass in senescent cells (Kurz et al. 2000). The loss of the p53-related gene, p63, has recently 
been shown to induce senescence (Keyes et al. 2005; Keyes and Mills 2006). The protein level 
of SIRT1 also appears to inverse1y corre1ate with age (Sasaki et al. 2006; Sommer et al. 2006). 
Other markers of senescence that exhibit increased expression levels include PLM (Ferbeyre et 
al. 2000; Pearson et al. 2000), p16INK4A (Alcorta et al. 1996; Hara et al. 1996), p14ARF; p19ARF 
(Camero et al. 2000), and p21 (Noda et al. 1994; Brown et al. 1997). Senescent cells also feature 
the accumulation of distinct heterochromatic structures. These SAHF structures are enriched for 
the silent chromatin markers methylated histone H3 lysine 9 and the HP 1 protein but are devoid 
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of the euchromatin markers acetylated histone H3 lysine 9 and methylated histone H3 lysine 4 
(Narita et al. 2003). 
1.3 RBPI Family 
1.3.1 Retinoblastoma Binding Protein 1 
Using affinity chromatography-purified recombinant pRB60 (a fragment of pRB containing 
the viral oncoprotein-binding domain) as a probe Defeo-Jones et al. identified Retinoblastoma 
Binding Protein 1 (RBP1) in a screen of a ,,-gtll human lung fibroblast cDNA expression library 
(Defeo-Jones et al. 1991). This new gene encodes two transcripts of 5.2kbp and 4.3kbp as 
revealed by Northem blot analysis of hum an lung tissue analysis (Defeo-Jones et al. 1991) and is 
ubiquitously expressed (Fattaey et al. 1993). Southem blot analysis shows that RBPI is 
conserved across species (chicken, cow, human, monkey, mouse and rabbit) (Defeo-Jones et al. 
1991). Four splice isoforms have been identified in humans to date (Otterson et al. 1993). AlI of 
them retain the capacity to associate with pRB both in vitro and in vivo. RBPI is a 200kDa 
(Fattaey et al. 1993; Otterson et al. 1993) phosphoprotein (Fattaey et al. 1993) that localizes 
mainly in the nucleus (Fattaey et al. 1993; Otterson et al. 1993) with weak immunostaining in 
the cytoplasm (Otterson et al. 1993). 
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Figure 1.4: The RBPI family of transcription repressors. 
RBPI and BCAA share extensive primary structure similarities (34% identical in overall amino 
acid composition) but also structural organization. The functional repression domains RI and R2 
of RBPI and BCAA are depicted in green and red respectively (58% and 44% identical). Their 
putative Tudor and ChrOMo domains are also illustrated (80% and 75% identical, respectively). 
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The RBP 1 protein contains a motif of 10 amino acid residues that is found in the pRB-
binding domain of HPY -16 E7 protein as well as within the adenovirus ElA protein and simian 
virus 40 large T antigen. Rabbit reticulocyte lysate-translated and 35S-methione-labelled RBPI 
specifically binds to GST-pRB. This interaction can either be partially or completely inhibited 
using HPY E7 LxCxE peptide or full-iength E7 protein, respectively. Furtherrnore, cysteine to 
alanine point mutation of RBPI LxCxE motif exhibited reduced ability to interact with pRB60 
and a 75 residue deletion encompassing the motifresulted in complete loss of interaction (Defeo-
Jones et al. 1991). RBPI is found in complex with pRB in vivo and this association is disrupted 
by the expression of the E7 protein (Fattaey et al. 1993) confirrning the previous studies 
conducted in vitro. These results demonstrate the importance of the LxCxE motif for the 
mediation of the interaction between RBPI and pRB but also suggest that additional sequences 
may be involved since only a large deletion of the pRB-binding motif or competition by E7 
protein (which has two regions required for pRB interaction) are needed to abrogate the 
interaction. Moreover, the in vitro translated RBPI peptide was from a 1050bp long cDNA 
fragment (roughly one third the full-iength ORF) so it could not be excluded that RBPI contains 
~. an LxCxE-independent pRB-binding domain beyond the peptide studied. 
Since pRB growth suppressive properties involve transcriptional represslOn of E2F-
dependent transcription, it was proposed early on that RBPI could have transcriptional properties 
and was shown to be selectively retained on immobilized calf thymus DNA under relatively 
stringent conditions (Fattaey et al. 1993), indicating that it could be a DNA-binding protein. 
Recent in vitro binding studies of ARID proteins demonstrated that the RBPI ARID domain 
could mediate sequence non-specific DNA-binding activity (Patsialou et al. 2005), confirrning 
earlier work (Fattaey et al. 1993) and establishing RBPI as a DNA-binding protein. Hitherto, 
RBPI is the sole confirrned DNA-binding protein stably associating in the core mSIN3A/HDAC 
complex. 
RBPI over-expression induces cell growth inhibition and represses E2F-dependent 
transcription in an LxCxE motif-dependent manner (Lai et al. 1999b), suggesting that the 
repression of E2F by RBPI requires an intact interaction with pRB leading to cell cycle arrest 
(see Figure 1.5). The transcriptional repression activities of RBPI were mapped to two regions, 
terrned RI and R2 and shown to have HDAC-independent and HDAC-dependent repression 
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activities, respectively (Lai et al. 1999a; Lai et al. 1999b). The latter is mediated by recruitment 
of the mSIN3A/HDACl chromatin-modifying complex, which associates with the R2 region via 
a direct interaction with the SAP30 subunit of the complex (Lai et al. 2001). This 
mSIN3A1HDAC1/RBPl complex co-Iocalizes with pRB/p130 and E2F4 within discrete nuc1ear 
loci of qui es cent ceUs (Lai et al. 2001). Although these loci were not demonstrated to be origins 
of DNA replication per se, it was suggested they could be DNA replication foci. The role of the 
complex at these nuc1ear sub-domains would be to prevent origin firing through nuc1eosome 
modification and formation of compact heterochromatin. In accordance with this line of thought, 
recent work has implicated the yeast SIN3 protein in the timing of DNA replication firing 
(Aparicio et al. 2004). 
Biochemical protein purification of BRMS1- (Meehan et al. 2004), ING2- (Doyon et al. 
2006a), p33 ING1b_, SAP30- (Kuzmichev et al. 2002) and mSIN3A- (Skowyra et al. 2001; 
Nikolaev et al. 2004) containing complexes, established RBP1 as an inherent component of the 
mSIN3A1HDACl chromatin-modifying complexes. 
Recent work aimed at deciphering the transcriptional role of ERa/p heterodimer in bone 
formation identified RBP1 as an estrogen-responsive gene (Monroe et al. 2003; Monroe et al. 
2005; Monroe et al. 2006). Therefore, loss of RBP 1 could possibly lead to bone differentiation-
related defects and estrogen-dependent malfunctions such as breast carcinoma. Interestingly, an 
HDAC complex containing the metastasis-associated protein 1 (Yao and Yang 2003), MTAl, is 
involved in downregulation of ER expression and inactivation of ERE-dependent transcription 
by interacting with the transactivation domain of ERa and concomitantly recruiting histone 
deacetylase activity (Mazumdar et al. 2001). Furthermore, expression of MTA1 in breast 
carcinoma ceUs enhances anchorage-independent growth and potentiates metastasis (Toh et al. 
1994; Mahoney et al. 2002; Hofer et al. 2004). Together, these observations indicate that down-
regulation of RBP 1 expression via ERE could possibly partiaUy account for increased cell 
growth. 
1.3.2 Breast Carcinoma Associated Antigen 
The Breast Carcinoma Associated Antigen protein was recently identified as an over-
expressed epitope in breast cancer patients (Cao et al. 2001). It is highly similar to RBPI at the 
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protein sequence level therefore, it has also been referred to as RBP1l1 and ARID4B. It was also 
purified as a core subunit of the mSIN3A/HDACl complex and was re-baptized SIN3-
Associated Protein, 180kDa (SAP180) by Ayer's group (Fleischer et al. 2003). 
The basic characterization of BCAA (Fleischer et al. 2003) was in accordance with our own 
data (elaborated in more detail in Chapter Two) showing that it represses transcription in both 
HDAC-dependent and HDAC-independent manners. The principal points that were established 
by this work were that BCAA is a core subunit of the mSIN3A/HDACl complex; its carboxy 
terminal region mediates both the interaction with the complex and Trichostatin A sensitive 
repression activity; the mechanism by which the HDAC-independent repression domain acts 
remains elusive; and the possibility that RBP 1 may also be a core subunit of the same 
mSIN3A/HDAC complex is suggested from the peptide masses and sequence information 
obtained by mass spectrometry analysis of the 180kDa polypeptide matched both RBPI and 
BCAA. 
Although fascinating, the initial identification of BCAA as an over-expressed peptide in 
breast carcinoma patients revealed very little information on its properties. We became interested 
in BCAA because ofits sequence homology with RBPl, but mostly because ofits apparent lack 
of an LxCxE pRB-binding motif. Surprisingly, it was detected as a cytoplasmic protein. But 
from data gathered from various communications on BCAA and the size of the proteins 
expressed from the cDNAs that were c10ned (see Chapter Two), it was conc1uded that the over-
expressed BCAA in breast carcinoma ceUs is in fact a truncated form of full-Iength BCAA. 
There are two isoforms of BCAA, the shorter one resulting from alternative splicing within the 
Chromo domain. It is unknown how the truncated forms of BCAA identified in breast carcinoma 
ceUs arise. They may occur through alternative splicing leading to a frame shift and early 
termination of translation or via a mutation on BCAA aUeles introducing a stop codon or a frame 
shift mutation leading to early translation termination. 
1.3.3 Animal Madel alRBP1 and BCAA 
Interestingly, both RBP 1 and BCAA emerged from a screen aimed at identifying genes 
required for the regulation of the Prader-Willi and Angelman syndromes (PWS/ AS) imprinting 
center (lC) (Wu et al. 2006). A gene trap strategy was used and both RBPI and BCAA were 
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found to be required for imprinting of the PWS/AS-IC, which overlaps with the promoter of the 
snoRNA-encoding SNRPN gene. Surprisingly, RBP rl- mice were viable and fertile whereas, 
BCAA-1- was embryonic lethal between days E3.5 and E7.5. As mentioned in sections 1.3.2 and 
2.2.3, BCAA lacks a functional LxCxE pRB-binding motif and therefore it was assumed that it 
could not mediate pRB-re1ated functions such as recruitement of histone deacetylase activity to 
E2F-dependent promoters. Consequently, it would be rational to hypothesize that RBPI would 
compensate for loss of BCAA, but the opposite would not be true. Nonethe1ess, the fact that the 
BCAA knockout is lethal at such an early developmental stage suggests that BCAA, but not 
RBP l, functions are essential and not redundant. Since BCAA and RBP I are transcriptional 
repressors and RBPI can not compensate for the loss of BCAA, it would be possible that these 
two pro teins regulate different subsets of genes and that BCAA in particular would regulate 
genes essential for embryonic development. It would therefore be essential to carry out a 
systematic transcriptome characterization of RBP rl- and BCAA-1- cells. Besides, knockdown of 
BCAA in the MCF-7 cellline, in which BCAA is truncated (see Chapter 2), leads to growth 
inhibition (Yang et al. 2006), suggesting that these aberant forms of BCAA may under certain 
r. circumstances have oncogenic properties. 
The lack of an obvious phenotype for the RBP r/- as opposed to BCAA-/- may be misleading, 
especially since the gene targeting strategy employed deleted the introns land 2 of RBP 1 and 
that various splice variants3 at the 5' -end are predicted in mouse and therefore could possibly 
lead to the expression of functional amino terminally truncated RBP 1 as three other methionines 
are present upstream of the RI region. Furthermore, RBPI expression at the protein leve1 was 
not addressed and thus the lack of phenotype may reflect the expression ofRBPI. 
Mutation of RBP 1 and BCAA (RBP rl- BCAA+1-) leads not only to CpG hypomethylation at 
the SNRPN promoter but also loss of histone H3 lysine 9 trimethylation and histone H4 lysine 20 
trimethylation (Wu et al. 2006), which are epigenetic markers for transcriptionally silenced 
heterochromatin. Interestingly, a recent report on pRB LxCxE-binding "pocket" cellular function 
3 Particularly, isofonns 5 (Genebank Accession XP _903286) and 9 (Genebank Accession XP _928605), whose 
~. initiation methionine lies within intron Il. 
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proposed that, while pRB LxCxE-binding defective mutants retain anti-proliferative potential 
(Dick et al. 2000), disruption of the LxCxE-binding cleft led to reduced pericentric 
heterochromatin histone H4 lysine 20 trimethylation and loss of RBP1 binding (Isaac et al. 
2006), suggesting that pRB necessitates association with RBP 1 (or another LxCxE-containing 
protein) to silence pericentric chromatin but that the association with these factors is dispensable 
for growth arrest. Whether RBP1 and BCAA act directly or indirectly on CpG and histone tail 
methylation remains to be clarified. At the very least RBP1 appears to associate with the SNRPN 
promoter and therefore may alter epigenetic markers via its associated HDAC activity. It would 
also be interesting to find out the sequence in which these events occur. More specifically, do es 
RBPlIBCAA-dependent histone deacetylation lead to recruitment of the histone H3K9 
methylase SUV39H1 via pRB/HP1 (Nielsen et al. 2001; Vandel et al. 2001) and subsequent 
DNA methylation by pRB-associated DNA methylase DNMTl (Robertson et al. 2000; Pradhan 
and Kim 2002)? 
1.3.4 The ARlD, ChrOMo and Tudor domains 
The ARID, ChrOMo and Tudor domains are generally present in chromatin-associated 
proteins and transcription regulators. The AT-Rich Interaction Domain (Herrscher et al. 1995) is 
in most cases a non-sequence-specific DNA binding domain (Patsialou et al. 2005), which 
recognizes the major groove ofDNA via an helix-turn-helix (HTH) motif and the adjacent minor 
grooves are contacted by a l3-hairpin and C-terminal a-helix (Yuan et al. 1998; Iwahara and 
Clubb 1999). The Chromatin Organization Modifier domain and the Tudor domain are 
structurally related domains and are thought to decipher the histone code by recognizing specific 
histone tail modifications. A corner stone experiment conducted with the heterochromatin 
protein HP1 ChrOMo domain demonstrated the association ofHP1 with histone H3 dimehtylated 
lysine 9 in a ChrOMo domain-dependent manner (Lachner et al. 2001). The Tudor domain from 
the SMN protein recognizes symmetrically dimethylated arginines (Sprangers et al. 2003; Coté 
and Richard 2005). The Tudor and ChrOMo domains of various proteins were used to probe for 
interactions with unmodified, mono-, di-, or tri-methylated histone H3 (K4 and K9) and H4 
(K20) tails, but only a small subset of Tudor or ChrOMo domains were actually demonstrated to 
recognize specific histone tail modification (Kim et al. 2006). The ChrOMo domains of dMi-2 
are important for nucleosome association but, unlike HP 1 ChrOMo domain, they do not bind to 
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histone tails but rather 100se1y associate with DNA (Bouazoune et al. 2002). The p53 binding 
protein 53BP1 has two Tudor domains, which associate with Arginine-Glycine-rich peptide 
(Charier et al. 2004) and can also bind to DNA (Iwabuchi et al. 2003; Charier et al. 2004) upon 
induction ofDNA damage (Iwabuchi et al. 2003; Pryde et al. 2005). 
Both BCAA and RBPI comprise aIl three of these domains, but their biological functions 
remain uncharacterized. Histone tails from Hl, H2, H3, and H4 can be modified on numerous 
lysine residues, which have not been assessed in the recent report (Kim et al. 2006) and 
therefore, BCAA and/or RBP1 could very well be associated with one or more specific modified 
histones or sorne other post-transiationally modified proteins. 
Another interesting related feature of RBP1 is the presence of an AT-hook (Aravind and 
Landsman 1998) and two AT-hook-like sequences in the vicinity ofits ChrOMo domain. As the 
name implies, AT-hooks are functionally related to the ARID, as they mediate protein-DNA 
interactions with the minor groove of AT-rich sequences (Reeves and Nissen 1990). RBP1 has 
early on been shown to associate with DNA under re1atively high salt conditions (Fattaey et al. 
f·~~ 1993) but, although its ARID domain alone mediates DNA-binding activity (Patsialou et al. 
2005), very little is known about the role of this function in vivo and whether other regions are 
involved in DNA recognition. The proximity of the AT hooks to the ChrOMo domain suggest 
that they may cooperate to interact with DNA and/or nuc1eosomes as seems to be the case for the 
AT-hook and the bromodomain ofBRG1 (Singh et al. 2006). 
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Figure 1.5: Model of E2F-dependent transcription regulation by RBP1. 
In the G j phase of the cell cycle, RBPI would presumably bind to pRB pocket domain via its 
LxCxE motif and repress transcription by both HDAC-independent (RI) and HDAC-dependent 
(R2) mechanism. 
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1.4 Histone Modifications 
In order to fit the genome of eukaryotic organisms within the nucleus, the DNA is compacted 
into chromatin. The hum an genome is 6 x 106 kbp or roughly 1.8m long and is compacted within 
a nucleus 6)lm in diameter. This packaging feat is achieved with the help of histones, which are 
basic nuclear proteins that are assembled together with DNA into nucleosomes. The 
nucleosomes form a structure resembling a pearl necklace. It contains a histone octamer 
consisting of two copies of each of the four core histones, H2A, H2B, H3 and H4 histones, 
wrapped by 146bp of DNA and stabilized by one histone Hl (Luger et al. 1997). The histone 
structure was resolved (Luger et al. 1997) and they all have what is known as the amino-terminal 
histone tail. This structure protrudes from the nucleosome and can be post-translationally 
modified to engender conformational changes resulting in either the opening of the chromatin 
into transcriptionally active euchromatin or the collapse of chromatin to form transcriptionally 
refractory heterochromatin. 
1.4.1 Acetylation 
The existence ofthis post-translational modification of the histone tails has been known since 
the 1960's (Allfrey et al. 1964). Its presence on the histone tails correlates with the formation of 
transcriptionally permissive state of chromatin known as euchromatin. The actual mechanism by 
which acetyled histones permit transcription remains elusive but it is generally accepted that the 
acetyl group neutralize the positive charge of the side chain of the lysine residues within the 
histone tails therefore diminishing the interaction with the negatively charged DNA (Hong et al. 
1993; Lee et al. 1993; Anderson et al. 2001). 
Histone acetylation is occurring through a family of enzymes known as histone 
acetyltransferases (HAT). A number of proteins have been shown to possess intrinsic histone 
acetyltransferase activity and these include AIB1 (also known as ACTR and TRAM1) (Chen et 
al. 1997), ATF2 (Kawasaki et al. 2000), CBP/p300 (CREB-Binding Protein 300kDa) (Bannister 
and Kouzarides 1996; Ogryzko et al. 1996), CDY1 and CDY2 (Lahn and Page 1999; Lahn et al. 
2002), ELP3 (part of the RNA polymerase II holoenzyme elongator complex) (Wittschieben et 
al. 1999), GCN5L2 (a component of the STAGA complex which interacts with ElA) (Yang et 
al. 1996b; Wang et al. 1997), HAT1 (Histone AcetylTransferase 1 was the first HAT enzyme to 
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be identified) (Verreault et al. 1998), PCAF (p300/CBP Associated Factor; competes with ElA 
for binding sites in p300/CBP) (Yang et al. 1996b), and the MYST proteins HB01, MOF, 
MORF, MOZ, SAS2, SAS3 and TIP60 (Stemer and Berger 2000; Utley and Côté 2003). 
The majority of these enzymes have been identified as factors associated with transcription 
factors and required to potentiate transcriptional activity. The extent of this large heterogenous 
family of enzymes highlights the importance of histone acetylation for the regulation of 
transcription. 
1.4.2 Methylation 
Histone methylation occurs via the action of proteins known as histone methyl transferases 
(HMTs) (Samow et al. 1981) and its role towards regulation of transcription has been infered 
more than fort Y years ago (Allfrey et al. 1964). These transferases inc1ude G9a (Tachibana et al. 
2001), SUV39H1 (Rea et al. 2000), and SET7/9 (Wang et al. 2001). Due to the high 
thermodynamic stability of the N-CH3 bond, arginine methylation was thought to be irreversible 
and therefore an interesting candidate for the transmission of epigenetic information. But the 
recent identification of the lysine-specific histone demethylase LSD 1, a nuc1ear amine oxidase, 
which specifically demethylates histone H3 lysine 4 (Shi et al. 2004), has invalidated the dogma 
that methylation-induced silencing was irreversible. Although not a demethylase per se, the 
peptidyl arginine deiminase 4 P ADI4 was shown recently to deiminate histone H3 arginine 
residues R2, R8, R17, and R26 resulting in the conversion of these arginines to citrulline and 
preventing their methylation and activation of transcription (Cuthbert et al. 2004). 
Histones can be mono-, di-, or tri-methylated on either arginine or lysine residues. For 
example, H3 can be differentially methylated on R2, K4, K9, R17, R26, K27, K36, and K79 
(Sims et al. 2003). Depending on the methylation site, histone methylation has divergent 
functions and can either enhance or repress transcription. For example, H3 met-K4 is found in 
euchromatin whereas H3 tri-met-K9 is found in silenced heterochromatin (Peterson and Laniel 
2004). 
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1.4.3 SUMOylation 
SUMOylation is now an established mechanism of repression used by a wide range of 
transcription factors (Gi112005). However, histones were not believed to be affected by this post-
translational modification until very recently (Nathan et al. 2003; Shiio and Eisenman 2003; 
Nathan et al. 2006). The precise mechanism by which histone H4 SUMOylation impedes 
transcription remains elusive, but histone SUMOylation was suggested to serve as a platform to 
recruit HDACI and HPly proteins leading to histone H3 deacetylation (Shiio and Eisenman 
2003). Although SUMOylation do es lead in sorne instances (p300, Elk-l, p66, and MafG) to 
association with HDACs (Girdwood et al. 2003; Yang and Sharrocks 2004; Gong et al. 2006; 
Motohashi et al. 2006), in other cases (Dnmt3a) it actually impedes the association with HDACs 
(Ling et al. 2004), or simply leads to HDAC-independent transcriptional repression (Gomez-del 
Arco et al. 2005; Binda et al. 2006). 
1.4.4 ADP-ribosylation, Biotinylation, Citrullation, Phosphorylation, Ubiquitination 
There are many other relevant histone post-translational modifications. This section 
summarizes their relative roles in regulating chromatin. 
ADP-ribosylation of histones was observed a long time ago. This modification appears in 
response to DNA damage (Thraves and Smulson 1982; Adamietz and Rudolph 1984; Kreimeyer 
et al. 1984) and was proposed to play a role in DNA excision repair (Althaus 1992). 
Very little information is available on the biological relevance of histone biotinylation but it 
appears to parallel cellular proliferation (Stanley et al. 2001) and to increase in response to DNA 
double strand breaks (Kothapalli et al. 2005). 
Methylation of arginine residues within histone H3 has been linked to active transcription. 
However, the mechanism of demethylation of histones has remained elusive. Recently, a process 
termed deimination has been described that converts histone arginine to citrulline and 
antagonizes arginine methylation (Cuthbert et al. 2004). Citrullation is therefore implicated in 
transcriptional repression. 
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The ATM kinase phosphorylates the histone variant H2AX in response to DSB (Burma et al. 
2001) whereas the ATR kinase phosphorylates H2AX in response to UV-induced DNA damage 
occurring at stalled replication forks (Ward and Chen 2001). H2AX phosphorylation is required 
for the concentration and stabilization of DNA repair pro teins to damaged chromatin (Celeste et 
al. 2003). Histone phosphorylation is also involved in apoptosis (Ajiro 2000; Ahn et al. 2006) 
via a poorly understood mechanism. 
Ubiquitination of histones H2A (Levinger and Varshavsky 1982) and H2B (Davie and 
Murphy 1988) correlat es with active gene transcription. In agreement with those early 
observations, the Rad6/Brel complex monoubiquitinates histone H2B on lysine 123, which 
signaIs for the activation of histone H3 methylation on lysines 4 and 79 by COMP ASS and 
Dotlp HMTs, respectively, and transcriptional elongation (Wood et al. 2005). 
1.5 Histone Deacetylases 
As their name implies, this family of enzymes revert the action of HAT by removing the 
acetyl group on histones, whose activity was discovered over thirty years ago (Inoue and 
Fujimoto 1969; Inoue and Fujimoto 1970). Like HATs, this is a large family of enzymes that 
consists of 18 members divided into 3 classes. The HDACs have been categorized on the basis of 
their sequence similarities and the regulation of their functions. 
1.5.1 Class 1 HDACs 
This class of HDAC is related to the yeast Rpd3 protein and comprises HDACI (Taunton et 
al. 1996), HDAC2 (Yang et al. 1996a), HDAC3 (Yang et al. 1997), and HDAC8 (Hu et al. 
2000). Rpd3 orthologues are evolutionarily conserved amongst aIl eukaryotes. Class 1 HDACs 
exist in large multi-subunit complexes including the mSIN3/HDAC (Hassig et al. 1997; Laherty 
et al. 1997), the NuRD (Xue et al. 1998; Zhang et al. 1998a; Zhang et al. 1999b) and the N-
CORlSMRT (Alland et al. 1997; Heinzel et al. 1997; Nagy et al. 1997) complexes. These 
complexes are recruited to particular promoters by sequence specifie transcriptional repressors 
where they deacetylate histone tails resulting in the formation of compacted transcriptionally 
refractory heterochromatin. Importantly, the histone deacetylase activity of HDACs is indeed 
essential for transcriptional repression (Hassig et al. 1998). Genetic experiments conducted in 
Saccharomyces cerevisiae, have demonstrated that in the absence of Rpd3, late firing origins of 
34 
repli cation fired as early as the early firing origins (Aparicio et al. 2004), therefore suggesting 
that Rpd3 not only regulates transcription but also other nucleosomal functions such as initiation 
of late-replicating origins and orchestration of the overall repli cation dynamics of the yeast 
genome. Equivalent experiments in mammalian systems have not been conducted hitherto but, 
mSIN3 and other components of the complex have been observed at origins of DNA repli cation 
in quiescent normal human cells (Lai et al. 2001), suggesting an evolutionarely conserved 
mSIN3 function in regulation ofDNA replication. 
1.5.2 Class II HDACs 
Class II HDACs are related to the yeast HDA1 protein and comprise HDAC4 (Grozinger et 
al. 1999), HDAC5 (Grozinger et al. 1999), HDAC6 (Grozinger et al. 1999), HDAC7 (Kao et al. 
2000), HDAC9 (Zhou et al. 2001), HDAC10 (Fischer et al. 2002; Guardiola and Yao 2002; Kao 
et al. 2002), and HDACII (Gao et al. 2002). The class II HDACs do not appear to associate with 
either the well characterized mSIN3/HDAC or the NuRD complexes but can be found in sorne 
instances to participate in the activity of the nuclear hormone receptor co-repressors N-
r' CORlSMRT (Huang et al. 2000; Fischle et al. 2001; Fischle et al. 2002). The principal feature 
characterizing the class II HDACs is their special regulation via nucleocytoplasmic shuttling. 
Furthermore, class II histone deacetylases are sensitive to class l inhibitors such as butyrate and 
Trichostatin A, suggesting a similar enzymatic mechanism of action (Finnin et al. 1999). 
1.5.3 Class III HDACs 
This last class of HDACs is related to the yeast SIR2 protein and are regrouped under the 
name sirtuins (SIR-two-ins). To date, seven sirtuins have been identified in humans (Frye 1999; 
Frye 2000). This particular class of HDACs is characterized by their NAD+ -dependent activity 
(Imai et al. 2000) and their insensitivity to general HDAC inhibitors such as TSA (Imai et al. 
2000; Barlow et al. 2001) and butyrate (Barlow et al. 2001). However, sirtuin activity can be 
modulated by a number of small molecules (Grubisha et al. 2005). A powerful anti-oxydant 
found in red wine (and grape juice), resveratrol, potently stimulates SIRT1 (Howitz et al. 2003; 
Borra et al. 2005; Kaeberlein et al. 2005) activity but is inactive towards SIRT2 (Borra et al. 
2005). Sirtuin activity can also be inhibited by nicotinamide (Bitterman et al. 2002), sirtinol 
(Grozinger et al. 2001), and splitomicin (Bedalov et al. 2001). The latter two can induce 
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senescence in H1299 and MCF-7 celllines (Ota et al. 2005). Sir2 activity is tightly regulated by 
the levels of NAD+/NADH and may (Lin et al. 2004) or may not (Anderson et al. 2003) 
therefore be linked to cellular energy metabolism, calorie restriction, and extended longevity. 
Work in Saccharomyces cerevisiae has established that the enzymatic activity of Sir2 (Lin et al. 
2000) or the Sir2 homo log Hst2 (Lamming et al. 2005) is required for life-span extension. 
Much like the other HDACs, sirtuins can deacetylate both histones H3 and H4 (Imai et al. 
2000) as weIl as non-histone substrates. More particularly, SIRT1 can deacetylate lysine residue 
382 from p53, which results in a reduction of its transcriptional activity (Luo et al. 2001; Vaziri 
et al. 2001), in agreement with its pro-survival functions (Haigis and Guarente 2006). The 
enzymatic activity of SIRT1 antagonizes PML-induced acetylation of p53 and prevents PML-
mediated premature senescence (Langley et al. 2002). The p300 HAT can also be deacetylated 
by SIRTI leading to SUMOylation of the deacetylated lysine residues and repression of 
transcription (Bouras et al. 2005). 
The human sirtuins have diverse enzymatic activities and restricted cellular localisation. 
SIRT1, SIRT6, and SIRT7 are nuclear. However, SIRT1 is excluded from nucleoli, SIRT6 is 
found within heterochromatic regions and SIRT7 is enriched in nucleoli (Michishita et al. 2005). 
SIRT3 (Onyango et al. 2002; Schwer et al. 2002), SIRT4, and SIRT5 are mitochondrial 
(Michishita et al. 2005) and SIRT2 is cytoplasmic (North et al. 2003; Michishita et al. 2005). 
Moreover, SIRT2 was recently shown to be actively excluded from the nucleus via an NES in an 
exportin CRM1-dependent manner (Wilson et al. 2006). Nuclear export and possible import of 
SIRT2 is consistent with its histone H4lysine 16 deacetylation (Vaquero et al. 2006) and tubulin 
deacetylation (North et al. 2003) activities as weIl as its association with the transcription factor 
HOXA10 (Bae et al. 2004). SIRT1 (Imai et al. 2000), SIRT2, SIRT3 (Onyango et al. 2002; 
Schwer et al. 2002), and SIRT5 have strong histone H4 deacetylase activity (North et al. 2003). 
SIRT6 and SIRT7 are, to a much lesser extent, also capable of deacetylating histone H4 in vitro. 
Furthennore, SIRT6 has recently been shown to possess ADP-ribosyltransferase activity (Liszt et 
al. 2005). SIRT4 is the only sirtuin without histone H4 deacetylase activity and SIRT2 is the sole 
sirtuin with tubulin deacetylation activity (North et al. 2003). Only SIRT1 can deacetylate p53 
(both in vitro and in vivo) (Michishita et al. 2005). Despite their resemblance within the SIR2 
homology enzymatic domain, the sirtuins share little overlap in substrate specificity, enzymatic 
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activity and cellular localisation, suggesting functional specialization. Moreover, SIRTI has been 
reported to be devoid of any substrate specificity in vitro (Blander et al. 2005), suggesting that 
the specificity in vivo could be conferred by either localization or protein-protein interactions 
with the substrates. 
1.5.4 lnhibitor of Histone Acetyltransferases (INHA T) 
Although not a histone deacetylase per se, the multiprotein cellular INHA T complex 
modulates histone acetylation and transcription by potently inhibiting the histone 
acetyltransferase activity of p300/CBP and PCAF (Seo et al. 2001). The first INHA T complex 
characterized contains the SET oncoprotein and pp32 (Seo et al. 2001; Seo et al. 2002; 
Schneider et al. 2004) both of which bind directly to histone H3 amino terminal tail (Schneider 
et al. 2004). Interestingly, the protein level of the three INHAT subunits, TAFIa, TAFl13, and 
pp32A sharply and rapidly decreased upon induction ofDSB (Dirksen et al. 2006). 
Little is known about the biological relevance of INHAT, but a novel INHAT, NIR, has 
recently been identified (Hublitz et al. 2005). Like the other INHAT (Kutney et al. 2004; 
Schneider et al. 2004), NIR associates with core histones, nuc1eosomes, and unmodified histone 
H3. Acetylation of histone H3 lysines 9, 14, 18, and 23 greatly reduces the association ofNIR 
with histone H3. Hublitz et al. showed that NIR is recruited by p53 to repress transcription and 
that NIR down-regulation results in histone hyperacetylation at p53-dependent promoters 
resulting in apoptosis. 
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Figure 1.6: mSIN3A1HDAC complexes. 
The factor mSIN3 is found in a so called "core" complex composed of mSIN3A, HDACll2, 
RBAP46/48, and SAP30. This "core" complex associates with peripheral factors in various 
subsets of chromatin moditying (exemplified by "1") and chromatin remodelling complexes 
(exemplified by "II"). 
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1.6 The mSIN3A/HDACl Complex 
The mSIN3A1HDAC1 chromatin modifiying complex, although it has a few differences in its 
core components, is evolutionarily conserved from yeast to human. Several independent groups 
have biochemically purified complexes containing mSIN3/HDAC. These complexes have in 
common what is known as the "core" components of the mSIN3/HDAC complex (see Figure 
1.6), which inc1udes HDAC1I2, RBAP46/48, SAP18, SAP30, and mSIN3A. Also identified in 
complex with mSIN3A1HDAC1 are "peripheral" components, which inc1ude the 
BRMSlIBRMS1-homologue p40, RBPlIBCAA, SAP130, and the tumour suppressors p33INGlb 
and ING2. These "peripheral" components could presumably target the mSIN3A/HDAC1 
complex to dis crete locations for specific purposes. 
1.6.1 Histone Deacetylases 
The general functions of HDACs have already been discussed in detail in section 1.5 but 
their specifie roles and regulatory mechanisms within the SIN3 complex will be e1aborated here. 
HDAC1 and HDAC2 are recruited to SIN3 via a direct interaction with SIN3 HID region 
(Laherty et al. 1997). SAP30 also makes direct contact with HDAC1 and HDAC2 (Zhang et al. 
1998b). The histone deacetylase activity associated with the mSIN3 complex is stimulated by 
mSDS3, most likely by maintaining the complex integrity (Lechner et al. 2000). HDAC1 activity 
seems to be regulated by a mechanism involving stabilization of the complex but also by post-
translational modifications such as acetylation (Qiu et al. 2006), phosphorylation (Cai et al. 
2001; Pflum et al. 2001), SUMOylation (Colombo et al. 2002; David et al. 2002), and 
phosphorylation-dependent SUMOylation (Colombo et al. 2002). 
1.6.2 mSIN3A/B Corepressors 
The mammalian orthologues of yeast SIN3 were c10ned as corepressors of Mad-Max (Ayer 
et al. 1995) and of Mxi1 (Schreiber-Agus et al. 1995). In Saccharomyces cerevisiae, 
transcription of the HO gene requires five SWI genes (also refered to as SNF). The yeast SIN 
genes were identified on the basis that mutation of those genes in the absence of SWI genes 
reconstituted the expression of HO (Sternberg et al. 1987). Mutations in the SIN3 gene suppress 
the requirement for the SWI5 activator for transcription at the HO promoter (Nasmyth et al. 
1987; Sternberg et al. 1987), suggesting that SIN3 and SWI5 have opposite functions. The 
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structure of SIN3 is composed of four paired amphipathic helix (PAH) motifs (Wang et al. 
1990), which mediates protein-protein interaction with SAP30 for example (P AH3) (Laherty et 
al. 1998; Zhang et al. 1998b). These P AH motifs are required for transcriptional repression 
mediated by SIN3, and PAH4 is sufficient for this activity (Wang and Stillman 1993). The 
region between P AH3 and P AH4 is reponsible for SIN3-associated HDAC activity and 
HDACl/2 binding (Hassig et al. 1997; Laherty et al. 1997). 
Recent work from the Aparicio laboratory on SIN3 functions in yeast revealed a role for 
SIN3 in the timing oflate firing origins of replication (Aparicio et al. 2004). These results agree 
with the observation that HDAC, SAP30, mSIN3, and RBP1 localize to origins of DNA 
replication following growth stimulation (Lai et al. 2001). Supposedly, the mSIN3A1HDAC 
complex would act by compacting nucleosomes at the origins, thus preventing either the 
formation of the origin recognition complex or the processivity of DNA polyrnerase. In accord 
with these observations, nucleosome acetylation was shown to be an important modulator of 
origin activity (Aggarwal and Calvi 2004). Furthermore, completion of the S phase can be 
hastened by HDAC inhibition (Kemp et al. 2005). 
The recent generation of a mSIN3A knockout mouse model (Dannenberg et al. 2005) 
revealed that mSIN3A-1- genotype is embryonic lethal between E3.5 and E6.5 consolidating the 
idea that mSIN3A is essential for early embryonic development. Interestingly, the BCAA-1-
genotype is also embryonic lethal between E3.5 and E7.5. mSIN3A was also shown to be 
involved in a vast number of cellular processes by regulating the transcription of genes involved 
in cell cycle regulation, apoptosis, DNA repair and repli cation, histone modification and 
chromatin remodelling, stress signalling pathways and transcriptional regulation. Interestingly, a 
number ofsubunits (ING1, HDAC2, mSDS3, BCAA, mSIN3B, SAP30) from the mSIN3/HDAC 
complex are themselves regulated by mSIN3A (Dannenberg et al. 2005), suggesting a regulatory 
feedback loop. 
The specific function of mSIN3B, as opposed to mSIN3A, is somewhat vague and the 
literature sparce. The mSIN3 proteins only share 53% identity, suggesting that they may have 
divergent functions. Although mSIN3B is located at E2F-responsive promoters in Go (Rayrnan et 
r-' al. 2002), important questions remain, such as: Are mSIN3A and mSIN3B part of distinct 
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complexes? Why can mSIN3B not compensate for mSIN3A loss? The latter finding appears to 
suggest distinct functions and thereby distinct complexes for mSIN3A and mSIN3B. 
1.6.3 SIN3 Associated Peptides 
1.6.3.1 SAP18 
The smallest mSIN3A/HDAC subunit SAP18 associates directly with mSIN3A (Zhang et al. 
1997). Consistent with its association with an HDAC complex, SAP18 can mediate transcription 
repression when tethered to a promoter (Zhang et al. 1997) although it has never been shown to 
repress in an HDAC-dependent manner. Its precise function within the complex is unknown but 
it associates with sorne transcriptional factors (Espinas et al. 2000; Cheng and Bishop 2002) and 
therefore could account for gene-specifie targeting of a subset of mSIN3A1HDAC complex. 
1.6.3.2 SAP25 
Yet another subunit of the mSIN3A1HDAC complex, SAP25 is required for efficient 
mSIN3A-mediated transcriptional repression (Shiio et al. 2006). Surprisingly, SAP25 is 
predominantly cytoplasmic and is actively exported outside the nucleus in a CRMI-dependent 
mechanism (Shiio et al. 2006). The nuclear fraction of SAP25 colocalizes with PML nuclear 
bodies. Furthermore, this nuclear colocalization was enhanced both by exogenous expression of 
PML and Ras-induced premature senescence (Shiio et al. 2006). These results suggest that upon 
senescence induction, SAP25 is shuttled to the nucleus to assist SIN3-dependent transcriptional 
repression at PML bodies and/or to sequester the mSIN3A/HDAC complex to PML bodies. 
Interestingly, although they were both able to induce senescence (Binda et al. 2006), neither 
RBPI nor BCAA were reported to be associated with this particular mSIN3A/HDAC complex, 
maybe suggesting a dual role for the mSIN3A1HDAC complex in the mediation of senescence. 
1.6.3.3 SAP30 and SAP30L 
SAP30 was identified as a bona jide subunit of the mSIN3A/HDAC complex (Laherty et al. 
1998; Zhang et al. 1998b), which binds directly to mSIN3A (Laherty et al. 1998; Zhang et al. 
1998b), HDACI (Zhang et al. 1998b; Binda et al. 2006), and RBAP46/48 (Zhang et al. 1998b). 
Although SAP30 is a fairly small protein (220 amino acids), it appears to be involved in bringing 
together most components of the mSIN3A/HDAC complex. Furthermore, the tumour suppressor 
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p33ING1b also associates directly with SAP30 (Kuzmichev et al. 2002) and this interaction is 
essential for induction of growth arrest by p33ING1b (Kuzmichev et al. 2002). Interestingly, 
deletion of p33ING1b PHD finger domain, which is required for both phosphatidylinositol 
(Gozani et al. 2003; Gozani et al. 2005) and histone H3 trimethyl-K4 binding (Shi et al. 2006), 
substantially enhanced p33ING1b-mediated growth inhibition (Kuzmichev et al. 2002). 
Recognition of H3 trimethyl-K4 by ING2 PHD finger is necessary for proper transcriptional 
repression in response to DNA damage (Shi et al. 2006), suggesting that phosphatidylinositol 
and H3 trimethyl-K4 binding may have antagonistic effects on ING proteins function. 
As is the case with SAP18, SAP30 associates directly with transcription repressors, but 
distinct from those bound by SAP18. Accordingly, SAP30 associates with YY1 (Huang et al. 
2003), N-COR (Laherty et al. 1998), and RBP1 proteins (Lai et al. 2001; Binda et al. 2006) and 
therefore could mediate targeting of a subset of mSIN3A/HDAC complex to distinct promoters. 
A SAP30-like protein, SAP30L, was c10ned recently (Lindfors et al. 2003) and demonstrated 
to also associate with the mSIN3A/HDAC complex, to self-associate as well as, along with 
SAP30, to target the complex to the nuc1eolus (Viiri et al. 2006), suggesting a possible role for 
the mSIN3A1HDAC complex in regulating rDNA transcription, which is, interestingly, a known 
function for the c1ass III deacetylases (see section 1.5.3). 
1.6.3.4 SAP45/mSDS3 
SDS3 was identified in yeast as an essential factor for SIN3-mediated repression and shown 
to preserve SIN3/RPD3 integrity and potentiate histone deacetylation activity (Dorland et al. 
2000; Lechner et al. 2000). The mamma1ian homo10g of yeast SDS3, mSDS3, was recently 
identified in a concerted effort to further characterize the mSIN3A HDAC-interaction domain 
and understand the contribution to transcriptional repression by other mSIN3A-associated 
peptides (Alland et al. 2002; Fleischer et al. 2003). Notably, SDS3 functions in yeast appear to 
be evolutionally conserved in mSDS3 (Alland et al. 2002). The apparent function of SDS3 and 
mSDS3 is to facilitate HDAC1 catalytic activity in vivo. 
An mSDS3-1- mouse model was recently developed (David et al. 2003; David et al. 2006). In 
contrast with mSIN3-1-, loss of mSDS3 leads to severe cytogenetic consequences, such as 
aneuploidy and defective karyokinesis. This effect is due to failure in pericentric 
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heterochromatin formation, which results in aberrant association of heterologous chromosomes 
at the centromeres and improper chromosome segregation. In a p5T/- background, mSDS3 
haploinsufficiency (mSDS3+1-) results in accelerated tumour onset. This phenotype can be 
circumvented by reintroduction of p53 (mSDS3+1- p53+1-), which is known to play a role in 
monitoring mitotic fidelity. 
The neuronal cyc1in-dependent kinase CDK5 associates with and phosphorylates mSDS3 at 
serine 228 (Li et al. 2004). Activation of CDK5 by the non-cyclin factor p35 enhances mSDS3-
mediated repression (Li et al. 2004). Furthermore, the mSDS3 phosphorylation defective mutant 
S228A fails to rescue normal growth in mSDS3-1- cells indicating a significant role of post-
translational modification in mSDS3 regulation and functions (Li et al. 2004). 
1.6.4 pRB Associated Peptides 
Two of the WD40 repeat proteins found to associate with pRB are also part of the 
SIN3/HDAC complex as well as the chromatin assembly factor complex CAFl. RbAP46 and 
RbAP48 are often refered to as histone chaperones, which associate directly with the histone H4 
(Verreault et al. 1996; Verreault et al. 1998). 
Although the contribution of histone deacetylase activity to the pocket of pRB as a 
mechanism of transcriptional repression was reported almost ten years ago (Brehm et al. 1998; 
Ferreira et al. 1998; Luo et al. 1998; Magnaghi-Jaulin et al. 1998), the debate concerning how 
HDACs are recruited to the pocket is still a matter of controversy. 
Taking advantage of yeast genetics, Kennedy et al. (Kennedy et al. 2001) have shown that 
pRB-mediated transcriptional repression activity required both RPD3 and MSIl (RPD3 is a c1ass 
l HDAC ortholog and MSIl an RbAP48-related protein). Mutation of the LxCxE-binding c1eft in 
pRB unaltered its repression potential, suggesting an alternative way to recruit histone 
deacetylase activity. Furthermore, RPD3 does not have an LxCxE motif and although HDAC1 
and HDAC2 have an LxCxE-like motif, HDAC3 does not, suggesting other means of HDAC 
recruitment to pRB. Finally, MSIl is specifically required by pRB but not RPD3 for repression 
implicating that MSIl may play a role the recruitment ofHDAC activity to pRB. 
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A systematic approach employing RNAi-mediated depletion of transcriptional repressors in 
Drosophila (Taylor-Harding et al. 2004) has demonstrated the requirement of p55/dCAF-1 
(Drosophila ortholog of RbAP46/48) for repression of E2F-dependent genes that are directly 
regulated by Drosophila pRB proteins RBF1 and RBF2 (Dimova et al. 2003). Furthermore, 
neither HDAC proteins nor SWIISNF, which is thought to be involved in pRB-mediated 
repression (Dunaief et al. 1994; Trouche et al. 1997), were required for repression of E2F-
dependent transcription. Noteworthy, the HDACs were depleted by RNAi individually so a 
possible compensation by the others should be considered. Nonetheless, p55 was shown to 
mediate an irreplaceable role in pRB transcriptional repression functions in Drosophila and it 
would be interesting to recapitulate this experiment in mammalian cells, which have potentially 
redundant functions such as RBP1 to recruit HDAC activity to pRB. 
1.6.5 Inhibitor ofGrowth Family ofTumour Suppressors (ING) 
The INGs are part of a third family oftumour suppressors in the same rank as pRB and p53. 
The ING1 gene was discovered based on the growth inhibitory properties it confers (Garkavtsev 
et al. 1996). The five human ING proteins are evolutionari1y conserved amongst vertebrates. 
Plant homeodomain (PHD) proteins related to ING are also found in lower organisms. ING1 and 
ING2 are found in complex with histone deacetylases (Skowyra et al. 2001; Kuzmiehev et al. 
2002; Doyon et al. 2006a) whereas ING3, ING4, and ING5 associate with histone 
acetyltransferase aetivity (Doyon et al. 2006a). 
The PHD of ING2 binds phosphatidylinositol-5-phosphate (Ptdlns-5-P) (Gozani et al. 2003), 
a phospholipid whose nuclear abundance increases more than 20-fold in the Gl phase of the eell 
cycle (Clarke et al. 2001a). A role for nuclear phospholipid signalling in cell cycle regulation 
and response to DNA damaging agents is currently emerging (Gozani et al. 2003; Shi et al. 
2006). The association of Ptdlns-5-P to ING2 forces a reloeation of ING2 from small nuclear 
foei into a diffuse nuclear distribution (Gozani et al. 2005). The PHD finger domain of ING2 is 
required for ING2 recruitment to chromatin, trimethylated histone H3K4 binding and p53-
dependent response to DNA damage (Gozani et al. 2005; Shi et al. 2006). ING2 PHD finger 
domain integrity is also necessary for cyclin D 1 down-regulation in response to DNA damage 
/"'--, (Shi et al. 2006). As an inherent subunit of the mSIN3A/HDAC1 complex, ING2 protein, and 
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possibly INGlb, may therefore engage the mSIN3A/HDACl complex III mediating 
transcriptional repression activity at promoters in response to DNA damage. 
1.6.6 Breast Metastasis Suppressor 1 
BRMS1 was identified as a metastasis suppressor gene positioned on chromosome 11q13 
(Seraj et al. 2000). BRMS 1 exogenous expression prevents metastatic migration of breast 
carcicnoma cells (Seraj et al. 2000) as well as me1anoma cells (Shevde et al. 2002) and ovarian 
carcinoma cells (Zhang et al. 2006) without altering the tumourigenicity of the cells. A two-yeast 
hybrid screen and a biochemical purification approach identified BCAA and RBPI as BRMS 1 
associated proteins (Meehan et al. 2004; Nikolaev et al. 2004). The region of BCAA (residues 
1109 to 1312)4 required for BRMS 1 association is a 101 amino acids larger than the R2 region 
(residues 1210 to 1312). It cannot be conc1uded that BRMSI associates directly with BCAA 
because SAP30 is conserved in Saccharomyces cerevisiae and may bridge the two proteins in the 
two-hybrid system used, thus BRMSI may associate with BCAA via the mSIN3A1HDACl 
complex or to sequences upstrearn of the R2 domain. However, it remains quite compelling that 
BCAA and RBPI can associate with both tumour suppressors (pRB, p33INGlb, and ING2) and 
metastasis suppressors. 
1.6. 7 The SWl/SNF Chromatin Remodelling Complex 
As explained in the previous sections, histones can be post-translationally modified resulting 
in either activation or repression of transcription. Transcription do es not occur on naked DNA in 
the cell, but rather the genome is embedded in higher order nuc1eosomes. Histone proteins have a 
critical role in DNA compaction and regulation of the genetic information. ln vitro experiments 
have shown that nuc1eosomes tend to inhibit transcription. But when nuc1eosomes are assembled 
after transcription factors such as TFIID have been pre-incubated with the template DNA, they 
no longer hinder transcription (Workman and Roeder 1987). These experiments argue that 
nuc1eosome are inherently stalling transcription by competing with GTF for access to promoter 
e1ements. Nuc1eosome remodelling activities require energy in the form of A TP and are therefore 
4 Danny Welch, personnal communication. 
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distinct from post-translational modification activities. An important chromatin remodelling 
complex is the ATP-dependent SWIISNF complex, which enhances access of transcription 
factors to the DNA by repositioning nucleosomes and allowing unwrapping of the DNA from the 
nucleosomes. 
In mammalian cells, there are two pro teins related to yeast SWI/SNF, namely BRM and 
BRGl. Both factors are found in a mammalian SWIISNF-like complex but are mutually 
exclusive. Therefore, at least two forms of the SWI/SNF complex coexist that may have distinct 
functions. In support of this idea, BRM and BRG 1 are differentially regulated during cell cycle 
progression with BRG 1 protein levels remaining stable throughout the cell cycle and BRM 
accumulating upon growth arrest (Muchardt et al. 1998). Furthermore, both BRM and BRGI 
associate with pRB in an LxCxE-dependent manner to induce cellular growth arrest (Dunaief et 
al. 1994; Strober et al. 1996) and repress E2F-dependent transcription (Trouche et al. 1997). 
AIso, BRGI is either mutated or absent in multiple tumour cell lines including H1299, C33A 
(Wong et al. 2000), and SW13 (Dunaief et al. 1994; Wong et al. 2000), suggesting an important 
role for chromatin remodelling not only as a transcriptional regulatory pro cess but also at sorne 
stage of cellular transformation. Indeed, re-introduction of BRG1 in SW13 human tumour cells 
induced a flat-cell morphology phenotype and senescence (Shanahan et al. 1999; Kang et al. 
2004). 
A restricted subset of SWIISNF complex subunits are biochemically purified in association 
with the mSIN3A/HDAC complex (Sif et al. 2001; Kuzmichev et al. 2002). The BRG1, 
BAFI70, BAFI55, p60, p53 (BAF53 actin-like protein), and p47 (also refered to as INIl or 
SNF5) subunits of the SWIISNF complex co-purifiy with the mSIN3/HDAC complex. In 
addition, BRGI and BAF155 were shown to associate directly with mSIN3A in vitro (Sif et al. 
2001). Stable interactions between INIl, BAFI55, and BAFl70 as well as between these 
proteins and BRG 1 are able to take place in the absence of other members of the human 
SWIISNF complex (Phe1an et al. 1999). The association of SWIISNF components with the 
mSIN3/HDAC repression complex conforms to the observation that SWIISNF subunits are 
involved in transcriptional repression of c-fos (Murphy et al. 1999) and pRB-regulated promoters 
(Trouche et al. 1997; Zhang et al. 2000) in an HDAC-dependent manner. Furthermore, p33 INGlb_ 
mediated repression can be enhanced by concomitant overexpression of BRG 1 but not by an 
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ATP-binding defective mutant BRGI (Kuzmichev et al. 2002). Interestingly, the BRGI-like 
protein BRM could not associate with the mSIN3/HDAC complex, suggesting divergent 
functions for the two SWIISNF complexes. These observations imply that BRG 1 and BRG 1-
Associated Factor ATP-dependent activity could enhance mSIN3/HDAC transcriptional 
repression activity by remodelling chromatin in the promoter vicinity and render histone more 
readily accessible to deacetylation. 
Interestingly, the subunit BAF53 is an actin-like protein that is required for full BRG 1 
ATPase activity (Zhao et al. 1998). Furthermore, the association between BAF53 and Ptdlns-4,5-
P2 targets the BRG 1 complex to chromatin (Zhao et al. 1998). The presence of two distinct 
PtdlnsP-binding proteins in the mSIN3NHDACl complex is intriguing and compels one to 
speculate that phospholipid signal transduction events may be regulating the timely localization 
and transcriptional repression of specific genes by the mSIN3A/HDACl complex in response to 
DNA damage or other growth inhibitory cues. 
1.6.8 The PHD Zinc Fingers Protein Pfl 
Pfl has two PHD zinc finger domains, PHDI and PHD2. Pfl binds mSIN3A via two distinct 
regions, SIDl, which binds mSIN3A PAH2 domain, and SID2, which binds the mSIN3A PAHI 
domain (Yochum and Ayer 2001). The polybasic region adjacent to the carboxy terminus ofPfl 
PHDI specifically binds to the lipid signalling molecules Ptdlns-3-P and PtdIns-5-P (Kaadige 
and Ayer 2006). Swapping experiments with the polybasic regions of other PHD-proteins (ING 1, 
ING2 and ACFl) suggest that the polybasic region confers PI-binding specificity (Kaadige and 
Ayer 2006). This idea was confirmed by another recent communication stating that the polybasic 
stretch of a number of proteins, inc1uding Ras and Arf, not only allowed Ptdlns-4,5-P association 
but also concurrent Ptdlns-4,5-P-dependent plasma membrane targeting (Heo et al. 2006). The 
polybasic stretches of other proteins have also been reported to mediate PtdlnsP-binding 
(Papayannopoulos et al. 2005). These observations are also in agreement with the prior 
observation that chromatin recruitment of the BAF complex and the tumour suppressors ING 1 b 
and ING2 is mediated via PtdlnsP binding. 
It appears evident that phospholipid signalling events are regulating mSIN3A nuc1ear 
functions via BAF53, INGlb, ING2, and/or Pfl. It would therefore be very informative to 
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identify the signalling pathway(s) leading to proper regulation of mSIN3A functions. Moreover, 
this information could have a huge impact on the scientific community considering the 
importance of p53 in tumourigenesis and that p53 itself regulates the expression of the two 
essential enzymes in PtdlnsP synthesis, PTEN (Stambolic et al. 2001) and the PI3K catalytic 
subunit pIlOu (Singh et al. 2002), both of which are either lost (Cantley and Neel 1999) or 
amplified (Liu and Roberts 2006), respectively, in numerous cancers. It is also widely accepted 
that an imbalance in phospholipid homeostasis can have a dramatic burden on the cell as 
observed in the pathogenesis ofboth diabetes and cancer. 
1.6.9 The Groucho Corepressor TLE1 
Because Pfl also associates with the Groucho corepressor TLEI (Yochum and Ayer 2002), it 
was proposed that Pfl could serve to bridge mSIN3A and TLE1, which associates directly with 
the Drosophila HDAC1 ortholog RPD3 (Chen et al. 1999). The TLE corepressors associate with 
chromatin through interactions with the amino terminus of histone H3 (Palaparti et al. 1997). 
Partial relief of Drosophila TLE-mediated repression by the HDAC inhibitor TSA suggest that 
TLE has both HDAC-dependent and -independent transcriptional repression activities. The latter 
could account for RBPlIBCAA RI repression activity as TLE1 was found to associate with the 
HDAC-independent repression domain ofBCAA (Ayer DE, personnal communication). 
1.6.10 Mortality Factors 
The mortality factor on chromosome 4, MORF4, was identified as an essential gene on 
chromosome 4 for induction of senescence in immortalized cell lines (Bertram et al. 1999). 
MORF4 and the MORF-related genes on chromosome X and 15, MRGX and MRG15, repress 
transcription. Furthermore, repression by MRG 15 requires association with the mSIN3A HID 
region (Yochum and Ayer 2002). Experiments using AESI (a TLE-like protein thought to 
function as a dominant negative by disrupting functional TLE tetramers (Chen et al. 1998; Chen 
and Courey 2000)) suggest that repression by MRG15 also requires interaction with TLE1 
(Yochum and Ayer 2002). Interestingly, MORF4, MRG15, and MRGX associate with mSIN3A 
while neither MORF4 nor MRGX associates with Pfl (Y ochum and Ayer 2002). 
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The observation that MRG 15 and MRGX are transcription repressors somewhat contradicts 
previous independent observations that MRG 15 and MRGX actually activate transcription 
(Leung et al. 2001; Pardo et al. 2002). These divergent conclusions were clarified by the recent 
demonstration that MRGX acts both as an activator and as a repressor of transcription in a cell 
line-dependent manner (Tominaga et al. 2003). 
As a concluding remark of interest, the association of MORFs with the mSIN3/HDAC 
complex may account for the HDAC-independent repression activity of RBPI and BCAA RI 
region but also the senescence phenotype associated with expression ofRBPl proteins. 
So, the mSIN3A/HDACl complex is indeed very intricate. In addition to a handful of core 
subunits, an increasing number of factors are found to associate with the mSIN3A/HDACl 
complex. Severa! of those factors have been shown to be regulated by phospholipid signalling 
events and their functions range from transcription regulation, chromatin remodelling, DNA 
damage response, and induction of senescence. It is more and more evident that the 
mSIN3A/HDACl complex is a versatile tool used by a variety of factors to respond to and to 
control cellular events by regulating transcription. 
1.7 SUMOylation 
The small ubiquitin-like modifier protein SUMO was first identified by five independent 
groups between 1996 and 1997. It was found in association with RAD511RAD52 as a novel 
protein in the RAD511RAD52-dependent DNA repair pathway (Shen et al. 1996). SUMO was 
also found to provide protection from anti-Fas/APO-l and TNF-induced cell death and to 
interact with Fas/APO-l and TNF receptor 1 (Okura et al. 1996). Another group reported SUMO 
as the first nuclear body-associated protein that associates with PML (Boddy et al. 1996). 
Finally, SUMO was also found to be covalently linked to RanGAPl and to regulate its 
association with the nuclear pore complex (Matunis et al. 1996; Mahajan et al. 1997). From the 
very beginning it was obvious that SUMO had diverse biological functions. 
Post-translational modification by SUMO has recently been shown to be linked to negative 
regulation of a growing number of transcription factors, including c-jun and p53 (Müller et al. 
2000), androgen receptor (Poukka et al. 2000), c-Myb (Bies et al. 2002), AP-2 (Eloranta and 
Hurst 2002), Sp3 (Ross et al. 2002), and p300 (Girdwood et al. 2003), and to increase 
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transcriptional activity of p53 (Gostissa et al. 1999; Rodriguez et al. 1999). It can also either 
enhance repression by transcription repressors, inc1uding HDACI (David et al. 2002), Ikaros 
(Gomez-del Arco et al. 2005), RBPI and BCAA (Binda et al. 2006), p66 (Gong et al. 2006), N-
CoR (Tiefenbach et al. 2006) or even prevent repression mediated by Dnmt3A (Ling et al. 
2004), MBDI (Lyst et al. 2006), and SIPI (Long et al. 2005). SUMOylation of transcription 
factors seems to have a "personalized" effect on their functions. 
In humans there are four SUMO proteins, SUMO-l, -2, -3, and -4. The activated forms of 
SUMO-2 and -3 differ by only three residues at the amino terminus and are 50% identical to 
SUMO-l, whereas, SUMO-4 differs from SUMO-2/3 by ten residues and cannot be processed to 
its active carboxy terminal di-glycine form due to proline P90 (Owerbach et al. 2005), which is a 
conserved glutamine in SUMO-l, -2, and -3. The majority of SUMO-1 is conjugated to 
substrates whereas SUMO-2/3 have a larger pool of free unconjugated forms, which rapidly 
become conjugated in response to stresses (heat shock, osmotic and oxidative stresses) (Saitoh 
and Hinchey 2000). 
Conjugation of SUMO to its target occurs on a lysine residue found generally within the 
consensus sequence lJ'-Lys-x-Glu (lJ'KxE) (where "lJ''' is a large hydrophobic amino acid and 
"x" is any residue) (Rodriguez et al. 2001; Sampson et al. 2001). In addition to modulating 
transcriptional activity, SUMOylation is involved in functionally altering protein-protein 
interactions, cellular localization and enzymatic activity. SUMOylation of non-consensus lysine 
residues does also occur but seems to be atypical. Indeed, BZLFI (Adamson and Kenney 2001), 
CENP-C (Chung et al. 2004), histone H4 (Shiio and Eisenman 2003), PCNA (Hoege et al. 
2002), PML (Kamitani et al. 1998), Smad4 (Lin et al. 2003), and TEL (Chakrabarti et al. 2000) 
have been reported to be SUMOylated on lysine residues outside of their lJ'KxE site. Moreover, 
some proteins such as Daxx (Jang et al. 2002) and MDM2 (Miyauchi et al. 2002; Xirodimas et 
al. 2002) do not have a lJ'KxE site at aIl. Since the E2 ligase UBC9 mediates the recognition of 
the lJ'KxE site, in vivo SUMOylation of non-consensus lysine is probably facilitated by the 
action of an E3 ligase that bridges the E2 ligase and the target protein. 
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Figure 1.7: SUMOylation pathway. 
Prior to post-translational modification by the small ubiquitin-like factors, SUMO proteins need 
to be activated by cleavage of the two carboxy terminal glycine residues by SENPI. The 
activated SUMO is covalently linked to the El ligase SAE1, transferred to the E2 ligase UBC9 
and finally with the help of an accessory E3 ligase such as PIAS 1, the \}IKxE-containing target 
protein is modified. The SUMO moiety can be removed by a SUMO-specifie protease such as 
SuPr-l and "recycled". 
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1.7.1 SUMO Conjugation Pathway 
A simplyfied depiction of the SUMOylation pathway is given in Figure 1.7 and is reviewed 
in (Gill 2004; Johnson 2004; Hay 2005). First, the SUMO proteins are expressed as precursors, 
which are then processed to their active form by SUMO-specific proteases that are also involved 
in deconjugating SUMO from modified substrates. SUMO proteins are activated by cleavage of 
a peptidic bond to reveal a carboxy terminal di-glycine. Subsequently, the El activating 
heterodimeric enzyme SAEl/SAE2 catalyses adenylation of SUMO, which is covalently linked 
to AMP by its carboxy-terminal carboxyl group. SUMO is then transferred to SAE2 by breakage 
of the SUMO-AMP linkage and formation of a thioester bond on the sulphydryl group of 
cysteine 173. The second step of SUMOylation involves the transfer of SUMO to the E2 ligase 
UBC9 by transesterification from SAE2 to UBC9 cysteine 93. Being able to directly recognize 
the \f'KxE consensus, UBC9, unlike other conjugating enzymes, can catalyze the formation of an 
iso-peptide bond between the C-terminal carboxyl group of SUMO and the f:-amino group of the 
substrate lysine. Although they are capable of enhancing SUMOylation, E3 ligases are not 
required in vitro. In higher eukaryotes, one of the most studied families of SUMO E3 ligases are 
the protein inhibitor of STAT (PIAS) proteins (PIASl, PIASxa, PIASxP, PIASy, and PIAS3). 
Other proteins, such as the polycomb group protein Pc2 (Kagey et al. 2003), have recently been 
shown to have E3 ligase activity, thereby linking SUMOylation to epigenetic events. 
1.7.2 Transcriptional Regulation Through SUMOylation 
An ever increasing number of transcription factors have been reported to be SUMOylated, 
thus making this post-translational modification virtually ubiquitous. SUMOylation generally 
leads to inhibition of transcriptional activity and/or transcriptional repression. One potential 
mechanism that was recently proposed involves the recruitment of HDACs to a modified 
transcription factor, such as p300 SUMO-dependent association with HDAC6 (Girdwood et al. 
2003), and recruitment of HDAC2 to SUMOylated Elk-l (Yang and Sharrocks 2004). This 
oversimplified mechanism is unfortunately not univers al. For instance, SUMOylation of 
Dnmt3A actually prevents association with HDACI/2 (Ling et al. 2004). Furthermore, HDACI 
and HDAC4 are themse1ves SUMOylated, with different outcomes. SUMOylation ofHDAC4, a 
~. class II HDAC, is necessary for its nuclear import (Kirsh et al. 2002), thereby indirectly 
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modulating its repression activity, whereas, SUMOylation ofHDAC1 appears to be required for 
strong transcriptional repression without affecting its cellular localization or association with 
mSIN3A (David et al. 2002). Another possible mechanism involves the recruitment of UBC9 by 
a transcription factor and subsequent SUMOylation of the transcription factor and the histones in 
the vicinity of the promoter allowing recruitment of transcription silencing factors (Nathan et al. 
2003). 
In conclusion, there are multiple SUMO-dependent mechanisms that modulate transcription 
and these may involve differential protein-protein and protein-DNA interactions between the 
SUMOylated transcription factor versus its unmodified form. Interestingly, a handful ofpotential 
SUMO-binding motifs have been proposed to mediate association, not modification, of short 
sequences to SUMO (Minty et al. 2000; Song et al. 2004; Hannich et al. 2005; Song et al. 2005; 
Hecker et al. 2006). The fact that those motifs are divergent suggests that SUMO could mediate 
multiple specific interactions and would explain the different outcomes of SUMOylation. 
1.7.3 SUMOylation Other Functions 
SUMOylation not only regulates transcriptional events but also other cellular processes such 
as protein degradation, cellular localization, and DNA-binding affinity. The SUMOylation of 
IKBa prevents its ubiquitination and subsequent degradation (Desterro et al. 1998). 
SUMOylation of TEL (Chakrabarti et al. 2000) and of HIPK2 (Kim et al. 1999b) allows their 
localization to nuc1ear dots, whereas SUMOylated c-Myb localizes to the cytoplasm (Morita et 
al. 2005). SUMOylation of RanGAPl allows the interaction with RanBP2 to occur (Mahajan et 
al. 1997). The SUMOylation of HSF2 (Anckar et al. 2006), Sox2 (Tsuruzoe et al. 2006), TDG 
(Steinacher and Schar 2005) and TFIID subunit hsTAF5 (Boyer-Guittaut et al. 2005) hinders 
their DNA-binding activity while it can also increase DNA-binding affinity of NF-E2 (Shyu et 
al. 2005) and HSF2 (Goodson et al. 2001). 
Interestingly, SUMOylation has, more often then not, an opposite effect on cellular functions, 
depending which protein is modified, suggesting a context-dependent effect of SUMOylation 
rather than a mechanism of action applicable to every substrate. 
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1.8 RNA pol II Mediated Transcription 
RNA polymerase II-dependent transcription necessitates two classes of factors, the general 
transcription factors, or GTFs, and the activators. The GTFs are nucleated at the core promoter 
by the TATAA box binding protein TBP. For their part, the activators are found in the vicinity 
and facilitate the fonnation of the pre-initiation complex (PIC) by interacting with the GTFs 
and/or by modifying/remodelling nucleosomes. This section is aimed to bring general knowledge 
on transcription and grossly differentiate between basal and activated transcription as the HDAC-
independent repression domains of RBP 1 and BCAA regulate transcription at both levels. 
Excellent reviews of the field are available (Carey 1998; Smale 2001; Smale and Kadonaga 
2003; Kadonaga 2004; Komberg 2005; Workman 2006). 
1.8.1 Basal Transcription 
Eukaryote RNA pol II promoters have a disparate architecture but are systematically 
recognized one way or another by the TA T AA box binding factor TBP, which nucleates the 
assembly of the pre-initiation complex (PIC). Other general transcription factors (GTF) are then 
recruited to the promoter to stabilize TBP-DNA association. The sequence of assembly of the 
GTFs around TBP is precisely orchestrated. First, the TFIID subunit TBP binds to the T AT AA 
motif, inducing a sharp bend in DNA. Then, TF lIB stabilizes TFIID at the promoter by 
contacting TFIID and sequences (TFIIB recognition element - BRE) adjacent to the TATAA 
box. An helix-tum-helix motif at the C-tenn of TF lIB mediates the recognition of the BRE. The 
RNA pol II containing TFIIF complex is subsequently recruited, followed by TFIIH and TFIIE, 
which stimulates TFIIH kinase activity involved in the transition from initiation to elongation. 
TFIIH is a DNA-dependent ATPase, ATP-dependent helicase and CTD kinase (Cdk7/cyclin H). 
The helicase activity of TFIIH is involved in the melting of the promoter, while its kinase 
activity mediates the phosphorylation of RNA pol II. The latter is the largest subunit of TFIIF 
and contains a carboxy-tenninal repeat domain (52 heptapeptide repeats), which is involved in 
the phosphorylation-dependent regulation of RNA pol II. The hypophosphorylated fonn of CTD 
is found in the initiation complex, whereas the hyperphosphorylated fonn is found in the 
elongation complex. The Mediator complex contains over 25 proteins and is involved in the rate 
of preinitiation complex fonnation and reinitiation. Mediator associates with the 
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hypophosphorylated form of RNA pol II and stimulates CTD phosphorylation by TFIIH in vitro, 
providing a switch between initiation and elongation. 
Once the PIC is formed at the promoter, the TFIIH helicase activity induces melting of the 
promoter and creation of a 12-15bp single-stranded DNA bubble. This is known as the open 
complex formation. Then, a few phosphodiester bonds are formed and typically the RNA 
polymerase initiates transcription and releases small RNAs repeatedly in a step known as 
abortive initiation, which is followed by the generation of longer a RNA and promoter clearance. 
After that RNA pol II pauses 25-30bp from start site where the transition to the elongation 
complex occurs and results in the promoter escape. For further details on the elongation phase of 
transcription see the following reviews (Sims et al. 2004; Eissenberg and Shilatifard 2006; 
Saunders et al. 2006). 
1.8.2 Activated Transcription 
The GTFs are essential for transcription, but for high level of expression and regulated timely 
activation of genes, other transcription factors are required. These can act in various ways such 
as facilitating PIC assembly, PIC reassembly, histone modification to losen DNA compaction, 
and nucleosome remodelling to reposition histones. 
Many transcriptional activation domains have been shown to interact with components of the 
basal transcriptional machinery and this function correlates with their ability to activate 
transcription. The transcriptional activator E2F1 provides an example of how these factors 
function. E2F1 transactivation relies on physical association between its acidic TAD and the 
TATA-box binding protein (TBP) and TFIIH GTFs (Pearson and Greenblatt 1997). TFIIH has 
cyclin-dependent protein kinase activity that phosphorylates the CTD of the largest subunit of 
RNA polymerase II. Therefore, E2F1 may assist the transition from transcription initiation to 
elongation by contacting TFIIH (Blau et al. 1996). E2F1 may also influence an early step in the 
assembly of the initiation complex by recruiting TBP, thereby facilitating nucleation of the PIC. 
E2F1 also associates with the p3001CBP, GCN5/PCAF, and Tip60 HATs. This association leads 
to hyperacetylation of histones H3 and H4 at target promoters in vivo and transcriptional activity 
in late G1 following mitogenic stimulation (Taubert et al. 2004). 
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1.9 Thesis ProposaI 
In the present thesis, l have continued studies initiated in the laboratory of Dr Philip Branton 
leading to the identification of transcriptional repression activities in the pRB associated protein, 
RBPI (Lai et al. 1999a; Lai et al. 1999b; Lai et al. 2001). Commencing my studies, an RBPl-
related protein, termed BCAA, was reported. Because of the similarities between RBP 1 and 
BCAA, we decided to take advantage of the sequence homologies and further characterize the 
regulation of their repression activities. l have organized the results l have obtained during the 
course of my PhD degree into four logical chapters. The first chapter relates to the cloning of 
BCAA cDNAs, the initial characterization of BCAA transcriptional repression activities, and 
comparative studies on the pRB-binding properties of RBP 1 and BCAA. The second chapter 
focuses on the regulation of the RI region by SUMOylation. The third chapter describes how the 
HDAC-dependent repression domain, R2, is regulated by the longevity factor SIRTl. Finally, the 
fifth chapter incorporates these transcriptional repression activities in the perspective of the 
growth inhibition and induction of senescence phenotypes associated with the over-expression of 
RBPI and BCAA. l will describe within this thesis how the transcriptional repression activities 
of the RBPI family are regulated and how these in tum, negatively regulate cellular proliferation. 
56 
"] da nat knaw what ] may appear ta the 
warld; but ta myself] seem ta have been anly a 
bay playing an the seashare, and diverting 
myself in naw and then fin ding a smaather 
pebble ar a prettier sheU than ardinary, whilst 
the great acean af truth lay aU undiscavered 
befare me. " 
-Isaac Newton, c. 1725 
Chapter Two: Cloning and Characterization of BCAA cDNAs 
2.1 Introduction 
Initially, the observation that BCAA protein sequence was highly similar to RBPI but lacked 
an LxCxE motif triggered a lot of interest. Functionally, BCAA could theoretically associate 
with the same repression complexes as RBP l, but could not target those to pRB because of its 
lack of an LxCxE motif, therefore acting as a dominant negative towards pRB-related RBP 1 
functions. Efforts were therefore focused on isolating a BCAA full-Iength cDNA, which was not 
available commercially or from other research groups at the time. As the cloning procedures 
progressed, initial comparative characterization of transcriptional repression properties was 
conducted. In parallel, due to the original identification of RBPI as a pRB-associated protein, 
pRB-binding capabilities of BCAA were probed. This chapter describes the isolation of breast 
carcinoma specific BCAA cDNAs, which encode aberrantly truncated mutant forms of BCAA, 
termed BCAAMCF-7• As previously described for RBPI, BCAA was found to also contain two 
independent transcription repression activities, an HDAC-independent (RI) and an HDAC-
dependent (R2) repression domain. The HDAC-dependent domain was able to associate directly 
with the mSIN3A complex subunit SAP30, suggesting utilisation of an identical mechanism of 
repression between RBPI and BCAA. The BCAA MCF-7 isoforms were defective for HDAC-
dependent repression activity and for association with SAP30, confirming their truncation status 
and the absence of R2. Association between RBPI proteins and pRB was shown to require an 
intact LxCxE pRB-binding motif as BCAA could not associate with pRB whereas an LxCxE 
insertion mutant permitted strong pRB-specific binding. The regulation of BCAA expression was 
also investigated. As discussed above, BCAA was first identified as an overexpressed breast 
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carcinoma specifie antigen. A number of tumour suppressors are epigenetically silenced in 
cancer (Esteller 2006; Feinberg et al. 2006; Ting et al. 2006) and this observation prompted us to 
initiate BCAA promoter studies. BCAA expression is driven by a powerful promoter, which has 
numerous putative transcription factor sites and CpG islands. Unfortunately, due to a number of 
other competing interests, full characterization of the BCAA promoter was not completed. 
2.2 Results 
2.2.1 Cloning OfBCAA cDNAs From MCF-7 
The MCF-7 breast carcinoma cellline was used as a source of RNA for the cloning of BCAA 
because it was shown to over-express its mRNA (Cao et al. 1999; Cao et al. 2001). The two 
known major isoforms (as predicted in GeneBank) of BCAA were cloned by reverse 
transcription coupled to PCR amplification of the specifie sequences co ding for BCAA. The 
cDNA of the longest isoform is 3939bp long, including the AUG and the stop codon. The 
shortest isoform appears to be a splice variant lacking a portion of a region predicted to be a 
ChrOMo domain (according to the data available from Genebank and as confirmed by 
sequencing ofthe isolated cDNAs). These two isoforms were cloned (Figure 2.1A) and inserted 
into the pcDNA3.1 mammalian expression vector in frame with an HA tag for easier detection of 
BCAA. When transfected and over-expressed in cells, these BCAA isoforms isolated from the 
MCF-7 cell line appeared to migrate extensively faster than predicted when analysed by 
denaturing polyacrylamide gel el ectrophoresis. According to the size of the protein predicted 
from the cDNA, BCAA should have been observed as a ~ 150kDa protein, but was observed as a 
100kDa species (Figure 2.lB). This observation was a major concem at the time, so the cDNAs 
were isolated again from fresh material. This time (as well as the subsequent attempts), BCAA 
isolated from MCF-7 also migrated as a 100kDa species. This observation was confirmed in a 
recent report (Cui et al. 2004). These results imply that the breast carcinoma cell line MCF-7 
expresses aberrantly truncated forms of BCAA and thus suggest that BCAA could be a tumour 
suppressor or that the truncated forms act as oncoproteins. These possibilities were indeed 
insinuated by the results from a recent publication in which it is shown that down-regulation of 
BCAAMCF-7 leads to inhibition of cellular proliferation (Yang et al. 2006). Interestingly, the 
wild-type BCAA isoform (Fleischer et al. 2003) used in the work constituting this thesis 
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migrates as a ~200kDa species instead of the predicted ~150kDa, suggesting that BCAA may be 
heavily post-translationally modified much like RBP1 (Fattaey et al. 1993). 
59 
Figure 2.1: BCAAMCF-7 cDNAs encode truncated peptides. 
A) Two splice isofonns of BCAA were isolated from MCF-7 cellline total RNA extracts. The 
fast migrating band on the agarose gel represents a splice variant of BCAA, which lacks a portion 
of the ChrOMo domain. B) Denaturing polyacrylamide gel electrophoresis analysis of proteins 
expressed from BCAA cDNAs. The expressed proteins were probed by immunoblotting using 
anti HA.II mouse monoclonal antibodies. The BCAA MCF-7 v2 isofonn is a ChrOMo domain 
splice variant. The BCAA Origene isofonn was obtained commercially from Origene™. The full-
length protein expressing cDNA of BCAA was provided by Dr. Donald E Ayer (Fleischer et al. 
2003). 
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2.2.2 Mapping Of BCAA Transcriptional Repression Domains 
BCAA is highly similar in amino acid composition to RBP1, which is itself a transcriptional 
repressor. Therefore, the repression activities of BCAA were explored. Two goals were of 
substantial importance: to ask whether BCAA acts as a transcriptional repressor like RBP 1; and 
to exploit the similarity between BCAA and RBP 1 to further characterize the transcriptional 
repression mechanisms employed by RBP1. 
To assess the transcriptional repression properties of BCAA and RBP1 we used the well-
characterized Ga14 system. Expression of the firefly luciferase gene reporter was under the 
control of a viral promo ter (HSV TK) with five upstream regulatory elements for specific 
recognition by the DNA binding domain (DBD) of Ga14, which was fused to the protein of 
interest. As previously demonstrated (Lai et al. 1999b), RBP 1 has little effect on luciferase 
reporter expression when fused only to an HA tag, whereas it significantly repressed luciferase 
expression when fused to the Gal4 DBD (Figure 2.2A). BCAA also displayed similar effects, 
indicating that, like RBP1, it possesses transcriptional repression activity. Figure 2.2B shows that 
in both cases, such activity depended on targeting to the promoter by the Gal4 DBD, as 
repression did not occur at a promoter that lacked the Gal4 DNA consensus sites. 
According to the alignment ofprotein sequences of BCAA and RBP1, represented in Figure 
1.4, considerable homology was detected in the regions of BCAA corresponding to the RI and 
R2 repression domains of RBP1 (Lai et al. 1999a). To determine if these regions are also 
responsible for the repression activity of BCAA, a series of constructs that express the RI and 
R2 regions of each ofthese proteins was prepared. Figure 2.3A shows that the adenovirus E1B-
55K protein, a known transcriptional repressor, considerably reduced luciferase expression, as 
found previously (Yew et al. 1994; Teodoro and Branton 1997). As a negative control, a form of 
RBP1 lacking both the RI and the R2 repression domains was used and it exhibited only very 
mode st repression activity. Full-Iength RBP1 and the individual RI and R2 regions of RBPI 
exhibited significant repression activity (43%, 40%, and 15% luciferase activity, respectively). 
BCAA and its corresponding RI and R2 regions also displayed repression activity at levels 
similar to those seen with RBP1 (35%, 47%, and 16% luciferase activity, respectively). The 
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BCAA MCF-7 isoforrn displayed leve1s of repression activity (47%) comparable to the RI region 
alone. Thus, BCAA appears to have transcriptional repression properties comparable to RBP 1. 
Previous studies had shown that, whereas the RBP 1 R2 repression activity is dependent on 
the association with the mSIN3A1HDAC histone deacetylase complex, the activity of RI is 
independent ofHDACs (Lai et al. 1999a; Lai et al. 2001). To examine this issue with BCAA, the 
repression activities of the corresponding RI and R2 domains of BCAA and RBPI were 
examined in the presence or absence of Trichostatin A (TSA), a known inhibitor of HDAC 
activity. Figure 2.3B shows that whereas repression of the adenovirus major late promoter 
(MLP) by the R2 regions ofboth BCAA and RBPI was considerably relieved by TSA, no effect 
was observed on RI repression activity. Furtherrnore, the repression activity of BCAAMCF-7 
remained unchanged by the addition of TSA, strengthening the idea that it lacks a functional R2 
domain. These results indicated that BCAA and RBP 1 are very similar, each containing both 
HDAC-dependent (R2) and HDAC-independent (RI) repression functions. 
Although we have previously shown that RBPI R2 HDAC-dependent transcriptional 
repression activity is mediated via an association with the mSIN3A1HDAC complex through a 
direct interaction with SAP30, it is uncertain how BCAA does so. We therefore purified His-
tagged SAP30 by metal ion affinity chromatography and GST-tagged R2 regions of BCAA and 
RBPI using glutathione Sepharose. GST alone and GST-Rl were used as negative controls and 
GST-HDACI as a positive control (Zhang et al. 1998b; Lai et al. 2001). In GST-pulldown 
experiments (Figure 2.3C), the RI regions of BCAA and RBPI were not able to associate with 
SAP30, whereas the R2 region of BCAA and RBPI physically interacted with SAP30. 
Furtherrnore, the amino-terrninal half (amino acids 1-120) of SAP30 was necessary and 
sufficient for this interaction; however, the carboxy-terrninal half (amino acids 121-220) did not 
appear to associate with R2. These results confirrned that, as with RBP 1, BCAA associates 
directly with SAP30 in vitro. 
To confirrn the binding of SAP30 to both BCAA and RBPl, and in addition to deterrnine if 
BCAAMCF-7, as predicted, is incapable of such an interaction, we immunoprecipitated Flag-
tagged SAP30 in the presence ofHA-tagged BCAA, RBPl, or BCAAMCF-7. To this end, H1299 
cells were co-transfected with plasmids expressing either Flag alone or Flag-SAP30 with BCAA, 
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RBPl, or BCAAMCF-7. Figure 2.3D shows that Flag alone was unable to co-immunoprecipitate 
neither BCAA nor RBPI. In contrast, Flag-SAP30 co-immunoprecipitated with both BCAA and 
RBPl; however, BCAAMCF-7 was undetectable in SAP30 immunoprecipitates. These results 
confirmed that the R2 region associates with SAP30 and that BCAA MCF-7, lacking the R2 region, 
is unable to form such a protein complex. 
63 
Figure 2.2: Transcriptional repression by RBPI and BCAA. 
(A) Repression assay with a reporter containing Gal4 binding sites. CHû-KI cells were seeded 
at a density of 2xI 05 per 35rnrn plate and transfected the next day with 0.25/-lg pG5 HSV TK luc, 
0.0025/-lg phRL RSV and 0.25/-lg pcDNA3 CMV Gal4 or HA expression plasrnids using 2.5/-lL 
Lipofectarnine (lnvitrogen). After 30 hours the cells were lysed and luciferase activity rneasured. 
(B) Repression assay with a reporter lacking Gal4 binding sites. Studies were perforrned as in 
panel (A) except that the reporters used were pGL3 SV40 luc (no Gal4 DNA binding consensus 
site (GO)) and pGL3 G5 SV40 luc (5 Gal4 DNA binding consensus sites (G5)) instead ofpG5 
HSV TK luc. These experirnents were conducted three tirnes in duplicate and the error bars 
represent the standard devitiations. The insert shows the reporter constructs. 
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Figure 2.3: Mapping of BCAA RI and R2 transcription repression domains. 
(A) Repression assay with a reporter containing Gal4 binding sites. CHO-KI cells were seeded 
at a density of2x105 per 35mm plate and transfected the next day with 0.25~g pG5 HSV TK luc, 
0.0025~g phRL RSV and 0.25~g Gal4-expressing fusion proteins using 2.5~L Lipofectamine 
(Invitrogen). Plasmids expressing Gal4DBD alone, GaI4-EIB-55K, full-iength GaI4-RBPI or 
GaI4-BCAA, GaI4-RI or Ga14-R2 from BCAA and RBPI, or GaI4-BCAAMcF-7 were used. After 
30 h the cells were lysed and luciferase activity measured. (B) Repression assay conducted as in 
panel A) but in the absence or presence of the HDAC inhibitor TSA at 330nM. (C) Direct 
interaction in vitro between affinity purified recombinant GST proteins and His-SAP30. N-120 is 
the His-tagged SAP30 120 amino terminal residues and CIOO is the His-tagged SAP30 100 
carboxy terminal residues. R2 interacts directly with SAP30. 5~g of purified GST- and His-
tagged recombinant proteins were incubated for 2 hours in binding buffer (PBS containing 0.1 % 
NP-40 supplemented with protease inhibitors) then washed six times in binding buffer. The 
proteins bound to the GST-tagged proteins were resolved by SDS-PAGE, transferred to PVDF 
membranes and analysed by anti-His immunoblotting. (D) In vivo association between SAP30 
and BCAA. H1299 cells were co-transfected with empty pCMV-Flag plasmid or pCMV-Flag-
SAP30 and pcDNA3.1 HA-BCAA, HA-BCAAMCF-7, or HA-RBPI. Whole cell protein extracts 
(250~g) were irnrnunoprecipitated with Flag M2 antibody and the immunoprecipitates analysed 
by immunoblotting using the HA. 1 1 antibody. Lanes l, 4, and 7 were loaded with 25 ~g whole 
cell protein extracts (1110 input). 
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2.2.3 The LxCxE-pRB Binding Motifls Required For Association With The Pocket 
As discussed in the introduction, RBP 1 was the first cellular protein to be isolated on the 
basis of its strong association with the viral oncoprotein binding domain of pRB. The most 
outstanding features ofBCAA are its extensive similarity to RBPI and its lack of an LxCxE pRB 
binding motif. We therefore investigated whether BCAA could associate with pRB. 
RBP 1, as its name suggests, was originally cloned on the basis of its pRB pocket interaction 
properties. The pocket region of the pRB family proteins is characterized by its ability to 
associate with a number of viral oncoproteins (as discussed in Chapter One). These proteins all 
have in common a short motif, LxCxE, which confers strong and specifie binding to the pocket. 
A number of cellular proteins, including RBP1, also contain this LxCxE-pocket binding motif. 
The early literature regarding the interaction between pRB and RBPI suggested a requirement 
for the LxCxE motif for proper interaction but also additional sequences. This idea was 
suggested by competition binding studies using either an LxCxE-containing peptide or an E7 
peptide (which is known to make contact with the pocket through both its LxCxE motif and 
additional sequences). Only the E7 peptide was capable of completely abolishing the interaction 
between pRB and RBPI. Moreover, the pRB binding protein RBP2 also retained its ability to 
associate with pRB in the presence of an excess of LxCxE peptide. RBP2 was later found to 
contain an LxCxE-independent pRB-binding region within its carboxy terminus (Kim et al. 
1994) confirming the early assumption that it contained additional sequences that made contact 
withpRB. 
The absence of an LxCxE motif within BCAA raised the issue of whether or not BCAA has 
the capability to associate with pRB. The high protein sequence similarity between RBPI and 
BCAA as well as their re1atively comparable transcriptional repression properties raise the 
possibility that BCAA, lacking an LxCxE motif, could act as a dominant negative towards pRB-
re1ated RBPI functions. Since pRB-LxCxE interactions are dispensable for anti-proliferative 
functions (Dick et al. 2000), over-expression of BCAA should not lead to deregulation of cell 
cycle progression. But, pRB-LxCxE interactions are required to maintain pericentric chromatin 
structure and disruption of those interactions leads to centromere fusions, chromosome 
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missegregation, and genomic instability (Isaac et al. 2006). It is therefore important to study the 
interaction between pRB and the RBPI family members. 
Figure 2.4A shows that RBPI associates solely with the "pocket" region (amino acids 379 to 
792) ofpRB whereas BCAA does not associate with any region ofpRB. AIso, neither RBPI nor 
BCAA could associate with the amino terminal or carboxy terminal regions of pRB, 
demonstrating the specificity of the interaction between RBP 1 and pRB "pocket" region. Figure 
2.4B demonstrates in a domain swap experiment that insertion of an LxCxE motif in BCAA is 
sufficient to confer strong pRB "pocket"-specific binding properties. Two independent LxCxE 
insertion mutants (tLxCxE (2) and tLxCxE (3)) of BCAA were tested and both reconstituted 
strong "pocket" -binding affinity. These data argue that the LxCxE motif is indeed sufficient and 
essential for cellular proteins to interact with pRB "pocket" region. 
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Figure 2.4: RBPI proteins association with pRB. 
(A) RBPI but not BCAA associates with pRB pocket region. H1299 cells were transfected with 
DNA from the indicated expression vectors. The cells were lysed and whole cell protein extracts 
used for immunoprecipitations using anti-M2-Flag agarose (Sigma). (B) LxCxE insertion 
mutation of BCAA reconstitutes strong pRB-specific binding. The BCAA insertional tLxCxE 
mutants were verified by sequencing and two positive clones (no. 2 and no. 3) were tested for 
pRB-binding. The immunoprecipitation experiment was conducted as in panel (A). 
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2.2.4 Cloning Of BCAA Promoter And Evaluation Of Its Activity 
BCAA was first identified as an over-expressed peptide in breast carcinoma. The mechanism 
that results in BCAA over-expression remains unknown. Its regulation could be occuring at the 
transcriptional or translationalleve1s or as a result of lower turnover rate or increased stability of 
the protein. The first approach we undertook was to look at the genomic sequence upstream of 
BCAA locus for a potential promoter since the mRNA level of BCAA was shown by quantitative 
reverse transcription-polymerase chain reaction assay to be e1evated in breast, lung, and ovary 
carcinomas as well as in colon and pancreatic adenocarcinomas (Cao et al. 2001), suggesting that 
it may be regulated transcriptionally. A region spanning 1.5Kbp upstream of the AUG was 
c10ned by PCR. A larger region was not c10ned since there is another gene on the (-) strand. The 
region cloned contains two putative CpG islands as well as a number of putative TF sites (see 
Figure Al and A2). This region was c10ned from genomic DNA ofMRC5 human fibroblasts in a 
promoter-less plasmid upstream of the luciferase gene to allow easy measurement of the putative 
promoter activity by measuring the luciferase enzymatic activity. 
In Figure 2.5A the sequence of the BCAA promoter region cloned is represented. The two 
CpG islands predicted are highlighted in red font. The transcriptional activity of the genomic 
region upstream of the BCAA co ding sequence was assessed in CHO-Kl cells (Figure 2.5B) and 
in MCF-7 cells (Figure 2.5C). In both celllines the whole region c10ned (pGL3 NcoI) had strong 
transcriptional activity, which was comparable to the SV 40 promoter. In contrast, the promoter-
less reporter (pGL3 (-)) exhibited very low activity. De1etion of a 283bp region (Ec1136II) at the 
5' end led to a significant decrease in transcriptional activity in both celllines tested, suggesting 
the presence of positive regulatory elements within this region. Further deletion reconstitutedt 
strong transcriptional activity in CHO-Kl cells and to a lesser extend in MCF-7 cells, suggesting 
that a negative regulatory e1ement(s) lies within the sequence between the Ec1136II and SmaI 
sites. Even the shortest region of the BCAA promo ter (HincII), which left 78bp upstream of the 
AUG, had very strong transcriptional activity in both cell lines tested. This region contains 
numerous potential sites for transcription factors binding (see Figures Al and A2) such as AP-l, 
c-Myc, E2F, and SpI. Interestingly, the activity of the pGL3 HincII luciferase reporter could be 
enhanced by over-expression of the E2Fl TF (data not shown), suggesting that BCAA expression 
f' may be regulated in a cell cyc1e-dependent manner. In addition, six putative ERa sites are 
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predicted (see Figure A2). This observation is quite interesting since RBP 1 was recently shown 
to be regulated at the transcriptionallevel by ERu in an estrogen-dependent manner (Monroe et 
al. 2006) but also because BCAA was itse1f identified as an over-expressed breast carcinoma-
specifie epitope (Cao et al. 1999; Cao et al. 2001) and that breast cancer progression and 
antiestrogen chemotherapy resistance are linked to 10ss of ERu expression (Clarke et al. 2001 b; 
Clarke et al. 2003). Furthermore, 39 out of 60 primary breast cancer tissues showed a strong 
positive staining for BCAA that corre1ates with estrogen receptor (ER) and progesterone receptor 
(PR) leve1s (Cui et al. 2004). 
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Figure 2.5: BCAA promoter cloning and transcriptional activity. 
(A) The human BCAA genomic sequence upstream of the ATG. The CpG Islands were predicted 
using "EMBOSS CpG Plot" from the European Bioinformatics Institute 
(http://www.ebLac.uklemboss/cpgplot/index.html) and are in red. The restriction enzymes used 
to generate the promoter truncations used in panel (B) are framed. (B) BCAA promoter activity in 
CHû-KI cens. cens were transfected with the indicated pGL3 firefly luciferase reporters and 
co-transfected with the renilla co-reporter phRL TKluc for normalization. This experiment was 
conducted at least thrice in duplicate. (C) BCAA promoter activity in MCF-7 cens. This 
experiment was conducted at least twice in duplicate as described in panel (B). 
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r~ 2.3 Material and Methods 
2.3.1 Plasmids and cDNA cloning 
Full-Iength RBPI cDNA was previously described (Lai et al. 1999b). Full-Iength BCAA 
cDNA expressing truncated fonus of the protein were obtained by reverse transcription, using 
SuperScriptII (Invitrogen), of total RNA isolated from MCF-7 breast cancer cellline (ATCC 
HTB-22) with Trizol (Invitrogen), followed by polymerase chain reaction amplification of 
BCAA transcripts. The cDNA expressing the full-Iength BCAA protein was obtained from Dr. 
Donald E. Ayer (Fleischer et al. 2003). The pGL3 SV40 luc (Promega) reporter expressing the 
firefly luciferase gene under the control of the simian virus 40 promo ter was modified by 
insertion of five Gal4 DNA binding consensus sites (G5) from pG5luc (Promega) to generate 
pGL3 G5 SV 40 luc. pG5 TK luc (herpes simplex virus minimal thymidine kinase promoter) has 
been described previously (Lai et al. 1999b). The pG5 MLP luc (adenovirus major late promoter) 
vector was obtained from Promega (pG5Iuc). BCAA promoter was c10ned by PCR from genomic 
DNA extracted from the MRC5 cell line using DNAzol (Invitrogen). The PCR fragment 
~' amplified and the truncations (EcI136II, SmaI, NaeI, EheI, and HincII) were inserted in pGL3 
(Promega) using the SmaI and NcoI restriction sites. 
2.3.2 Celllines and transfection 
The H1299 (ATCC # CRL-5803) and MCF-7 (ATCC # HTB-22) celllines were grown in D-
MEM (Gibco) supplemented with 10% fetal bovine serum (Cansera) lOOU/mL Penicillin G, 
lOOf.lg/mL Streptomycin and 2mM Glutamine (Invitrogen). CHO-Kl Chinese Hamster Ovary 
(ATCC # CCL-61) cells were maintained in Alpha Minimum Essential Medium (Invitrogen) 
supplemented with 10% fetal bovine serum (Cansera), 100U/mL Penicillin G, 100f.lg/mL 
Streptomycin and 2mM Glutamine (Invitrogen). DNA transfections were conducted using 
Lipofectamine (Invitrogen) or DMRIE-C (Invitrogen) according to the manufacturer 
recommendations. 
2.3.3 Luciferase activity assays 
Transcriptional repression assays were conducted by co-transfection of plasmids expressing 
firefly luciferase, renilla luciferase to allow nonualization of transfection efficiency and other 
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plasmid when specified. The cells were rinsed once with PBS then lysed with 500!-lL IX passive 
lysis buffer (Promega). A 20!-lL aliquot of each sample lysate was used for measurement of 
luciferase activity by Dual-Luciferase Assay (Promega) on a Lumat LB 9507 (Berthold 
Technologies) luminometer. The activity was normalized for transfection efficiency against the 
renilla luciferase activity. 
2.4 Discussion 
The CUITent chapter described the isolation of cDNAs coding for the RBP1-like protein, 
BCAA and the functional characterization of the protein products encoded by these BCAA 
cDNAs. Unexpectedly, these cDNAs isolated from the MCF-7 breast carcinoma celI line 
encodes aberrantly truncated proteins lacking the carboxy terminal half. These cDNA isoforms 
may have arisen from chromosomal rearrangements (often associated with cellular 
transformation) and/or mutation due to defective DNA repair machinery (as seen in the cases of 
BRCAA1, p53, etc.). Preliminary sequence analysis of the cDNAs revealed that the BCAAMCF-7 
isoforms are full-Iength and identical to the published sequences in the GeneBank repository, 
/~ suggesting that these cDNAs did not originate from chromosomal rearrangement such as 
observed with chromos omal translocations involving RARa in acute promyelocytic leukemia 
(APL) for example (Lin et al. 2001; Pandolfi 2001). Sequence analysis pointed to a short region 
adjacent to the ChrOMo domain, roughly 100bp towards the 3'-end of the gene, in which an out 
of frame, single base pair deletion was found. This mutation would lead to premature termination 
of translation shortly thereafter and to the expression of a truncated peptide of predicted 
molecular mass averaging 100kDa, which is exactly what was observed experimentally (see 
Figure 1.1, panel B, fourth and fifth lanes). Because of the presumed cellular growth regulatory 
functions of RBP1 via the pRB tumour suppressor, it was hypothesised that BCAA or its 
truncated forms, which lack the LxCxE pRB-binding motif, might act to negatively regulate in a 
dominant negative manner pRB-related RBP1 functions. Thus BCAA functions were extensively 
characterized and compared to those ofRBPl. 
It was observed that BCAA could repress transcription as efficiently as RBP1 when tethered 
to an artificial promoter containing Ga14 DNA-binding elements. Moreover, the regions of 
BCAA corresponding to the HDAC-independent (RI) and the HDAC-dependent (R2) repression 
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r--. domains of RBPI had the potential to strongly repress transcription to a similar extent as the 
RBPI RI and R2 domains. Furthermore, the R2 region of BCAA demonstrated transcriptional 
repression in an HDAC-dependent manner when assessed in the presence of the well 
characterized HDAC inhibitor Trichostatin A, whereas the repression activity of its RI region 
was refractory to such treatment, suggesting that RBPI and BCAA RI and R2 regions repress 
transcription via similar mechanisms. The R2 domain of RBPI was previously shown to recruit 
the mSIN3A/HDACl complex via a direct protein-protein interaction with the complex subunit 
SAP30. By showing that the BCAA R2 domain is also able to associate with the SAP30 subunit, 
1 have demonstrated that both R2 domains operate by docking with the SAP30 protein to recruit 
the same histone modifying mSIN3A/HDACl enzymatic complex. Of note is the fact that the 
BCAA MCF-7 isoforms failed to associate with SAP30 and possessed only HDAC-independent 
transcriptional repression activity. It is therefore possible that the aberrant BCAA isoforms could 
function to deregulate as yet unindentified functions of BCAA/RBPI relying on the amino 
terminal half of the proteins. These may inc1ude, but are not restricted to, protein-DNA 
interactions mediated by the ARID region or protein-protein interactions mediated by the Tudor 
or ChrOMo domains, which could potentially bind to histone tails as observed with other 
proteins such as HP 1. It is also possible that these truncated isoforms are the only BCAA 
proteins present in MCF-7 cells, in which case they would be expected to be defective in growth 
regulation (see more in Chapter Five). 
Since RBP 1 was originally identified as a pRB-binding protein, 1 was interested in finding 
out whether or not BCAA could also associate with pRB, especially since both RBPI and BCAA 
appeared to be quite similar functionally. Three regions of pRB covering the entire protein were 
tested for their ability to interact with BCAA and RBPl. Only the "pocket" region ofpRB could 
associate with RBPI whereas none of the recombinant proteins tested could associate with 
BCAA. Although RBP 1 and BCAA were recently shown to associate with each other in 
immuno-complexes, BCAA was not detected in pRB immuno-complexes, suggesting that RBP 1 
may be involved in BCAA-independent complexes, at least in the context of its proposed pRB-
related functions. Because both RBP 1 and BCAA are found in association with the 
mSIN3A/HDACl complex, and BCAA cannot form immuno-complexes with pRB, over-
expression of this breast carcinoma antigen may lead to aberrant regulation of pRB by RBPI. 
Interestingly, down-regulation of BCAA expression by use of siRNA was recently shown to 
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correlate with inhibition of cellular proliferation in MCF-7 cells (Yang et al. 2006), suggesting 
that BCAA MCF-7 rnay indeed have oncogenic properties in sorne instances, thus validating the 
assurnption that BCAA or its truncated BCAA MCF-7 forms could impair RBPI anti-proliferative 
activity. 
As its narne irnplies, BCAA was identified as an over-expressed protein in breast carcinorna 
cells, but BCAA rnRNA was also was found to be elevated in breast, lung, and ovary carcinornas 
as weIl as in colon and pancreatic adenocarcinornas, suggesting that BCAA expression rnay be 
deregulated at the transcriptional level. 1 was therefore curious to investigate how high levels of 
BCAA rnRNA were achieved in breast carcinorna and how its expression was regulated. It was 
observed that the genornic region upstrearn of BCAA is G/C-rich and has two putative CpG 
islands. The latter can be rnethylated by DNA-rnethyltransferases, which rnay be involved in the 
recruitrnent of transcriptional regulators and epigenetic silencing. Thus, as an initial step towards 
a better understanding of the rnechanisrn of BCAA transcriptional regulation, the BCAA promo ter 
was cloned frorn "normal" hum an genornic DNA. 1 was able to dernonstrate that the genornic 
region upstrearn of BCAA could rnediate strong transcriptional activity in a variety of celllines, 
suggesting that this region rnay serve as a prornoter for BCAA expression. The increased level of 
BCAA rnRNA in gastric carcinorna (Cui et al. 2005) as weIl as in breast cancer specimens (Cui et 
al. 2004) rnay indicate that the BCAA prornoter is transcriptionally rnisregulated. Furthermore, 
the presence of CpG islands within BCAA prornoter could be responsible for this upregulation of 
BCAA expression. It is generally accepted that the prornoters of sorne genes are hypermethylated 
in cancer, but, notably, on the genornic scale, the DNA is found to actually be hypornethylated, 
thus resulting in the transcriptional activation of certain genes and in genornic instability (Ehrlich 
2002; Wilson et al. 2007). In conjunction with the observations described within this thesis, the 
over-expression of a transcriptional repressor such as BCAA could eventually lead to the 
silencing of turnour suppressors (such as INGI and pJ30, which are regulated by the 
rnSIN3NHDACl cornplex (Dannenberg et al. 2005)) and under sorne genetic contexts lead to 
turnour progression instead of cell growth inhibition induced by BCAA. For exarnple, p33 INGlb 
can induce cell growth inhibition independently of p53, and so in a p53-1- background, loss of 
p33 INGlb expression could lead to failure by the cell to stop proliferating in response to DNA 
damage. 
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"If excessive smoking actually plays a role in 
the production of lung cancer, if seems ta be a 
. " mmor one. 
Dr. W.C. Heuper, National Cancer Institute to 
the New York Times, April 14, 1954 
Chapter Three: SUMO-Dependent Transcriptional Repression Properties of 
The RBPI Family 
3.1 Introduction 
In this Chapter experiments are focused on the mapping and characterization of the 
transcriptional repression activity associated with the RI region. Unlike the R2 domain, the RI 
domain represses transcription via an HDAC-independent mechanism as highlighted by its 
refractory response of its transcriptional repression activity to the known (Finnin et al. 1999) 
inhibitor of zinc-dependent histone deacetylases (class land class II), Trichostatin A. Different 
/- approaches have been exploited in the past in an attempt to identify the mechanism of 
transcriptional repression of RI. There are a number of logical possibilities including enzymatic 
activities that were thought to contribute to RI-mediated repression. One such enzyme, is the 
DNA methyltransferase DNMTI, which can participate in the repression of E2F-dependent 
transcription by forming a multi-proteins complex with pRB and HDACI (Robertson et al. 2000; 
Pradhan and Kim 2002; Macaluso et al. 2003). Another is the histone methyltransferase 
SUV39Hl, which is also able to associate with the pRB pocket and modulate its transcriptional 
repression activity (Nielsen et al. 2001; Vandel et al. 2001; Macaluso et al. 2003). Because 
RBPI is an LxCxE-dependent pRB-binding protein, it was speculated that the RI region could 
be involved in the recruitment of either DNMTl, SUV39Hl, or both to the pRB pocket and that 
these enzymatic activities involved in transcriptional silencing would account for the HDAC-
independent repression activity of RI, however, in vivo interactions as determined by co-
immunoprecipitation experiments have not been observed between RBPI and DNMTl or 
SUV39Hl. Nonetheless, it was observed very early in studies by our group that the integrity of 
the carboxy terminal end of RI (residues 398 to 452) was essential for strong transcriptional 
(' repression activity (see (Lai et al. 1999b)), and also that within the region spanning residues 241 
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/"". to 398 resided a weaker transcriptional repression activity (see (Lai et al. 1999b)). These results 
suggested that important sequences reside within the carboxy terminal portion of RI. Indeed, 
three putative SUMOylation sites were unearthed (Roy 2003). The very first account that SUMO 
may be involved in an HDAC-independent mechanism of transcriptional repression is quite 
possibly the report of TEL HLH repression domain, which associates with UBC9 (Chakrabarti et 
al. 1999) and represses transcription in a TSA-insensitive manner (Chakrabarti and Nucifora 
1999), but the role of SUMOylation in transcriptional repression mechanism was established 
only 4 years later by demonstrating that p300 CRDI repression domain was SUMOylated and 
repressed transcription in a SUMO-dependent manner (Girdwood et al. 2003). So, in this 
Chapter the possible role of SUMOylation in the mechanism of transcriptional repression by RI 
was investigated and RI SUMOylation was shown to account for the majority of RI activity. 
3.2 ResuUs 
3.2.1 The R1 Region of BCAA and RBP 1 Represses Both Basal and Activated Transcription 
Although previous studies characterized the mechanism of action of the R2 HDAC-
dependent repression activity of RBPl, little is known about RI and its function. We noted that 
the RI region ofboth RBPI and BCAA was composed of a predicted a-helical region within the 
ARID sequence, and a carboxy-terminal sequence that contained two (BCAA) or three (RBPl) 
predicted SUMOylation sites (see Figure 3.2A). 1 therefore assessed the transcriptional 
repression activities of the intact RI regions as weIl as of de1etion mutants of RI that expressed 
only the predicted a-helical region (RIa) or the region containing the predicted SUMOylation 
sites (RIo) fused to Ga14. AIl polypeptides were expressed at similar high leve1s (data not 
shown). Transcriptional repression activity was measured either using pG5TKluc to observe 
effects on activated transcription or using a reporter construct in which the expression of the 
luciferase gene was sole1y under the control of a TATAA box (pUAS5TATAAluc) to measure 
repression of basal transcription. Figure 3.1 shows that whereas the removal of the carboxy-
terminal RIa portion of RI in both RBPI and BCAA did not affect repression of basal 
transcription (RI vs. Rldla), repression of activated transcription was significantly reduced. 
Furthermore, when constructs expressing only the carboxy-terminal RIa portion were tested, 
r" this region alone was found to repress both activated and basal transcription. These results 
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;--- suggested that the RI transriptional repression domain was actually composed of two activities, 
one associated with RIa within the ARID that repressed only basal transcription, and a second, 
RIa within the carboxy-terminal region of RI that repressed both basal and activated 
transcription. 
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Figure 3.1: Repression of basal and activated transcription by RI. 
Repression activities of the amino- and carboxy-terminal portions of RI of BCAA and RBPI. 
Repression assays were conducted in HI299 cells by transient expression of full-Iength RI, the 
amino-terminal part of RI containing a predicted a-helical region (RI dISigma), and the 
carboxy-terminal region containing putative SUMOylation sites (RI Sigma), using a reporter 
construct pUAS5TATAAluc containing on1y a TATAA box (basal transcription, in black) or the 
pG5TKluc (activated transcription, in white). The experiment was conducted at least five times 
in duplicate and the data was normalized against the expression of the renilla luciferase from the 
co-reporter phRL RSVluc. 
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/~ 3.2.2 The RI Region of BCAA and REPlis SUMOylated and Mediates Repression of A ctivated 
Transcription 
As mentioned ab ove, close inspection of the ammo acid sequence of RI revealed the 
presence of three putative SUMO modification sites in RBPI and two in BCAA within the 
carboxy-terminal region (amino acids 396-448 for BCAA and 399-452 for RBPI) (Figure 3.2A 
bold and underlined), suggesting that repression of activated transcription may be regulated by 
SUMO post-translational modification of RI. 
3.2.2.1 Mutation Of The SUMOylation Sites Abrogates RI-Mediated Transcriptional 
Repression 
Figure 3.2B shows the results of Gal4 repression assays using BCAA and RBPI RI mutants 
in which the lysine residues within the \f'KxE SUMOylation consensus sites (K418 and K444 in 
RBPI and K429 and K440 in BCAA) were converted to arginine (see Figure 3.2B, bottom panel 
for expression levels of the mutants versus wild-type RI). Conversion of the individual lysine 
residues within each consensus site resulted in a partial relief of repression, whereas alteration of 
both lysines aboli shed Rl-associated repression activity (Figure 3.2B). It should be noted that the 
third putative SUMOylation site in RBPI RI (K433, Figure 3.2A) was also mutated, and no 
effect on repression activity was observed (data not shown, indicated by strikethrough, Figure 
3.2A) (Roy 2004). 
3.2.2.2 The SUMO-Specifie Protease SuPr-1 Impairs The Transctiptional Repression Activity 
Of RI 
To obtain further evidence that SUMOylation plays a role in Rl-mediated repression activity, 
Gal4 repression assays were carried out in the presence of over-expressed SUMO-specifie 
protease SuPr-1 (Best et al. 2002; Ross et al. 2002), which deconjugates SUMO from its 
substrate. Figure 3.2C shows that co-expression of SuPr-1 significantly relieved the repression 
associated with RI of both BCAA and RBPI, whereas there was no effect on the HDAC-
dependent repression activity of the R2 domains. In contrast, co-expression of a non-functional 
SuPr-1 catalytic mutant (C466S) had no effect on the repression activity of RI or R2 (data not 
shown). Figure 3.2C (bottom) shows that co-expression of SuPr-1 did not affect the expression 
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/' Ievei of RI. These results confinned a role for SUMOylation events in regulating Rl-rnediated 
transcriptionai repression. 
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Figure 3.2: The RIO' region of RBPI and BeAA is SUMOylated. 
(A) Alignment of the RI regions of RBPI and BCAA. The amino acid sequences of the RI 
regions of RBPI and BCAA are shown and the locations of the putative SUMOylation sites 
(\lfKxE) have been indicated in bold and underlined. The RBPI K433 putative SUMOylation site 
(strikethrough) was found experimentally not to be modified (Roy 2003). (B) Repression by 
RBPI and BCAA RI domains bearing alterations at the putative SUMOylation consensus sites. 
Mutants of RI were prepared by site-directed mutagenesis that converted K4I8 and K444 of 
RBPI and K429 and K440 of BCAA to arginines. The repression assays were conducted as in 
Fig. 3.1. This experiment was conducted at least five times in duplicate and the error bars 
represent the standard deviations. The bottom panel shows representative expression levels of 
GaI4-RBPI RI and GaI4-BCAA RI proteins by western blotting using anti-Gal4 antibodies. (C) 
Effect of the SUMO protease SuPr-1 on repression activity. The repression assays were 
conducted as in Fig. 3.1 using cells co-transfected with RI or R2 of RBPI or BCAA in the 
presence or absence of the SUMO protease SuPr-l. This experiment was conducted at least five 
times in duplicate and the error bars represent the standard devitiations. The bottom panel shows 
representative expression leve1s of GaI4-RBPI and GaI4-BCAA proteins in the absence or 
presence of SuPr-1 by western blotting using anti-GaI4. (D) Analysis of in vivo SUMOylation of 
RBPI and BCAA RI regions by SDS-PAGE and western blotting analysis of 
immunoprecipitates. CHO-KI cells were co-transfected with plasmids expressing GaI4-RI and 
HA-SUMO-I, -2, -3 or -4. Cell extracts were immunoprecipitated with anti-Gal4 antibodies and 
precipitates were resolved by SDS-P AGE and analysed by western blotting using anti-HA or 
anti-Gal4 antibodies, as indicated in the figure. Lane I-GaI4; lane 2-GaI4-RBPI RI wild-type; 
lane 3-GaI4-RBPI RI K418R; lane 4-GaI4-RBPI RI K444R; lane 5-GaI4-RBPI RI 
K4I8R1K444R double mutant; lane 6-GaI4-BCAA RI wild-type; lane 7-GaI4-BCAA RI 
K429R; lane 8-GaI4-BCAA RI K440R; lane 9-GaI4-BCAA RI K429R/K440R double mutant. 
The symbol "*,, represents the singly SUMOylated forms of RI, "**,, the doubly SUMOylated 
forms and "#" an unidentified SUMOylated peptide associated with the BCAA RI region. AIso, 
"a" denotes the doubly SUMOylated form of RBPI RI, "b" a SUMOylated doublet, "c" being 
the faster-migrating species and "d" the slower-migrating species of the doublet "b". The species 
"g" and "h" are the non-SUMOylated forms of RBPI R1. The species "e" is the doubly 
SUMOylated form of BCAA RI and "f' the singly SUMOylated form of BCAA RI. 
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/,,-, 3.2.2.3 The Carboxy Terminus OfRl 1s SUMOylated 
To confinn that these residues were in fact SUMOylated, CHO-KI cells were co-transfected 
with plasmids expressing either wild-type or mutant fonns of Ga14-tagged RI regions of BCAA 
or RBPI, as well as those encoding HA-tagged SUMO-l, -2, -3, or -4. Following 
immunoprecipitation using a Ga14-specific antibody and separation by SDS-PAGE, Ga14-RI 
species were detected by western blotting using anti-Ga14 antibodies and the presence of 
SUMOylated species was confinned by western blotting using anti-HA antibodies. Figure 3.2D 
shows the results obtained with extracts from cells over-expressing HA-SUMO-I. The major 
Ga14-RI species of both BCAA and RBPI detected by anti-Ga14 antibodies were non-
SUMOylated fonns whereas the slower-migrating SUMOylated fonns (Figure 3.2D, bottom 
panel (a-GaI4), species marked by an "*") represented only a small proportion of the population 
of both BCAA and RBPI. Although non-SUMOylated BCAA Gal-RI predominantly migrated 
as a single species, two RBPI Ga14-RI species were evident (Figure 3.2D, bottom panel (a-
Ga14), species marked "g" and "h"), suggesting that two major variants existed, possibly due to 
sorne other post-translational modification. In the case of the SUMOylated fonns, singly or 
doubly modified fonns have been indicated in Figure 3.2D as "*,, and "**", respectively. With 
RBPI, conversion ofindividual acceptor lysine residues K418 and K444 to arginines resulted in 
the disappearance of the slowest-migrating SUMOylated fonn of RI (Figure 3.2D species "a" in 
lane 2), whereas simultaneous conversion of both sites eradicated the singly and the doubly 
SUMOylated species (Figure 3.2D species "a" and "b" in lane 2). The singly SUMOylated fonn 
of wild-type RBPI RI appeared as two major closely migrating species (depicted by a "b" in 
Figure 3.2D lane 2, panel a-HA) and a minor faster-migrating doublet. We noted that the singly 
modified fonn present with the K444R mutant (Figure 3.2D lane 4 species "d") represented the 
slowest-migrating species in this doublet whereas that produced by K418R (Figure 3.2D "c" in 
lane 3) corresponded to the fastest-migrating fonn. Mutation of residues K429 and K440 within 
BCAA resulted in a similar loss of the SUMOylated fonns (Figure 3.2D "e" and "P'). 
Interestingly, a SUMOylated peptide appeared to associate specifically with BCAA RI (depicted 
# in Figure 3.2D), but not with RBPI RI. The identity ofthis species and its importance are not 
known. Similar results were observed with the other SUMO family members SUMO-2, -3, and -
4 (see Appendix), although the SUMOylation process seemed somewhat less efficient than with 
SUMO-I. 
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Taken together, the results in this series of experiments have delineated a region in RI of 
both BCAA and RBPI that exhibits strong repression activity that is highly dependent on 
SUMOylation. 
Silver staining of the Ga14 immunoprecipitates used to identified the above SUMOyiated 
species of RI were not clean enough to allow detection of the unidentified SUMOylated peptide 
(denoted by the symbol "#" in Figure 3.2D). Further purification would have been necessary to 
isolate and identify that SUMOylated peptide by mass spectrometry. Furthermore, the 
importance of the association of BCAA RI with this SUMOylated peptide is dubious since the 
double K429R1K440R mutant that completely failed to repress activated transcription retained 
binding capability to this peptide. Therefore, not knowing the value of the possible identification 
of the peptide, its characterization was put on hold. 
3.2.3 Regulation of RI a SUMOylation 
3.2.3.1 Inhibition of deacetylase activity potentiates RI arepression activity. 
Previous studies on the transcriptional repression activities of RBP 1 proteins showed that the 
HDAC-dependent repression domain R2 was sensitive to the HDAC inhibitor TSA, whereas the 
HDAC-independent repression domain was not only insensitive, but frequently had about a two-
fold increased repression activity (data not shown). 
3.2.3.2 Systematic conversion of RI a lysines to arginines. 
In search of SUMOylation sites within the RIO' region, a number of lysine residues were 
found to be essential for SUMOylation but were not SUMOylated. Figure 3.3A shows the lysine 
residues that were mutated in BCAA RIO' (highlighted in red). The bottom panel shows the 
repression activity associated with each of these mutants. Conversion of lysines K415, K4I8, 
K424, K429, and K440 to arginines resulted in an equivalent partial relief of repression activity 
but only the K429R1K440R double mutant led to complete relief of repression. Furthermore, 
Figure 3.3B shows that these single mutants (K4I5, K4I8, and K424) prevented SUMOylation at 
one \jfKxE site, presumably K440 since concomitant mutation of K440 did not lead to further 
repression activity relief (Figure 3.3A) or to loss of SUMOylation (data not shown). Together, 
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/~~~ these results are compelling and suggest a second level of regulation of RI transcriptional 
repression activity possibly involving acetylation-coupled SUMOylation. 
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Figure 3.3: Regulation of RIa SUMOylation. 
(A) Non-SUMOylated lysine residues in RI affect repression activity. The top panel illustrates 
the RI region ofRBPI and BCAA. The non-SUMOylated lysine residues ofBCAA RI that have 
been mutated to arginine are highlighted in red. The repression assays were conducted using the 
pG5TKluc reporter and the graphic in the bottom panel represents the average of five 
independent experiments done in duplicate. BCAA RI repression is in black and the mutants that 
gave a partial relief of repression are highlighted by diagonal bars. (B) Non-SUMOylated lysine 
residues in RI affect SUMOylation. Immunoprecipitations were conducted as in Figure 3.2. The 
doubly SUMOyiated forms of RI are depicted by "**,, whereas "*,, represents the singly 
SUMOylated forms ofRl. 
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3.2.4 Mapping of the Basal Transcription Repression Activity 
The RI a activity was further dissected by generating a series of truncation mutants. Figure 
3.4B shows that all constructs were expressed at equallevels. Figure 3.4A shows that following 
removal of the carboxy-terminal region of BCAA RI domain, the remaining portion of RI 
(Figure 3.4A SpeI/ ScaI construct) was capable of repressing basal transcription (21 % luciferase 
activity) driven solely by a TATAA box. Analysis of the series of constructs delineated a 
minimal region (residues 316 to 355 in BCAA; RIa) with significant repression activity (33% 
luciferase activity). Based on its amino acid sequence, this region was predicted to contain a 
cyc1in recognition motif embedded in a helix-turn-helix secondary structure. Similar repression 
activity was detected with the RBPI ARID region (data not shown). In summary, and as 
suggested by results shown in Figure 3.1, the RI regions ofboth BCAA and RBPI were found to 
contain two separable repression functions, one capable of repressing both basal and activated 
transcription (RIo') and the other active against basal transcription only (RIa). 
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Figure 3.4: Mapping ofR! basal transcription repression activity. 
Fine mapping of the RI repression actitities. A series of amino- and carboxy-terminal deletions 
in BCAA GaI4-RI was generated and tested in repression assays as conducted previously except 
that the TATAA box-only reporter pUAS5TATAAluc (illustrated in the insert) was used. The 
nature of these BCAA regions, induding the restriction enzymes sites used to generate them and 
the amino acids involved have been illustrated in the figure and the residual luciferase activity 
(%) associated with each have been indicated. Similar studies yielding comparable results have 
also been done with RBPI (data not shown). The bottom panel shows immunoblotting analysis 
using anti-Gal4 antibodies showing the representative protein levels of the truncation mutants 
used. The experiments were conducted at least five times in duplicate and the standard deviations 
are given beside the luciferase activity (% +/- error). 
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3.3 Material and Methods 
3.3.1 Plasmids and site-directed mutagenesis 
The RI truncations used in transcriptional repression assays were constructed by subc10ning 
the various regions into pSG424 vector using the appropriate restriction endonuc1eases. The 
pEBB mammalian vector driving the expression of the SUMO protease SuPr-l and the catalytic 
mutant SuPr-l (C466S) were described elsewhere (Best et al. 2002). pcDNA3 HA-SUMO-l, -2 
and -3 were provided by Dr. Ronald T. Hay (Desterro et al. 1997; Desterro et al. 1998; Tatham 
et al. 2001). pcDNA3 HA-SUMO-4 was constructed from pCMV myc-SUMO-4 which was 
kindly provided by Dr. David Owerbach (Bohren et al. 2004). The HindIII-XbaI fragment 
encompassing Gal4 DBD from pSG424 was inserted into pcDNA3.1 (Invitrogen). The lysine to 
arginine RI mutants were generated by PCR using Pfu turbo (Stratagene) and appropriate 
primers. The PCR products were then sub-c1oned in frame with Gal4 DBD in pcDNA3.1 Ga14. 
AlI the plasmids were sequenced by Génome Québec. 
3.3.2 Celllines, transfections and immunoprecipitations 
CHO-Kl Chinese Hamster Ovary (ATCC CCL-61) cells were maintained in Alpha 
Minimum Essential Medium (Invitrogen) supplemented with 10% fetaI bovine serum (Cansera), 
lOOU/mL Penicillin G, lOO/-lg/mL Streptomycin and 2mM Glutamine (Invitrogen). H1299 non-
small celIlung cancer (ATCC CRL-5803) cells were maintained in Dulbecco's Modified Eagle 
Medium (Invitrogen) supplemented with 10% fetal bovine serum (Cansera), lOOU/mL Penicillin 
G, 100/-lg/mL Streptomycin and 2mM Glutamine (Invitrogen). 
CHO-Kl cells were seeded at a density of 1.5*106 cells per 60mm plate. One hour prior to 
transfection, the cells were infected with vaccinia virus expressing T7 RNA polymerase to 
increase the amount of expressed proteins. The cells were then transfected with 1.5/-lg of 
pcDNA3.1 Ga14-Rl and 1.5/-lg pcDNA3 HA-SUMO-l, -2, -3 or -4 plasmid DNA using DMRIE-
C (Invitrogen). After 24 hours, the adherent and floating cells were collected and lysed in RIPA 
lysis buffer supplemented with protease inhibitors (lmM aprotinin, ImM leupeptin, ImM 
pepstatin A, ImM PMSF and 25mM N-ethylmaleimide). The protein concentration was 
!" determined by the Bradford assay. Whole cell protein extracts (l50/-lg) were incubated with 
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0.51lg of RK5Cl antibody for 30-45 minutes at 4°C with constant mixing. Then, 20llL of a 1:1 
Fast-Flow Protein A agarose (Upstate) slurry were added and the immunoprecipitates were 
further incubated ovemight at 4°C. The samples were washed 4-6 times with ImL RIPA buffer. 
The samples were separated by SDS-PAGE (10% polyacrylamide), and pro teins were transferred 
to PVDF membrane. The membranes were probed by western blotting using mouse monoclonal 
HA.11 antibody (Sigma; 1:1000). The membranes were then stripped with NaOH (O.2M) and 
reprobed with anti-Gal4 RK5Cl antibody (Santa Cruz; 1:500). 
3.4 Discussion 
Transcriptional regulation requires the recruitment of various enzymatic activities to elicit 
proper mRNA expression. These activities can act on general transcription factors, histones, or 
DNA itself. In order to narrow down the possible targets of Rl-mediated transcriptional 
repression, luciferase reporters under the control of either a minimal promoter, containing only a 
TA TAA box (basal transcription), or a strong viral promoter (TK), which can be stimulated by 
transcriptional activators (activated transcription), were used. This system allowed the 
identification of two distinct regions within the RI domain. One, which repressed both basal and 
activated transcription (RIo), and a second that was effective solely at repressing basal 
transcription (RI a,). These results point at two mechanisms of transcriptionai repression, one, 
which would target generai transcription factors, and a second that would antagonize 
transcriptional co-activators. 
We were able to demonstrate that the RIa reglOn represslOn activity is regulated by 
SUMOylation, which in tum may itself be regulated by a second layer of post-translational 
modification such as acetylation. There are two pieces of indirect evidence that suggest that RI 
may also be acetylated and that this post-translational modification may regulated SUMOylation. 
First, conversion of non-SUMO-acceptor lysines within RIa to arginines led to relief of 
transcriptional repression as well as Ioss ofSUMOyiated forms ofRl. Second, in the presence of 
the HDAC inhibitor TSA, Rl-mediated transcriptional repression was systematically enhanced 
by a factor of two-fold. SUMOyiation of transcriptional repressors has in sorne instances been 
shown to elicit the recruitment ofHDAC activity. It is unlikely that SUMOyiation of Ria results 
in HDAC-dependent repression since repression by the RI region is strongly resilient to the 
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effects of histone deacetylase inhibitors. The process of SUMOylation requires the E2 ligase 
Ubc9, which was shown to repress transcription by SUMOylating histone H4 and subsequent 
recruitment of the epigenetic silencer HP1y and HDACl. Therefore the association ofUbc9 and 
RI cr for its own SUMOylation may lead to transcriptional repression in an E2 ligase-dependent 
manner. Altematively, R1cr may repress transcription by a hitherto unknown mechanism. Precise 
details of the process of post-translational modification by ubiquitin-like proteins, such as 
SUMO, are in many cases unresolved and much remains to be discovered. As discussed in the 
introduction, SUMOylation occurs on a wide variety of targets with as nearly as many outcomes 
as there are targets and there does not appear to be a general rule in terms of the role of 
SUMOylation. Because the portion of SUMOylated target relative to the unmodified form is 
generally very low, functional studies on SUMOylation are quite difficult to conduct. However, a 
system was recently developed to investigate the role of SUMOylation by utilizing a 
recombinant form of the protein of interest fused to Ubc9 in order to obtain a significant 
population of SUMOylated target. Such a system could be used to obtain high levels of 
SUMOylated R1cr to allow co-purification of associated proteins and potentially to the 
identification of the factors involved in the mechanism oftranscriptional repression by R1cr. 
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'Tou too were young once, and ignorant once, 
and from a future stand point - perhaps your 
own - you are young and ignorant still. " 
Ken MacLeod, Leaming the world, 2005 
Chapter Four: The R2 Repression Domain Functionaly Associates With Class 
III Histone Deacetylase SIRTI 
Previous studies have shown that both RBPI and the highly related protein BCAA play a role 
in the induction of growth arrest and cellular senescence via mechanisms involving 
transcriptional repression. Eukaryotes possess three classes of histone deacetylases that regulate 
the formation of transcriptionally refractory heterochromatin. The carboxy terminal R2 domain 
ofboth RBPI proteins was previously found to functionally associate via SAP30 with the class l 
HDAC complex mSIN3A1HDACl to repress transcription. This chapter describes the functional 
association of both RBPI family members with the class III HDAC, SIRTl. This association, 
~~ which maps to the R2 region, is restricted to the nuclear sirtuin, SIRTl. Reduction of the 
mSIN3A/HDACl subunit SAP30 by siRNA led to the loss of SIRTI association with RBPI 
family proteins. In vitro and in vivo binding studies indicated that the p33 INGIb and p33 ING2 
subunits of the mSIN3A/HDACI complex are responsible for the recruitment of SIRTI. To 
investigate the biological relevance of this interaction, the sirtuin activator resveratrol and the 
sirtuin inhibitor sirtinol were used in transcriptional repression assays and demonstrated that 
SIRTI activity is detrimental to R2-mediated repression. Therefore a novel mechanism of class l 
HDAC regulation by class III HDAC is proposed. Explicitly, SIRTI activity is recruited by ING 
proteins and inhibits R2-associated mSIN3A1HDACI transcriptional repression activity. 
4.1 Introduction 
Histone deacetylation has a pivotaI role in the regulation of epigenetic events leading to 
transcriptional silencing. A number of processes linked to cell cycle control and tumourigenesis 
appear to be regulated by histone deacetylases, including cell cycle progression, cellular 
differentiation, senescence and apoptosis. Indeed, considerable effort is being focused on 
targeting histone deacetylase activity as part of cancer therapy as a number of tumour 
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suppressors have been reported to be epigenetically silenced in cancer (Baylin et al. 2001; 
Rountree et al. 2001; Minucci and Pelicci 2006). 
Three major classes of histone deacetylases have been characterized thus far (Khochbin et al. 
2001; Thiagalingam et al. 2003). Class l includes the nuclear histone deacetylases HDAC1 
(Taunton et al. 1996), 2 (Inouye and Seto 1994; Yang et al. 1996a), 3 (Yang et al. 1997; 
Emiliani et al. 1998), and 8 (Hu et al. 2000), which are re1ated to the yeast RPD3. Class II 
comprises HDAC4 (Fischle et al. 1999; Grozinger et al. 1999), 5 (Fischle et al. 1999; Grozinger 
et al. 1999), 6 (Fischle et al. 1999; Grozinger et al. 1999), 7 (Kao et al. 2000), 9 (Zhou et al. 
2001), and 10 (Fischer et al. 2002), which are related to yeast HDAI and are localized in the 
cytoplasm until required and shuttled in the nucleus (reviewed in (Verdin et al. 2003; Yang and 
Grégoire 2005)). These two classes share a common mechanism of action and the common 
property of being sensitive to the histone deacetylase inhibitor Trichostatin A (Finnin et al. 
1999). Class III shares homology within its cata1ytic core domain with the yeast NAD+-
dependent histone deacety1ase Silent Information Regu1ator 2 (SIR2) (reviewed in (Blander and 
Guarente 2004)). 
In yeast, SIR2 is involved in the formation of heterochromatic structures at the telomeres 
(Aparicio et al. 1991), silencing of the mating type loci (Klar et al. 1979; Rine et al. 1979; Rine 
and Herskowitz 1987) and inhibition of rDNA recombination (Gottlieb and Esposito 1989). Its 
activity is required in a number of model organisms including yeast (Kaeberlein et al. 1999), 
nematode (Tissenbaum and Guarente 2001), and Drosophila (Rogina and Helfand 2004) for the 
extended lifespan phenotype induced by calorie restriction (reviewed in (Guarente 2005; 
Guarente and Picard 2005; Longo and Kennedy 2006)). In mammals, the SIR2 homologue 
SIRTI is the best charactarized sirtuin. Its activities range from histone deacetylation (Braunstein 
et al. 1993; Irnai et al. 2000; Vaquero et al. 2004; North et al. 2005) and transcriptional silencing 
(Shore et al. 1984; Parsons et al. 2003; Vaquero et al. 2004) to regulation of p53 (Luo et al. 
2001; Vaziri et al. 2001; Langley et al. 2002) and p300 (Bouras et al. 2005) transcriptiona1 
activities. 
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In vitro, SIR2 has no apparent substrate specificity (Blander et al. 2005) suggesting that the 
specificity may not be conferred by the catalytic core domain but rather may actually be 
mediated through other protein-protein interactions with the substrate or an intermediary. 
RBPI and BCAA are transcriptional repressors (Lai et al. I999a; Lai et al. 1999b; Fleischer 
et al. 2003; Binda et al. 2006) found in association with the mSIN3A/HDACl complex (Lai et 
al. 2001; Skowyra et al. 2001; Kuzmichev et al. 2002; Fleischer et al. 2003; Meehan et al. 2004; 
Nikolaev et al. 2004; Doyon et al. 2006b). RBP 1 and BCAA repress transcription in both 
HDAC-independent (RI) and HDAC-dependent (R2) manners (Lai et al. 1999a; Fleischer et al. 
2003; Binda et al. 2006). The HDAC-independent RI repression activity can be further dissected 
into a domain that targets basal transcription (RIa) and one that represses both basal and 
activated transcription (RIa), SUMOylation of which is essential for its repression activities 
(Binda et al. 2006). Both RBPI and BCAA can associate with the mSIN3A/HDACl complex via 
a direct interaction with the SAP30 subunit (Lai et al. 2001; Binda et al. 2006). The region 
responsible for this interaction (R2) mediates HDAC-dependent transcriptional repression (Lai et 
al. 1999a; Lai et al. 1999b; Fleischer et al. 2003; Binda et al. 2006). Over-expression of either of 
these two RBP 1 family members leads to celI growth inhibition and induction of senescence 
(Binda et al. 2006), a phenomenon also attributed to the mSIN3A1HDACl complex subunits 
p33INGlb (Garkavtsev et al. 1996; Garkavtsev and Riabowol 1997) and p33 ING2 (Pedeux et al. 
2005). Induction ofthis phenotype requires the presence of an intact RIa/RIa SUMO-dependent 
as weIl as the R2 HDAC-dependent repression domains (Binda et al. 2006). 
Here we demonstrate for the first time that association of the c1ass III HDAC SIRTI with the 
mSIN3A1HDACl complex bound to the R2 region of RBPI and BCAA proteins alIeviates R2 
transcriptional repression activity. These findings suggest a novel mechanism of regulation of the 
c1ass 1 deacetylase HDACI by the enzymatic activity ofthe c1ass III deacetylase SIRTI. 
4.2 Results 
4.2.1 The R2 region of BCAA and RBP 1 associa tes with SIRT1 
H1299 celIs were transfected with plasmids expressing fulI-length BCAA or RBPI along 
with Flag alone or Flag-SIRTI. Figure 4.lA shows that both RBPI family members associate 
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specifically with SIRTI Flag immunoprecipitates (lanes 3 and 4) but not with the control 
immunoprecipitates (lanes 1 and 2). The latter experiment was then conducted using a panel of 
amino and carboxy terminal deletion mutant forms of RBP 1 and BCAA and weIl as the 
BCAA MCF-7 isoforms to determine which region of RBPI proteins was required for SIRTI 
association. Figure 4.1B shows that the association with SIRTI was dependent on the presence 
of the R2 region, suggesting that SIRTI associates with RBPI proteins through the R2 region. 
For simpler interpretation, the results obtained in Figure 4.lB have been summarized in the 
diagram shown in Figure 4.1 C. 
In mammals, there are seven members in the sirtuin family of proteins. SIRT1, SIRT6 and 
SIRT7 are nuclear whereas SIRT2, SIRT3, SIRT4 and SIRT5 are cytoplasmic, although a small 
pool of nuclear SIRT2 exists (North et al. 2003; Bae et al. 2004) that probably accumulates via 
regulation of its nuclear export (Wilson et al. 2006). To determine if sirtuins other than SIRTI 
associate with RBPI proteins, co-immunoprecipitation experiments were conducted in cells 
transiently expressing either HA-RBPI or HA-BCAA and Flag-SIRTI-7 (Figure 4.1D). As 
expected, the cytoplasmic sirtuins did not co-immunoprecipitate with either BCAA or RBPI. 
However, SIRT4 expression being very low, as reported elsewhere (North et al. 2005), a possible 
interaction could not be neglected. Furthermore, neither SIRT6 nor SIRT7 nuclear sirtuins 
associated with RBPI family members. These results suggested that SIRTI may perform a 
specialized function towards RBPI and BCAA that cannot be compensated by the other nuclear 
sirtuins. In addition, they indicated that the R2 domain ofRBPl family members associates with 
two distinct classes of HDACs, the class 1 present in the mSIN3NHDACl complex and an 
hitherto uncharacterized class I1I-containing complex. 
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Figure 4.1: The R2 region of BCAA and RBPI associates with SIRTI. 
(A) Hl299 cells were co-transfected with plasmids expressing Flag alone or Flag-SIRTI and 
HA-RBPI or HA-BCAA. Whole cell extracts were immunoprecipitated using anti-Flag M2-
agarose and analysed by immunoblotting using either the HA.11 or the anti-Flag M2 antibodies, 
as indicated. (B) Immunoprecipitation and immunoblotting studies were conducted as in panel A 
with the additional expression of the indicated truncated forms of HA-RBP 1 and HA-BCAA. (C) 
A graphical representation of the RBP 1 and BCAA truncated forms used in panel B and their 
relative association with SIRTl. Binding of SIRT to RBPI proteins is indicated by a (+) symbol 
whereas lack of association is depicted by a (-) symbol. (D) Plasmids expressing Flag-tagged 
sirtuins (SIRTI to SIRT7) were co-transfected with those expressing either HA-BCAA or HA-
RBPI and a-Flag immunoprecipitates were resolved by SDS-PAGE and analysed by 
immunoblotting using either the a-HA.II or the a-Flag M2 antibodies, as indicated. 
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4.2.2 SIRTI is recruited ta the RBPI prateins via the ING subunits afthe mSIN3A/HDACl 
camplex 
SIRTI could interact with the R2 region of RBP 1 proteins either directly or indirectly via an 
R2-associated protein such as a subunit of the mSIN3A/HDACl complex. We have shown 
previously that the mSIN3A/HDACl complex is recruited to R2 through a direct interaction with 
the SAP30 subunit (Lai et al. 2001; Binda et al. 2006). Thus, if the SIRTI interaction with R2 
occurs via the mSIN3A/HDACl complex, depletion of SAP30 might reduce the amount of R2-
bound SIRTI. To determine if SIRTI association with the R2 region requires the presence of 
SAP30, the latter was knocked down by RNA interference methods. Figure 4.2 shows that 
treatment with SAP30-specific siRNA significantly reduced the amount of SAP30 protein in the 
cells. In addition, RBPI lost the capacity to associate with SIRTI with decreased levels of 
SAP30. Thus, these observations implied that the interaction between R2 and SIRTI occurs via 
the mSIN3A/HDACI complex as SAP30 is the sole subunit making direct contact with the R2 
region. 
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Figure 4.2: SIRTI is recruited to RBPI via the mSIN3A/HDACl complex. 
H1299 cells were co-transfected with the indicated siRNAs, as described in the Materials and 
Methods section, and a DNA vector expressing HA-RBPl. Anti-HA.ll immunoprecipitates 
from whole cell extracts were resolved by SDS-P AGE and analysed by immunoblotting using a-
HA, a-SIRTl, or a-SAP30 antibodies, as indicated. 
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The tumour suppressor inhibitor of growth protein p33INGlb associates with SIRTI (Kataoka 
et al. 2003) and both p33INGlb and p33 ING2 are found in association with the mSIN3A/HDACl 
complex (Skowyra et al. 2001; Kuzmichev et al. 2002; Doyon et al. 2006b). It is therefore 
plausible that these two ING proteins could bridge SIRTI to the R2 region ofRBPl proteins. To 
confirm that ING pro teins associate with the RBPI proteins, cells were transfected with Flag-
tagged ING pro teins and their ability to interact with RBPI proteins was examined by co-
immunoprecipitation. Figure 4.3A shows that indeed RBPI proteins co-immunoprecipitated with 
both p33INGlb and p33 ING2 whereas, the isoform p24INGl C, which has a distinct and shorter amino 
terminal region, did not. The amino terminal portion is conserved between p33INGlb and p33 ING2 
but is absent from the p24INGlc isoform, therefore strongly suggesting that this region may be 
important for association with the mSIN3A1HDACl complex. These results are in agreement 
with previous studies, which demonstrate that both p33INGlb (Skowyra et al. 2001; Kuzmichev et 
al. 2002) and p33 ING2 (Doyon et al. 2006b) are inherent components of the mSIN3A1HDACl 
complex whereas the p24INGlc isoform cannot form the complex (Skowyra et al. 2001). 
To address whether ING proteins could directly associate with SIRT1, in vitro binding assays 
were conducted with GST, GST-HDACl, and GST-SIRTI affinity purified recombinant 
proteins. Figure 4.3B confirms that LV.T. SAP30 could bind directly to HDACI (Zhang et al. 
1998b). Interestingly, all ING proteins tested were found to bind directly to both HDACI and 
SIRTI. These results were then confirmed in vivo in co-immunoprecipitation studies. Figure 
4.3C shows that both INGI isoforms p24INGlc and p33INGIb associated in vivo with the c1ass l 
deacetylase HDACI and the c1ass III deacetylase SIRTI. In addition, although p33ING2 
expression was lower than that of INGI isoforms, p33 ING2 was also seen to associate with both 
HDACI and SIRTI (data not shown). Figure 4.3D demonstrates that p33INGlb associates in vivo 
with both SAP30 and HDACI whereas the shorter isoform p24INGlc could only associate with 
HDACI. A diagram of the ING proteins and their binding properties to SAP30 and the 
deacetylases HDACI and SIRTI is presented in Figure 4.3E. These findings imply that p33INGlb 
and p33ING2 are capable of bridging SIRTI to the mSIN3A1HDACI complex by associating 
directly with the SAP30 subunit via their conserved amino terminal region and to deacetylases 
via the PHD-containing carboxy terminal half. 
99 
Figure 4.3: The tumour suppressors p33INGlb and p33ING2 subunits of the 
mSIN3A1HDACl complex allow SIRTI recruitment by direct interactions. 
(A) DNA vectors expressing Flag-tagged INGs were co-transfected with HA-RBPI or HA-
BCAA expressing plasmids in HeLa cells. Whole cell extracts were immunoprecipitated using 
a-Flag M2-agarose and analysed by immunoblotting using either the a-HA. 1 1 or the a-Flag M2 
antibodies, as indicated. (B) In vitro transcribed and translated SAP30 and ING proteins were 
incubated with GST, GST-HDACl, or GST-SIRTl. Complexes were pulled-down using 
glutathione Sepharose 4, washed extensively, resolved by SDS-P AGE, transferred to a PVDF 
membrane and analysed by immunoblotting using HRP-conjugated streptavidin (Promega). (C) 
In vivo association between ING proteins and the deacetylases HDACI and SIRTI. Flag-tagged 
HDACI and SIRTI were expressed in HeLa cells along with HA-tagged INGI isoforms. Whole 
cell extracts were immunoprecipitated using a-Flag M2-agarose and analysed by 
immunoblotting using either the a-HA or the a-Flag M2 antibodies, as indicated. (D) In vivo 
association between INGI isoforms and mSIN3A complex subunits HDACI and SAP30. Flag-
tagged HDACI and SAP30 were expressed in HeLa cells along with HA-tagged INGI isoforms. 
Whole cell extracts were immunoprecipitated using a-Flag M2-agarose and analysed by 
immunoblotting using either the a-HA or the a-Flag M2 antibodies, as indicated. (E) Schematic 
representation ofING proteins association with SAP30 and the deacetylases HDACI and SIRTl. 
The amine terminal region absent in p24INGlC is responsible for the association with SAP30 
whereas, the remaining region conf ers the capability to associate with HDACI and SIRTl. The 
previously identified (Goeman et al. 2005) TSA-sensitive and TSA-insensitive transcriptional 
repression activities ofp33 INGlb are indicated by shades of gray. 
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4.2.3 The repression activity of the R2 region is negatively regulated by SIRTI 
To decipher the functional role of SIRT1 interaction with the R2 transcriptional repression 
domain, luciferase reporter assays were conducted in the presence or absence of resveratrol, a 
sirtuin activator (Howitz et al. 2003), using the Gal4 heterologous system with the Gal4 DNA 
binding domain fused to R2 and the Gal4-responsive reporter G5TKluc. HeLa cells were used in 
these studies as R2 was found to inconsistently repress transcription in H1299, most probably 
due to the absence of BRG 1 (Wong et al. 2000; Medina et al. 2005), which is a mammalian 
SWIISNF-like ATPase required for strong p33 lNGlb-mediated repression activity (Kuzmichev et 
al. 2002). Figure 4.4A shows that increasing amounts of resveratrol (O!-tM, lO!-tM, 50!-tM, 
lOO!-tM) resulted in proportional relief of repression mediated by R2, such that at a concentration 
of lOO!-tM, the resveratrol treatment complete1y alleviated the repression activity of R2. On the 
contrary, using the sirtuin inhibitor sirtinol (Grozinger et al. 2001) at 1 00 !-tM , R2-mediated 
repression was significantly enhanced (approximately three-fold induction) (Figure 4.4B). These 
results suggested that SIRTI activity is detrimental to the mSIN3NHDACI transcriptional 
repression activity associated with the R2 region. 
HDAC1 was recently shown to be acetylated (Qiu et al. 2006) and thus could be a target of 
the SIRT1 deacetylase activity recruited to the mSIN3A/HDAC1 complex. The highly acetylated 
form of HDAC1 is found in repressed chromatin, while the deacetylase found on 
transcriptionally active chromatin has a lower leve1 of acetylation (Qiu et al. 2006). Furthermore, 
this post-translational modification appears to regulate HDAC1 histone deacetylase activity in 
vitro (Qiu et al. 2006). We therefore introduced Ga14-tagged HDAC1 in the transcriptional 
repression experiments described above. Figure 4.4C shows that similarly to R2, HDAC1-
mediated transcriptional repression activity can be alleviated by sirtuin activation (resveratrol) 
whereas sirtuin inhibition (sirtinol) dramatically enhanced HDAC1 repression activity. 
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Figure 4.4: SIRTI activity negatively regulates R2-mediated repression. 
(A) HeLa cens were co-transfected with pG5TKluc, phRL RSVluc, and Ga14 or Ga14-R2. The 
cens were either mock treated with DMSO or increasing amount of the sirtuin activator 
resveratrol, as indicated on the graphic, for a period of 24 hours. The luciferase activity was 
arbitrarily set at 100% for the Ga14-alone control. (B) This experiment was conducted as in panel 
A except that the cens were treated with the sirtuin inhibitor sirtinol, instead of resveratrol. (C) 
This experiment was conducted as in panel A except that a GaI4-HDACI expressing plasmid 
was inc1uded. The results are shown as "Fold Repression" on the graphic for easier comparison 
between R2 and HDACI repression. The experiments for this figure were conducted at least 
thrice in duplicate. 
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4.3 Material and Methods 
4.3.1 Cel/lines and DNA transfections 
H1299 non-small celliung cancer (ATCC CRL-5803) cells and HeLa cells (ATCC CCL-2) 
were maintained in Dulbecco's Modified Eagle Medium (lnvitrogen) supplemented with 10% 
fetal bovine serum (Cansera), lOOU/mL Penicillin G, lOO)lglmL Streptomycin and 2mM 
Glutamine (lnvitrogen). DNA transfections were conducted using TranIT LT1 (Mirus) using a 
DNA:LT1 ratio of 1 :3. 
4.3.2 Plasmids 
RBP1 and BCAA cDNA expression vectors were previously described (Binda et al. 2006). 
pcDNA3-SIRT1-Flag was obtained from Fuyuki (Takata and Ishikawa 2003). The Flag-tagged 
SIRT2-7 mammalian expression vectors were obtained from Eric Verdin (North et al. 2005). The 
cDNAs of p33INGIb and p24INGlc were c10ned from human total RNA by RT-PCR into pCMV 
3xFlag (Stratagene) using EcoRI and Xho! restriction sites, while p33ING2 cDNA was subc10ned 
from pFLAG-CMV-6c-ING2 (Pedeux et al. 2005) by PCR into pCMV 3xFlag (Stratagene) using 
EcoRI and Xho! restriction sites. Flag-INGs were also subc10ned into pET-33b(+) (Novagen) 
using Sac! and Xho! for in vitro transcription/translation and in vitro binding assays. 
4.3.3 Luciferase assays 
Transcriptional repression assays were conducted by co-transfection of plasmids expressing 
firefly luciferase, renilla luci feras e, and either RBP1 or BCAA. Usually, 30 hours post-
transfection, the cells were rinsed once with PBS then lysed with 500)lL IX passive lysis buffer 
(Promega). From these lysates, 20)lL were used for measurement of luciferase activity by Dual-
Luciferase Assay (Promega) on a Lumat LB 9507 (Berthold Technologies) luminometer. The 
activity was normalized for transfection efficiency against the renilla luciferase activity. To 
assess SIRTI-dependent biological function on R2-mediated repression, cells were treated with 
resveratrol (Sigma), sirtinol (Sigma) or DMSO for 24 hours prior to the luciferase assay 
measurements. 
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4.3.4 RNAi depletion ofSAP30 
The siRNA duplexes were obtained from Dharmacon and the information on the targeted 
sequences is provided in the Addendum section, Figure A5. H1299 cells were seeded at a density 
of 5 x 105 cells per 60mm-diameter plate the day prior to transfection. Before transfection, the 
media was replaced with 2mL of fresh D-MEM containing 10% FBS. Then the cells were 
transfected with 8.0/lg of HA expression vector using 24/lL TransIT LT1 in 500/lL serum-free 
D-MEM. In parallel, the siRNAs were transfected using 7.5/lL of 20mM stock (50nM final 
concentration) and 15/lL TransIT TKO (Mirus) in 500/lL. The media was changed 24 hours 
post-transfection. The cells were rinsed with PBS, harvested and lysed in 450/lL nuclear lysis 
buffer 48 hours post-transfection. 
4.3.5 Immunoprecipitation 
Co-immunoprecipitation experiments were conducted either in H1299 or in HeLa cells. 
Briefly, 4.0/lg of HA plasmid and 4.0/lg of Flag plasmid DNAs were transfected into the cells. 
~, The cells were lysed 48 hours post-transfection in nuclear lysis buffer (Lai et al. 1999b) 
supplemented with protease inhibitors cocktail (Roche). The whole cell protein extracts were 
quantified by Bradford and 400/lg of proteins were used for co-immunoprecipitations in nuclear 
lysis buffer (lOOmM KCl). Anti-Flag M2-agarose (Sigma) was used to co-immunoprecipitate the 
complexes, which were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred to PVDF membrane and analysed by immunoblotting using either anti-HA 
monoclonal antibody (HA.l1 from Covalence) or HRP-conjugated anti-Flag M2 (Sigma). 
4.3.6 Recombinant protein purification and in vitro binding assays 
GST, GST-HDAC1 and GST-SIRT1 were purified essentially as described previously (North 
et al. 2005; Binda et al. 2006). In vitro transcription/translation (LV.T.) was performed using the 
TNT Coupled Reticulocyte Lysate System (Promega) and biotinylated lysine-tRNA 
(Transcend™ tRNA; Promega) according to the manufacturer's guidelines. Equivalent amounts 
of LV.T. products were incubated with 2.0/lg GST recombinant proteins in nuclear lysis buffer 
(10OmM KCI), washed six times with 1mL nuclear lysis buffer (1 OOmM KCI), resolved by SDS-
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PAGE, transferred to a PVDF membrane and analysed by immunoblotting using HRP-
conjugated streptavidin (Promega). 
4.4 Discussion 
The finding that BCAA and RBPI could associate not only with the class l deacetylase 
HDACI but also with the class III deacetylase SIRTI was very exciting. But since SIRTI is a 
deacetylase it was puzzling to observe that SIRTI activity actually prevented transcriptional 
repression mediated by R2. After reflection about the biological functions associated with the 
expression of BCAA and RBPl, l realized that it actually made more sense if SIRTI could 
antagonize the repression activity associated with the R2 domain. More precisely, SIRTI is a 
longevity factor, which prevents the onset of senescence by regulating p53. Also SIRTI 
expression is found to be gradually lost in aging cells (Sasaki et al. 2006). Therefore, because R2 
activity is required for induction of growth arrest and senescence, the R2 activity should be in 
sorne way be regulated so that it would be active only in aging cells. And that is exactly what 
was observed. So, l propose that SIRTI regulates senescence not only by activating p53 via 
deacetylation but also by antagonizing R2-mediated transcriptional repression. Interestingly, 
immuno-precipitation studies, in vitro binding studies using GST-purified SIRTI and in vitro 
transcribed-translated ING proteins as weIl as siRNA-mediated SAP30 depletion experiments 
showed that SIRTI is recruited to the R2 region via the mSIN3A1HDACl complex through a 
direct interaction with the tumour suppressors p33 INGlb or ING2, which appear to also regulate 
p53 transcriptional activity by conteracting SIRTI regulation of p53 by preventing p53 
deacetylation and inactivation (Kataoka et al. 2003). Consistent with my results demonstrating 
that SIRTI activity negatively regulates HDACI-dependent transcriptional repression, abolition 
of the Rpd3 deacetylase expression (Kim et al. 1999a) or increased expression of the Sir2 
deacetylase (Tissenbaum and Guarente 2002) extends life-span in yeast. Recent studies in yeast 
suggest a genetic pathway that begins with caloric restriction (Sir2-dependent) and proceeds to 
down-regulation of Rpd3 (Rogina et al. 2002). 
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« When a distinguished but elderly scientist 
states that something is possible, he is almost 
certainly right. When he states that something 
is impossible, he is very probably wrong. " 
Sir Arthur C. Clarke, c. 1962 
Chapter Five: Growth Inhibition and Senescence 
5.1 Introduction 
DNA damage and inappropriate mitogenic signaIs can induce a permanent withdrawal from 
the cell cycle. Accordingly, cells seem to respond to potentially oncogenic stimuli by adopting a 
senescent phenotype, suggesting that senescence is a fail-safe mechanism that protects cells from 
tumorigenic transformation. Since the p53 and pRB converge to initiate senescence and that 
RBPI was identified as a pRB-binding protein and subsequently shown to inhibit cellular 
proliferation, this phenotype was further investigated. The following chapter presents evidence 
that both RBPI and BCAA can obstruct cell growth and induce senescence in an LxCxE-
independent manner that requires intact transcriptional repression activity. 
5.2 Results 
5.2.1 Overexpression ofRBPI Family of Pro teins lnhibits Cellular Proliferation 
Although the growth inhibitory properties of RBPI have been previously explored, the role 
of the LxCxE pRB-binding motif in RBP 1 and the effects of BCAA on cell growth are not 
known. To address these questions colony formation assays were conducted in which DNA of an 
empty vector (negative control), or plasmids expressing pRB, RBPI or BCAA was transfected 
into C33-A cells. Transfected cells were then seeded on plates and colonies were allowed to form 
over a period of two weeks in the presence G4l8. Cells were then either stained with crystal 
violet (Figure 5.lA) or collected by trypsinization and counted to examine the effects of over-
expression of BCAA and RBP 1 on cell growth (Figure 5.1 C). Figures 5.1 Band 5.1 D show that 
RBP1 and RBP1 ~LxCxE (deletion mutant that lacks the LxCxE pocket-binding motif) were 
expressed at similar levels in these experiments. Over-expression ofRBP1 and the LxCxE RBP1 
mutant appeared to reduce colony formation as efficiently as over-expression of pRB (Figure 
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5.1A). Figure 5.1 C demonstrated this effect more quantitatively. The number of cells present 
using the empty vector negative control was arbitrarily set at 100%. Both RBP 1 wild-type and 
the RBP1 L1LxCxE mutant proteins had potent growth inhibitory activity (64%, and 60% 
inhibition, respective1y). Interestingly, over-expression of BCAA had a similar growth inhibitory 
effect (a 76% reduction in cell count). Thus, both BCAA and RBP1 proteins appear to play a role 
in cellular growth inhibition and this phenotype is independent of the presence of the LxCxE 
"pocket" -binding motif. 
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Figure 5.1: RBPI proteins inhibit cellular proliferation. 
Effect of over-expression of BCAA and RBPI on cellular proliferation. (A) Colony fonnation 
assay with pRB and RBPl. Plasmid DNAs expressing the Neomycin resistance gene and the 
HA-tag only orthe cDNA ofpRB, HA-RBPl, or HA-RBPI ilLxCxE mutant were transfected in 
C33-A cells. Colonies were allowed to fonn for two weeks in the presence of G4l8 and then 
were stained with crystal violet. (B) Expression levels ofHA-tagged RBPI proteins in C33-A by 
western blotting using anti-HA antibody (representative of cells in panel A). (C) Cell growth 
with BCAA and RBPl. Plasmid DNAs expressing the Hygromycin B resistance gene and the 
HA-tag only or the cDNA ofBCAA, RBPl, or ilLxCxE mutant were transfected in C33-A cells. 
Cells were selected using Hygromycin B for two weeks and collected by trypsinisation and 
counted. (D) Expression levels of HA-tagged RBPI and BCAA proteins by western blotting 
using anti-HA antibody (representative of cells in panel C). These experiments were conducted 
at least three times in duplicate and the error bars represent the standard deviations. 
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Since BCAA was first identified as an over-expressed epitope in breast cancers, it was 
postulated that it could have transforming properties. BCAA was therefore tested in 
transformation assays in NIH3T3 mouse embryonic fibroblasts. NIH3T3 cells were transduced 
with retroviruses expressing adenovirus ElA 12S (243-residue) protein, oncogenic Ras (V12), 
RBP1, BCAA, BCAAMCF-7, or empty vector. Two weeks following initial infection, the culture 
plates were examined and none, with the exception of Ras (V12) and ElA 12S to a lesser extent, 
exhibited a growth pattern characterized by multi-Iayered cell growth or the formation of 
colonies as a result of transformation and loss of contact inhibition (data not shown). The growth 
of these cells was also tested for growth factor requirement. As expected, only Ras (V12) 
expressing cells were able to grow in medium supplemented with only 0.5% serum instead of 
10% (data not shown). Thus, BCAAMCF-7, although isolated from a breast carcinoma cellline, 
does not appear to be actively involved in cellular transformation. 
5.2.2 The Growth Inhibitory Phenotype Associated with RBP 1 Pro teins Overexpression is 
Related to Senescence 
Recent work has demonstrated a role for pRB and p130 in the establishment and maintenance 
of oncogenic Ras stress-induced senescence (Narita et al. 2003). We therefore postulated that 
RBP1 through its interaction with the pocket proteins as well as with the mSINA3/HDAC 
complex might play a role in the senescence function attributed to pRB and p130. It was also 
possible that BCAA MCF-7, while not inducing transformation, could be involved in 
immortalisation. H1299 cells (p53-/-) were used for studies on the senescence phenotype as these 
cells had been shown to become senescent in response to over-expression of tumour suppressors 
(Wang et al. 1999). Over-expression of the p53-like protein p73-a had previously been shown to 
induce a senescence phenotype (Jung et al. 2001) and was used as a positive control in this 
experiment. Over-expression of the p14ARF protein, which prevents p53 degradation by binding 
to MDM2 (Weber et al. 1999), had also been shown to induce a senescence phenotype (Dimri et 
al. 2000) and was used as a negative control since H1299 are deficient for p53. Figure 5.2A 
shows that, in this experimental context, BCAA and RBP 1 were both capable of inducing a 
significant increase (~1 O-fold) in activity of the senescence specific biomarker SA-p-Gal when 
compared to cells transfected with empty vector or a p14ARF expression vector. Moreover, 
BCAAMCF-7 was unable to induce SA-p-Gal activity although it was expressed at level similar to 
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that of BCAA and RBPI (Figure 5.2B). This truncated peptide of BCAA, which migrates as a 
protein of about 100kDa instead of 200kDa (Figure 5.2B), lacks the carboxy-terminal half of the 
protein and therefore is devoid of the potential R2 HDAC-dependent repression domain 
identified previously in RBPI (see Figure 2.3). These results suggested that the over-expression 
of BCAA isoforms in cancer cells might help to bypass senescence, thus promoting 
immortalization. Further work will be required to address this hypothesis. 
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Figure 5.2: Over-expression of BCAA or RBPI induces a SA-p-Gal activity phenotype. 
(A) H1299 cells were transfected with empty plasmid, or plasmid DNAs expressing p14ARF, p73-
a, RBP1, BCAA, or the BCAA isoform isolated from the MCF-7 cellline. The transfected cells 
were grown for 10 days in the presence of G418, stained for SA-p-Gal, and the positive1y stained 
cells counted. (B) Immunoblot using anti-HA antibodies showing the representative protein 
leve1s of HA-RBP 1 , HA-BCAA, and HA_BCAAMCF-7. 
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5.2.3 Senescence and growth inhibition phenotypes are abolished by mutations interfering with 
transcriptional repression activities 
To demonstrate the functional roles of the RI and R2 transcriptional repression domains of 
RBP 1 and BCAA in the induction of growth arrest and senescence, studies were carried out in 
which mutants that lacked either RI, R2 or both RI and R2, or in which SUMOylation sites had 
been altered, were over-expressed. Figure 5.3 show that following over-expression of wild-type 
forms of RBPI (panel A) and BCAA (panel B), growth of C33-A cells was significantly 
decreased, as was the case in figure 5.1. With both RBPI and BCAA, removal of either RI or R2 
significantly reduced this growth arrest. In addition, the BCAA MCF-7 isoform isolated from breast 
cancer cells, which lacks the R2 region, was also partially defective in inducing growth arrest 
(Figure 5.2B). Deletion of both RI and R2 of RBPI eliminated virtually aIl of its growth 
inhibitory properties (Figure 5.2A); however, with a similar mutant in BCAA, although growth 
arrest was considerably reduced, it was not completely abolished (Figure 5.2B). These results 
may suggest that BCAA harbours additional growth arrest activity. Nonetheless, these results 
imply that both RI and R2 are required for regulation of cell proliferation. Interestingly, 
alteration of the SUMOylation sites within RI of RBPI (Figure 5.2A) and BCAA (data not 
shown) also reduced growth inhibition, suggesting that SUMOylation of the RIO' repression 
function is important in RI-dependent growth arrest. 
Experiments were also conducted with these RBP 1 and BCAA mutants to determine their 
ability to induce the senescence specific biomarker SA-I3-Gal. Figure 5.2C shows that with both 
RBPI and BCAA, deletion of either RI or R2 significantly reduced SA-I3-Gal expression, as was 
the case with the BCAA MCF-7 form that lacks the R2 domain relative to full-Iength BCAA. Figure 
5.2D shows the levels of expression of the various constructs used in the senescence induction 
assay. These results indicated that both RI and R2 are considerably important in the induction of 
both growth arrest and the senescence phentotype. 
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Figure 5.3: Role of the RI and R2 repression regions in growth arrest and induction of a 
senescence marker. 
Experiments similar to those described in Figure 5.1 and 5.1 were conducted in which cells were 
transfected with cDNAs expressing full-length RBP1 or BCAA, mutant forms lacking either the 
RI or R2 reSions or both, RBP1 containing alterations on the SUMOylation sites within RI, or 
the BCAAM F-7 isoform that lacks the carboxy-terminal R2 domain. (A) Effect on cell growth of 
over-expression ofRBPl in C33-A cells. (B) Effect on cell growth of over-expression of BCAA 
in C33-A cells. (C) Effect on expression of senescence marker SA-p-Gal. These experiments 
were conducted at least five times (panel A) or twice (panels Band C) times in duplicate and the 
error bars represent the standard deviations. (D) Representative expression levels of the various 
constructs used in panel C by immunoblotting using anti-HA antibodies. 
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5.3 Material and Methods 
5.3.1 Celllines and transfections 
C33-A human carcinoma (ATCC HTB-31) and H1299 non-small celllung cancer (ATCC 
CRL-5803) cells were maintained in Dulbecco's Modified Eagle Medium (lnvitrogen) 
supplemented with 10% fetal bovine serum (Cansera), 100U/mL Penicillin G, 100/-lgimL 
Streptomycin and 2mM Glutamine (lnvitrogen). DNA transfections were conducted using 
Lipofectamine (lnvitrogen) or DMRIE-C (Invitrogen) according to the manufacturer 
recommendations. 
5.3.2 Growth assays 
C33-A cells were transfected with the appropriate plasmids. 24 hours post-transfection the 
cells were subjected to selection using either 200/-lgimL Hygromycin B (lnvitrogen) or 
1000/-lgimL G418 (lnvitrogen) for a period of two weeks. Finally, the cells were either trypsined 
and counted or stained with crystal violet (0.5% in methanol). 
5.3.3 Senescence-Associated p-Galactosidase Assay 
SA-p-Gal assays were performed essentially as described in section 5.3.2 in H1299 cells with 
the exception that following selection, the cells were stained as described previously (Dimri et al. 
1995). 
5.4 Discussion 
Over-expression of RBP1 has already been shown by our group to inhibit cellular 
proliferation (Lai et al. 1999b). But, because RBP1 is a pRB binding protein, it had always been 
believed that it mediated this growth arrest phenotype in a pRB-dependent manner by recruiting 
transcriptional repression activities to the pRB tumour suppressor, an established cell cycle 
regulator. The studies described in this chapter demonstrated that over-expression of both RBP 1 
and BCAA induced growth inhibitIon, indicating that, at least in the case of BCAA, which does 
not interact with pRB, the effect is independent of pRB association. The induction of growth 
arrest was heavily dependent on intact transcriptional repression activities of both RI and R2. 
This finding suggested that the BCAA protein and probably RBP1 are negatively regulate genes 
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that are required for cell cycle progression independently of pRB. It was recently shown by 
microarray experiments on mSIN3A-1- and wild-type cells and chromatin immuno-precipitations 
that the mSIN3A/HDACI complex was involved in the transcriptional regulation of genes 
implicated in cell cycle control, such as Cyclin E, Cyclin D3, Securin, Caspase 3, Mcm5, Mcm7, 
ceU division cycle 2A, and ceU division cycle 6, which are known targets of pRB/E2F, in addition 
to mSin3B, lngl, Arid4b, Sap30, 53Bpl, Set, and p130. Further work should be conducted to 
identify of the transcriptional targets of RBPI and BCAA to understand exactly how these 
transcriptional regulators inhibit cellular proliferation. 
The over-expression of either RBPI or BCAA induced the expression of the senescence bio-
marker, acidic p-galactosidase activity, suggesting that the growth inhibition phenotype 
associated with the expression of RBPI and BCAA is related to a permanent cell cycle exit 
rather than a basic arrest in the G j phase. Like growth inhibition, induction of senescence by 
RBP 1 and BCAA also required intact transcriptional repression activities, suggesting that both 
types of growth inhibition are regulated in similar ways by the RBP 1 family of proteins and that 
the growth inhibition is actually a permanent cell cycle arrest. 
These cellular proliferation studies relied on the over-expression of RBP 1 and BCAA and the 
senescence phenotype as weIl as the growth inhibition may therefore be artefactual 
demonstrations of the experimental system. But the fact that simple mutation or ablation of the 
RI or R2 domains led to a failure to induce growth inhibition phenotypes remains very 
informative in terms of their relative importance for biological functions of RBPI family 
proteins and argues that the observed phenotypes were not the mere result of toxicity due to the 
over-expression of these proteins. The findings also suggest that the proteins function by 
transcriptionally repressing the expression of genes required for cell cycle progression since the 
repression activities ofboth RI and R2 were absolutely required to induce growth inhibition. 
The next logical step would be to generate transgenic mice and cells to dissect the structure-
function of RBPI and BCAA. RBPrl+ BCAA-1- cells have lowered levels of tri-methylated 
histone H3 lysine 20 (H3K20). Reconstitution of RBP 1 or BCAA expression using RI or R2 
mutants would allow the determination of the repression domains relative importance in 
r' mediating methylation ofH3K20. The R2 domain is probably ofprimary importance for H3K20 
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trimethylation. Through the recruitment of histone deacetylase activity it could allow H3K20 
deacetylation thereby allowing its subsequent methylation. The role of RI is more hypothetical, 
but it could be involved in targeting the complex to the proper chromatin region, stabilize the 
complex on the chromatin template, or recruit histone methyltransferase activity. 
An alternative to the use transgenic models would be to use morpholinos to either interfere 
with the translation (Summerton and Weller 1997; Summerton 1999; Nasevicius and Ekker 
2000) of BCAA and RBP 1 mRNA or to alter the splicing of exons (Giles et al. 1999; Schmajuk et 
al. 1999; Hudziak et al. 2000; Draper et al. 2001) encompassing their RI or R2 regions, resulting 
in the expression of mutant forms with endogenous expression level. The importance of RI and 
R2 in vivo could then be determined by analysis of cellular proliferation and cellular response to 
growth inhibitory signaIs such as DNA damage, which involves a response mediated by the 
mSIN3A1HDACI complex subunit ING2 (Shi et al. 2006). 
The BCAAMCF-7 isoform was shown in Chapter Two to lack the carboxy terminal half 
encompassing the R2 region, and it consequently failed to associate with the SAP30 subunit and 
to be insensitive to HDAC inhibition. Not surprisingly, and similar to artificially truncated 
mutants of RBP 1 and BCAA used in growth inhibition experiments, BCAA MCF-7 also failed to 
induce cell growth inhibition and senescence. The failure of BCAAMCF-7 to negatively regulate 
cell proliferation is very interesting because this isoform of BCAA is over-expressed in MCF-7 
cells, and because unknown forms of BCAA are also over-expressed in many tumours (Cui et al. 
2005). A logical question coming out from these observations is do es the BCAAMCF-7 isoform 
contributes to the MCF-7 transformed phenotype? AIso, are there other tumours or cell lines 
expressing aberrantly truncated forms of BCAA? Because RBP 1 and BCAA appear to have 
similar functions in terms of proliferation control, it would be imperative to investigate cells and 
tumours for expression of aberrant forms ofboth BCAA and RBP 1. 
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"Imagine there's no Heaven; It's easy if you 
try; No heU below us; Above us only sky; 
Imagine aU the people; Living for today. 
Imagine there's no countries; It isn't hard to 
do; Nothing to kiU or die for; And no religion 
too; Imagine aU the people; Living life in 
peace. You may say that l'm a dreamer; But 
l'm not the only one; 1 hope someday you'U 
join us; And the world will be as one. Imagine 
no possessions; 1 wonder if you can; No need 
for greed or hunger; A brotherhood of man; 
Imagine al! the people; Sharing aU the world. 
You may say that l'm a dreamer; But l'm not 
the only one; 1 hope someday you'U join us; 
And the world will live as one. " 
John Lennon, Imagine, 1971 
Chapter Six: General Discussion 
6.1 Establishment of the BCAA and RBPI proteins as a family of transcriptional repressors 
The RBP1 protein was the first cellular protein found to associate with the prototypical 
tumour suppressor pRB. Like viral oncoproteins, RBP1 has an LxCxE pRB-binding motif but 
also has transcriptional repression activities that can account for the known repression 
mechanisms reported for pRB involving both HDAC-dependent and HDAC-independent 
activities. The identification of an LxCxE deficient RBP1-like protein over-expressed in breast 
carcinomas triggered a lot of interest because it could potentially act as a naturally occuring 
RBP1 dominant negative that would abrogate RBP1 pRB-related functions. 
The primary objective that was set was to clone the RBP1-like protein BCAA to allow basic 
functional characterization and comparison to known RBP1 functions. Because BCAA was first 
identified in breast carcinoma and shown to be expressed in the MCF-7 breast carcinoma cell 
line, BCAA cDNAs were cloned by reverse transcription and PCR from MCF-7 total RNA. This 
led to sorne "difficulties" in cloning a cDNA expressing the full-length protein as we eventually 
discovered that BCAA cDNAs derived from MCF-7 cells, although being full-length, encode 
truncated isoforms of BCAA protein lacking the carboxy terminal HDAC-dependent repression 
domain. Nonethe1ess, repression activity assays with BCAA regions corresponding to the known 
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represslOn domains RI and R2 in RBPI demonstrated that BCAA could indeed act as a 
transcriptional repressor. Furthermore, exploitation of the HDAC inhibitor TSA permitted me to 
show that BCAA, like RBPI, could also repress transcription in both HDAC-independent and 
HDAC-dependent manners. Finally, co-immunoprecipitation and in vitro binding experiments 
permitted me to confirm that the R2 HDAC-dependent repression activity of BCAA was 
mediated via direct association with the mSIN3A/HDACI complex subunit SAP30 and, in 
conjunction with the TSA results, suggested concomitant recruitment of histone deacetylase 
activity through mSIN3A/HDACl. These results place BCAA within an RBPI family of high 
sequence homology transcriptional repressors that act by similar mechanisms involving both 
HDAC-dependent and HDAC-independent activities. 
Another aspect of BCAA that was critical to explore was its pRB-binding potential. These 
experiments would suggest whether BCAA could act as a dominant negative towards RBPI 
pRB-related functions. RBP 1 binds pRB in an LxCxE-dependent manner. Mutation of RBP 1 
LxCxE motif or addition of viral oncoproteins-derived LxCxE-containing peptides demonstrated 
the necessity of this motif for RBPI association with pRB. This association was shown to be 
required for E2F -dependent transcription repression by RBP 1. These observations explain the 
importance of studying BCAA and pRB binding. In the experimental context in which this 
aspect of BCAA functions was explored, BCAA could not associate with pRB "pocket" region 
nor the amino and carboxy terminal regions of pRB, whereas RBP 1 could associate with the 
"pocket" only as previously established. In "domain swap" experiments, an LxCxE motif was 
introduced in BCAA and shown to confer strong pRB "pocket" binding properties. The 
preceding data demonstrate the importance of the LxCxE motif for the association of cellular 
pro teins to the pRB "pocket". It remains to be elucidated whether BCAA could act as a dominant 
negative of RBP 1. The only known RBP 1 transcriptional target is the promo ter of E2F 1, but 
repression of the latter could not be recapitulated in in vivo experiments (data not shown) and 
therefore efforts should be focused on the identification of novel in vivo RBPI and BCAA 
targets (see section 6.5 for further details). 
Since BCAA was identified as an over-expressed protein in breast carcinomas, we decided to 
initiate studies to understand how BCAA was over-expressed. One possibility is that BCAA is 
transcriptionally misregulated. Analysis of a 5000 base pair genomic region upstream of BCAA 
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ATG revealed two CpG islands and putative consensus sites for a number of important 
transcriptional factors such as E2FI, WTI, and YYl, It was hypothesised that BCAA could be 
epigenetically misregulated via hypomethylation of the CpG islands or via important cell cycle 
regulatory factors. Insuingly, the BCAA promoter was cloned from MRC5 genomic DNA. 
Compared to strong viral promoters, the BCAA promoter was able to drive high levels of 
transcription in various cell lines. Unfortunately, expression of E2FI, WTI, or YYI had no 
obvious effect on BCAA promoter activity. Besides, epigenetic regulation of the promoter was 
tested by over-expression of the DNA methyltransferase DNMTI and again no discemible effect 
could be observed. More intensive work such as bisulfite sequencing of tumour genomic DNA 
could discem altered patems of BCAA promoter CpG island methylation and footprinting 
experiments on the promoter could lead to identification of regions occupied by transcription 
factors and eventually yield insight into how BCAA is over-expressed in breast carcinoma. 
Interestingly, the knockout of mSIN3A revealed that BCAA was negatively regulated, at Ieast 
in mouse, by the mSIN3A/HDACl complex (Dannenberg et al. 2005). 
6.2 Regulation of RBPI proteins HDAC-independent repression activity by SUMOylation 
At an early stage during the characterization of RBPI repression domains, it was observed 
that the carboxy terminal third of the HDAC-independent region RI was required for strong 
transcriptional repression. Analysis of that region revealed three putative SUMOylation sites in 
RBPI RI and two in BCAA equivalent region. Many complementary approaches to confirm RI 
SUMOylation were used. Site directed mutagenesis of the SUMO-acceptor lysine \}'KxE 
demontrated the requirement of this residue for repression of transcription. Over-expression of 
the specific SUMO protease SuPr-i led to a relief of repression and suggested an important role 
for SUMOylation in RI-mediated repression. Finally, co-immunoprecipitation experiments 
confirmed that the RI region ofboth RBPI and BCAA was SUMOylated at lysine K4I8/K444 
for RBPI and K429/K440 for BCAA. Taken together, these results demonstrate that RI 
repression activity is regulated by SUMOylation. 
SUM04 was recently shown to be refractory to activation due to a non-conserved proline at 
position 90, thus preventing cleavage and exposure of the di-glycine necessary for conjugation 
(Owerbach et al. 2005). In Chapter Three, both RBPI and BCAA were shown to be 
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SUMOylated in vivo by SUM04, but the form of SUM04 used in those experiments was already 
"processed" to its active form (Bohren et al. 2004). Therefore, modification of RI by SUM04 
may not have any functional relevance. 
The recent literature suggests that at least sorne transcription factors repress transcription by 
recruiting HDAC activity in a SUMO-dependent manner. It does not appear to be the case for 
RBPI and BCAA since Rl-mediated repression was shown to be insensitive to the HDAC 
inhibitor TSA. Besides, the repression is even enhanced (consistently two-fold increase) by 
inhibition of deacetylation, suggesting that crucial steps of the repression mechanism by RI may 
involve acetylation events. While screening for SUMOylation sites in BCAA RIa, all lysine 
residues were mutated to arginines. Surprisingly, K4I5R, K4I8R, and K424R mutants had 
defective repression activity and impaired SUMOylation to the same extent as the bona jide 
SUMO-acceptors K429R and K440R. These results suggest that something more than the lysine 
positive charge, conserved by mutation to arginine, was necessary for effective SUMOylation. 
To this end, recent work from Sharrock's lab showed that an extended SUMOylation consensus 
motif involved an acidic patch following the core consensus \f'KxE. Modelling using the crystal 
structure of the SUMO E2 ligase UBC9 suggests that the \f'KxExx(E/D)4 acidic patch could 
stabilize an interaction with a basic patch next to the catalytic core ofUBC9. These findings are 
in agreement with other studies showing that a phosphorylation site, which conf ers a negative 
charge, next to the \f'KxE site, enhances SUMOylation. Therefore, positively charged residues 
are predicted to impair the stability of the interaction between the target and the E2 ligase. We 
did indeed observe that arginine residues were de1eterious to SUMOylation as opposed to 
lysines. This finding may suggest that the positive charge on the lysines could be neutralized by 
acetylation thereby allowing stable interaction with UBC9 and efficient SUMOylation. This 
effect would confer a second leve1 of regulation of RIa activity. So, in response to signalling 
cues, acetylation events at RIa could permit neutralization of inhibitory positive charges, 
efficient SUMOylation and robust transcriptional repression activity. Work inc1uded in this 
thesis describes how RI repression activity is regulated, but the exact repression mechanism still 
remains e1usive. 
The observation that RI can mediate repression of both basal and activated transcription via 
the RIa and RIa regions, respective1y, suggests two mechanisms of action, one that would 
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target the general transcription factors nucleated at the minimal promoter of genes and a second 
that would involve recruitment of other co-repressors. 
6.3 Regulation of RBPI proteins HDAC-dependent repression activity by the class III 
HDAC longevity factor SIRTI 
lronically, the role of the class III HDAC SIRTI in R2 regulation originated from earlier 
studies on the mechanism of transcriptional repression by RI. A transposon screen conducted in 
Saccharomyces cerevisiae suggested a possible genetic link between the longevity factor SIR2 
and the repression activity of the RI region (Lai, 2000). However, attempts to demonstrate 
physical association between SIR2 and RI failed (O. Binda and A. Lai, 2000, unpublished). 
Despite those results, SIRTI was found in immuno-complexes with both full-Iength BCAA and 
RBPI. The latter interaction surprisingly required the R2 region but not RI. The use of an 
activator or an inhibitor of SIRTI activity demonstrated that SIRTI activity was de1eterious 
towards R2-mediated repression and therefore NAD+-dependent mechanisms regulate R2 known 
biological functions. Knowing that R2 associates with the mSIN3A/HDACI complex via a direct 
interaction with the SAP30 subunit, the requirement of this subunit for SIRTI association with 
the R2 region was addressed and shown to be essential, thus strongly suggesting that SIRTI is 
recruited via the mSIN3A/HDACI complex. The tumour suppressors INGlb and ING2 were 
found to be the direct link between SIRTI and the mSIN3A/HDACI complex subunits HDACI 
and SAP30. Recently, HDACI was shown to be acetylated and this post-translational 
modification to be involved in the targeting of HDACI to heterochromatic regions of the 
nucleus, thus suggesting a possible regulatory mechanism via localization of histone deacetylase 
activity. As a consequence, it was postulated that SIRTI may negatively regulate the 
mSIN3A/HDACI repression activity associated with R2 via a mechanism involving 
deacetylation ofHDACl. 
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Figure 6.1: Model of regulation of RBPI proteins transcriptional repression activities. 
In the absence of SUMOylation, the RI region inhibits basal transcription (fine red line) 
whereas, when it is SUMOylated RI represses activated transcription (thick red line). The R2 
region represses transcription in an HDAC-dependent manner by deacetylating histones. The R2 
repression activity is negative1y regulated by the NAD+-dependent activity of SIRTI. 
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The mammalian SWI/SNF chromatin remodelling complex is recruited to chromatin following 
BAF53 binding to PtdlnsP. The association of the actin-like protein BAF53 with the ATPase 
subunit BRG 1 is required for full chromatin remodelling activity. The latter is essential for 
strong transcription repression activity mediated by ING 1 b. The ING family members ING 1 b 
and ING2 tumour suppressors are regulated at least by sub-nuc1ear localization by the 
phosphatidylinositol phosphate Ptdlns(5)P, which allows recruitment of INGlb and ING2 to 
heterochromatin and association with the mSIN3A/HDACl complex. These two ING proteins, 
as shown in the present work, bridge the NAD+-dependent longevity factor SIRTI to the 
mSIN3A/HDACl complex, where SIRTI activity negatively regulates repression by possibly 
deacetylating HDACl. It is very exiting to observe the convergence of two metabolically 
significant pathways to regulate repression activity associated with the HDAC-dependent R2 
region ofRBPl proteins, as it suggests a higher order ofregulation by divergent factors. 
SIRTI has been shown to be a longevity factor in many model systems and can prevent 
induction of senescence by p53/PML. Since SIRTI activity negatively regulates a transcription 
repression activity (R2) necessary for induction of senescence by RBPI proteins, it is attractive 
to hypothesize that SIRTI could also prevent senescence via regulation of RBPI proteins and it 
would therefore be very informative to design experiments to address this question. 
6.4 Requirement of transcription al repression activites of RBPI and BCAA for growth 
inhibition and induction of a senescence phenotype 
It was quite informative to link the biochemical analysis of transcriptional repression 
activities of RBPI and BCAA to biologically relevant functions of RBPl. The latter has 
previously been shown to induce growth inhibition in the RB-1- C33A cellline (Lai et al. 1999b). 
Therefore, the requirement of the transcriptional repression activities associated with RBP 1 and 
BCAA was assessed by a simple growth assay. In reference to what was known about RBP 1 and 
the requirement of its LxCxE pRB-binding motif for repression of E2F-dependent transcription, 
an LxCxE mutant of RBPI or BCAA should not have induced growth inhibition. Surprisingly, 
both the RBP 1 LxCxE mutant and BCAA were able to induce cell growth inhibition following 
their over-expression in the C33A cellline. These results suggest that RBPI and BCAA may 
have pRB-independent growth inhibitory functions since both the RBPI LxCxE mutant and 
BCAA fail to associate with pRB "pocket" in vivo. Interestingly, LxCxE-dependent interactions 
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with pRB are dispensable for cell cycle regulation (Dick et al. 2000) providing further evidence 
that pRB and RBPI may act autonomously to negatively regulate cell cycle progression. 
The growth inhibition phenotype induced by the over-expression of RBP 1 proteins is related 
to senescence. The expression of both proteins led to a sharp induction of the widely used 
senescence biomarker SA-p-Gal. 
6.5 Regulation of E2F-dependent transcription. 
As was proposed by earlier work (Lai et al. 1999a; Lai et al. 1999b), RBP 1, by interacting 
with both pRB and the mSIN3A/HDACl complex, was believed to at least partially account for 
HDAC-dependent repression of E2F-dependent transcription and therefore be a negative 
regulator of cell cycle progression. Although it was possible to recapitulate the growth inhibition 
phenotype observed by over-expressing RBPI (Lai et al. 1999b), repression of E2F-dependent 
transcription could not be reproduced. In addition to reproducing the experimental approach 
described (Lai et al. 1999b), which consisted of transfecting C33A RB-1- cells by the calcium 
phosphate method with DNA expressing RBPI along with the E2F-responsive reporter pGL2-
E2Flluc, other tactics were used to address whether RBPI and BCAA could regulate E2F-
dependent transcription. The E2F-responsive promoters of E2Fl and c-myc P2 and mutants in 
their respective E2F-binding sequences were cloned into luciferase reporters in addition to an 
artificial sequence containing four E2F sites and used in repression assays in C33A, CHO-Kl, 
and H1299 cells. Normally, pRB over-expression was capable, to sorne extent, of inhibiting 
reporters containing wild-type E2F consensus binding sites but not the mutant forms, therefore 
validating the system used. On the contrary, neither RBPI or BCAA over-expression led to 
consistent, reproducible repression of E2F -dependent transcription. Another approach tested that 
failed to show that RBP 1 proteins could enhance pRB-mediated transcriptional repression 
involved the tethering of pRB "pocket" to a reporter using the Gal4 system and again over-
expressing RBPI and BCAA. Finally, because pRB is involved in the response to growth factor 
deprivation, cell-cell contact inhibition and DNA damage, different cell culture conditions were 
tested to assess their influence on RBPI proteins in the context of E2F-dependent transcription. 
So, asynchronously growing cells, serum starved cells, UV -irradiated cells, as well as confluent 
cells were used in repression assays, but still neither RBP 1 nor BCAA over-expression seemed 
to have an impact on E2F-dependent transcription. This large body of evidence argues against a 
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potential role for RBP 1 proteins in the regulation of E2F -dependent transcription. These results 
are also in agreement with the apparent absence of RBPI at E2F-regulated promoters in Go-
arrested cells (Dynlacht, BD, personal communication). 
Interestingly, RBPI and BCAA over-expression leads to a permanent cell cycle exit (Chapter 
Five (Binda et al. 2006)). Senescence can be induced by excessive stress caused by substandard 
cell culture conditions. As addressed previously, pRB and p130 are important factors involved in 
the establishment and maintenance of senescence and transcriptionally silenced heterochromatin 
domains at E2F-dependent genes. It is therefore plausible to reconcile the previously published 
data (Lai et al. 1999a; Lai et al. 1999b), the observation that RBP 1 proteins do not appear to 
regulate E2F-dependent transcription in normal growing conditions and the induction of 
senescence in the following model. Upon stress signalling and cellular commitment to 
senescence, RBPI proteins with mSIN3A1HDACl, INGlbl2, and BRGI would be assembled 
into a large multi-proteins complex and recruited to pRBlE2F at promoters of genes required for 
cell cycle progression to permenantly shutdown transcription. 
6.6 Future Directions 
After the last seven years of studies on RBPl, the big question that remains is "What does 
RBPI do in the mSIN3A1HDACl complex"? We now know that RBPI and BCAA are found in 
the mSIN3A1HDACl complex and mediate transcriptional repression by HDAC-independent 
and HDAC-dependent manners. But what is their actual role in the complex? Are they involved 
in targeting the complex to to specific promoters, to chromatin in general or to specific 
heterochromatic structures such as centromeres or te1omeres? Or are RBP 1 and BCAA involved 
in bridging the mSIN3A1HDACl complex and other enzymatic activities? 
6.6.1 DNA-binding Functions 
We know that the RI region ofRBPl and BCAA overlaps with a DNA-binding domain, the 
ARID, which mediates sequence non-specific interaction with DNA, but we also know that 
within the ARID a basal transcription inhibitory activity (RIa) is detected and that this activity 
could be enhanced by SUMOylation. So, it is tempting to speculate that the RI region interferes 
with transcription in the Gal4 system by interacting with promoter elements, which may or may 
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not be physiologically relevant; however, in vivo the RI region may have a different role within 
the full-length protein other than to repress transcription. It could possibly be involved in the 
stabilization of the mSIN3A/HDACI complex on the chromatin template by contacting DNA via 
the ARlD region in a manner regulated by SUMOylation. This model could be tested in BCAA-/-
RBP 1 -/- cells by reconstituting their expression using mutants, such as the K418R1K444R 
SUMOylation-defective mutant, and subsequent analysis of chromatin occupancy by 
mSIN3A/HDACl. So, it would be expected that if BCAA/RBPI stabilize the mSIN3A/HDACl 
complex on chromatin by concomitantly associating with DNA, the expression of RI mutants 
would dissociate the mSIN3A/HDACI complex from chromatin. 
The RBPI protein contains other putative DNA-binding domains. The AT-hook motiffound 
in RBPI (residues 663-675) correspond to the consensus sequence within the highly conserved 
central region GRP, which allow recognition of A/T-rich DNA sequences. RBPI also has two 
AT-hook-like sequences, one preceding the ChrOMo domain (residues 580-592) and another one 
following the ChrOMo domain (residues 631-643). A/T-rich repeat sequences are found at 
pericentric regions of mammalian chromosomes and are important for the formation of 
heterochromatin and proper chromosome segregation (Sullivan et al. 2001; Partridge et al. 
2002). 
The reduced H4K20 trimethylation (H4K20 methylation correlates with chromosomal 
silencing) at pericentric heterochromatin observed in pRB mutant cells and failure of pRB to 
associate with RBPI while still associated with the Suv4-20h histone methyltransferase (Isaac et 
al. 2006), provides evidence that RBPI may be involved in heterochromatin formation at 
pericentric regions. Disruption of heterochromatin structure in this chromosomal region leads to 
centromere fusions, chromosome missegregation, and genomic instability. lmportantly, RBP 1 
and BCAA null cells exhibit reduced trimethylation of histone H4K20 (Wu et al. 2006). AIso, 
mutations of RBP 1, BCAA, or RB suppressed an AS imprinting defect caused by a mutation at 
the AS-lC (Wu et al. 2006), suggesting a converging function for the RBPl, BCAA, and pRB 
proteins in the formation ofheterochromatin. 
lnterestingly, failure of pericentric heterochromatin formation is also observed in mSDS3-/-
r-, mouse (David et al. 2003). This phenotype is not observed in the mSIN3A-/- mouse, but mSDS3 
126 
can fonn complexes with both mSIN3A and mSIN3B (Alland et al. 2002), suggesting that one 
mSIN3 may compensate for the loss of the other and not necessarily that mSDS3 functions 
independently of mSIN3 to regulate the fonnation of pericentric heterochromatin. Nothe1ess, it is 
very intriguing that an RBPl-binding defective pRB mutant, and mSDS3-1- cells failed to silence 
pericentric chromatin, and that the RBPI-binding defective pRB mutant or loss of BCAA/REPI 
lead to reduced level of trimethylation of histone H4K20. There seems to be a functional 
convergence emerging between a number of subunits of the mSIN3A/HDAC1 complex in the 
regulation ofheterochromatin fonnation at pericentric DNA. 
It would also be infonnative to further investigate BCAA and RBP 1 function in the 
fonnation of heterochromatin, espacially at pericentric DNA not only because of the possible 
role in preserving proper chromosome segregation during mitosis but also in the prevention of 
aberrant chromosomal rearrangements. The recent development of BCAA-1-, REP r l-, and BCAA-1-
REP rl- cells as well as the ease of use of the RNAi technologies now offer unparallel 
opportunities to probe BCAA and RBPI functions. More precisely, pericentric DNA occupancy 
by BCAA and RBP1 should be investigated by chromatin immunoprecipitation and histone 
modifications at pericentric heterochromatin should also be analysed by chromatin 
immunoprecipitation in the presence or absence of the BCAA and RBP 1 proteins. After 
confinnation of failure of pericentric heterochromatin fonnation in the absence of the RBP 1 
family of proteins, the possibility of aberrant chromos omal rearrangements should also be 
examined. 
6.6.2 Convergence ofREPI, REP2, and the induction ofsenescence 
Methylation of histone H3 lysine 4 (H3K4) is a mark oftranscriptionally active euchromatin. 
Tri-methylated H3K4 serves as a docking site for the nuc1eation of the mSIN3A1HDAC1 
complex around the tumour suppressor ING2, which binds specifically and directly to tri-
methylated H3K4 to repress transcription of active genes, such as cyc1in Dl in response to DNA 
damage (Shi et al. 2006). Interestingly, loss of expression of the pRB-associated protein, RBP2 
induces cellular morphology changes similar to the enlarged and flat morphology of senescent 
cells. AIso, RBP2 was recently shown to demethylates H3K4. So, it appears that RBP2 and 
RBP1 functions are antagonistic in the sense that RBP2 by dernethylating H3K4, removes the 
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docking site for the nucleation of the mSIN3A/HDAC1 complex, preventing transcriptional 
silencing by RBP1-containing complexes. But in the absence of RBP2, the increase in H3K4 
methylation and consequent recruitment of transcriptional repression activities associated with 
ING2 would lead to cell cycle arrest and explain the enlarged cell morphology phenotype 
associated with loss ofRBP2. 
6.6.3 Transformation Potential of the BCAAMCF-7 
As briefly described in section 5.2.1, the BCAAMCF-7 isoforms failed to induce 
transformation in NIH3T3 cell assays using standard protocols. The BCAAMCF-7 isoforms are of 
human origin and their study may be irrelevant in mouse cells such as NIH3T3. AIso, the genetic 
background of NIH3T3 and MCF-7 cells is most likely very different. The MCF-7 cells are 
tumour-derived cens whereas NIH3T3 cens are immortalized but not transformed. So, to 
investigate the possible transformation role of the BCAA MCF-7 isoforms, BCAAMCF-7 expression 
in MCF-7 cells should be attenuated using RNAi technology. A recent report has suggested that 
the depletion of BCAAMCF-7 by siRNA may lead to growth inhibition of MCF -7 cens (Yang et al . 
. ~" 2006), thus suggesting that BCAA MCF-7 may act as an oncoprotein and that unknown functions 
could be found within the amino terminal half of either BCAA or RBP 1. 
In order to identify functions associated with BCAA and RBP1 amino terminal half and 
understand how the BCAA MCF-7 isoforms function, it would be interesting to identify nove! 
protein-protein interactions mediated with this region. This could also help elucidate the role of 
BCAA and RBPl within the mSIN3A/HDAC1 complex and also identify possible divergent 
functions for the two RBPI family proteins. Tandem affinity purification of BCAA- and RBPl-
containing complexes should be conducted. The experimental approach should involve the use of 
wild-type forms as well as of ~R2 mutants to identify proteins other than mSIN3NHDACl-
associated subunits. The purification scheme should also take into account that expression of 
BCAA and RBP 1 leads to growth inhibition, so the use of an inducible system should be 
considered in order to be able to grow enough cells to obtain reasonable amounts of protein 
extracts. Considering all these constrains, inducible stable celllines expressing GST-Flag-BCAA 
and GST-Flag-RBPI should be generated. Then, following induction of expression, nuclear 
r protein extraction could be used as an initial purification step, priOf to gentle GST -affinity 
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purification, c1eavage of the GST moiety using the PreScission protease (Amersham), a protease 
that functions at 4°C, and final purification by immuno-affinity using a-Flag antibody. The 
purified complex would then be analysed by denaturing polyacrylamide gel electrophoresis and 
specific proteins analysed by mass spectrophotometry. 
6.6.4 Metastasis Suppression by BRMSI 
The metastasis suppressor BRMS 1 and the BRMS l-like protein p40 are found in association 
with the mSIN3A/HDACl complex and the RBPI family of proteins (Meehan et al. 2004; 
Nikolaev et al. 2004). Because BRMS 1 potently inhibits metastasis (Seraj et al. 2000; Samant et 
al. 2006), and also associates with the mSIN3A/HDACl complex, it would be very interesting to 
investigate a potential role for the mSIN3A/HDACl in the suppression ofmetastasis formation. 
As described in section 5.2.1, the BCAAMCF-7 isoform could not transform NIH3T3 ceUs, but 
may still be involved in the transformed phenotype ofMCF-7 ceUs, as discussed in section 6.6.3. 
Furthermore, because the BCAAMCF-7 isoform lacks the region required for BRMSI association, 
the over-expression of BCAAMCF-7 in cancer ceUs may contribute to the formation ofmetastasis. 
It would therefore be informative to verify if the mSIN3A/HDACl complex plays a role in the 
suppression of metastasis. To study the potential contribution of the mSIN3NHDAC 1 complex 
in the suppression of metastasis formation, experiments, such as in vivo metastasis studies, could 
be conducted in murine models in the absence of mSIN3NHDACl complex subunits such as 
RBP1, BCAA, which associate with BRMSl, or SAP30, which bridges mSIN3A to the RBPI 
family of proteins. 
6.6.5 The Mechanism of Action ofS/RTl on R2-mediated Transcriptional Repression 
The mSIN3A1HDACl complex contains about 20 subunits, sorne ofwhich have been shown 
to be involved in the stabilization of the complex (mSDS3) or in the generation of maximal 
BRGI-associated ATPase activity (BAF53). There are a few logical targets for SIRTI that may 
be involved the regulation of the transcriptional repression activity of R2. The first is HDACI 
because it was recently been shown to be acetylated and to localize to heterochromatin region in 
the acetylated form (Qiu et al. 2006). 
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R2-mediated transcriptional repression activity is modest in Hl299 relative to that in CHO-
KI, HEK293, or HeLa cells (personal observation), suggesting that Hl299 cells lack a factor 
required for strong repression activity by R2. The tumour suppressor BRG 1 has been reported to 
be absent in a number of ceIl lines such as H1299 and BRGI enhances repression by Ga14-
p33INGlb, suggesting an important role for chromatin remodelling in the mSIN3A/HDACI 
complex-associated transcriptional repression activity. To assess a possible role for BRG 1 in the 
regulation of R2 activity by SIRT1, the expression of BRGI was reconstituted in H1299. Three 
Hl299 ceIl lines were made: one expressing a puromicin resistance gene only, a second 
expressing wild-type BRGI, and a third expressing a catalytically inactivated mutant form of 
BRGI (K798R). The Hl299 ceIl line stably expressing exogenous BRGI, expresses slightly 
lower levels of BRG 1 then the ceIl line expressing the mutant BRG 1 K798R form. AIso, these 
cell lines express lower levels of BRG 1 when compared to HeLa ceIls, which express 
endogenously BRG 1. In this context, R2-mediated transcriptional repression remained minimal 
and comparable to the control Hl299 cells. Furthermore, R2 activity remained unchanged 
following SIRTI activation using resveratrol in identical conditions as used initially in HeLa 
/~, cells (see Figure 4.4, panel A). The effect of inhibition of SIRTI activity with sirtinol on R2 
activity remains to be tested in the BRGI expressing H1299 ceIllines. 
The BRGI associated factor BAF53, which is also a subunit of the mSIN3A1HDACI 
complex, is required for maximal ATPase activity ofBRGI and for the association of the BRGI 
complex with chromatin and could therefore be a potential target of SIRTI for the regulation of 
R2-mediated transcriptional repression. Preliminary investigation of expression levels of various 
subunits of the mSIN3A1HDACI complex led to the observation that the BAFl55 protein level 
was upregulated upon treatment of HeLa ceIls with the SIRTI inhibitor sirtinol. By directly 
interacting with mSIN3A, BAFl55 may facilite the recruitment of BRGI to the complex and 
thereby account for the increased R2-mediated transcriptional repression observed when SIRTI 
deacetylase activity is inhibited by sirtinol. 
6.6.6 Identification of the Transcriptional Repression Mechanism by Ri 
The work presented in this thesis and elsewhere (Roy 2003) demonstrate that the RI 
~' transcriptional repression domain of BCAA and of RBPI represses activated transcription in a 
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SUMOylation-dependent manner. Interestingly, my very first project related to RBPI was 
conducted as an undergraduate project and aimed at identifying RI-associated proteins to 
elucidate the mechanism of repression by RI. The experimental approach used at the time 
involved the screening of two cDNA expression libraries (Àgt1I placenta and Àzap human 
ovarian follic1e) in Escherichia coli using 32P-Iabelled GST-purified RI recombinant protein as a 
probe. This approach failed to identifY any RI binding partner. It was conc1uded that this failure 
could be because RI had to be post-translationally modified in order to associate with binding 
partners involved in the mediation of transcriptional repression activity. We now know for a fact 
that RI-mediated repression is indeed regulated by post-translational modification(s) and that the 
repression mechanism and therefore protein-protein interactions mediating the repression activity 
rely heavily on SUMOylation. Two other "generations" of graduate students have attempted to 
identifY the mechanism oftranscriptional repression by RI. One ofthese (described (Roy 2003)) 
made use of immobilized GST-RI on a matrix and application of HeLa nuc1ear extract to the 
column. This approach also failed to provide binding partners, most probably because GST-RI 
was not SUMOylated. Logically, the E2 SUMO ligase Ubc9 should have been identified as an 
r-" R I-associated protein, but then again RI contains an extensive positively charged region 
adjacent to RI cr that, according to a recent report on the mechanistics of Ubc9 interaction with 
target proteins, would impede the binding of Ubc9. The SUMO ligase would, through a basic 
patch bind to the target. Because RI region is basically charged, it could prevent interactions 
with Ubc9 and mayrequire neutralization of the positive charge by acetylation. To support the 
contention that the positive charges within the RIcr region are deleterious to Ubc9 interaction, 
mutant forms of RI in which the lysine residues were converted by site-directed mutagenesis to 
arginines, which conserve the charge but cannot be acetylated, have impaired transcriptional 
repression activity and fail to be SUMOylated. So, the identification of RI associated proteins 
may not only require SUMOylation but also prior acetylation. 
Two approaches could be exploited in order to obtain the high levels of SUMOylated RI 
necessary for the identification ofbinding partners. The use of a prokaryotic system in which the 
SUMOylation pathway is expressed exogenously (Mencia and Lorenzo 2004; Uchimura et al. 
2004a; Uchimura et al. 2004b) would allow the production of SUMOylated recombinant GST-
r RI at high level. The SUMOylated GST-Rl form could then be immobilized on a matrix, as 
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previously described (Roy 2003), on which nuclear protein extracts could be applied , allowing 
protein-protein interactions under mild conditions. Associated pro teins then would be eluted 
under increasingly stringent conditions before being analysed by SDS-PAGE and identified by 
mass spectrophotometry. A second approach, described in recenty (Jakobs et al. 2007), employs 
a Ubc9-target fusion protein to force SUMOylation of the target in a way that is not limited by 
interactions between Ubc9 and the target. It was found that conjugation by endogenous SUMO 
. 
of up to 40% of the total protein pool of the specific targets tested using this method could be 
achieved. So, the RI region could be fused in frame with Flag-tagged Ubc9, over-expressed in 
HEK293 cells in which high transfection efficiency can be achieved, and protein extracts 
immuno-purified using the highly specific a-Flag M2 monoclonal antibody and analysed by 
SDS-PAGE. 
6.7 Conclusion 
The work within this thesis has described how the RI and R2 transcriptional repression 
activities of RBPI and BCAA are regulated and how they in tum control cell growth and the 
onset of senescence. Interestingly, these effects seem to be independent of the pRB tumour 
suppressor. This work also lays the groundwork for a considerable amount of future studies into 
the roles ofthe RBPI family. 
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Addendum 
This section provides additional results supporting this thesis. In Figure Al and Figure A2 
the putative TF sites predicted using "AliBaba2.l" (http://www. gene-
regulation.com/pub/programs/ alibaba2/index.html) and "PATCH" (http://www . gene-
regulation.com/cgi-bin/pub/programs/patch/bin/patch.cgi), respectively, are given. Figure A3 
shows that in the absence of the SUMOI protein, the slow migrating forms BCAA RI are absent, 
strongly suggesting that these are SUMOylated forms of RI. Figure A4 shows that both RBPI 
and BCAA RI region can by post-translationally modified by SUMO-2 (panel A), SUMO-3 
(panel B), and SUMO-4 (panel C). Figure AS shows the efficiency of SAP30 knockdown using 
SAP30-specific siRNAs (Dharmacon) compared to the controls. 
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Figure Al: Putative transcription factor binding sites in BCAA promoter. 
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Segments: 
1.1.3.0 
4.1.1.0 
3.5.2.0 
2.3.1.0 
2.1.2.3 
3.5.3.0 
seq ( 60 .. 
Segments: 
9.9.701 
2.3.1.0 
1.3.1.2 
2.3.1.0 
4.5.1.0 
2.3.1.0 
seq( 120 .. 
Segments: 
2.3.1.0 
9.9.150 
9.9.1202 
1.1.3.0 
3.1.1.7 
2.3.1.0 
4.3.2.0 
3.5.1.2 
2.3.2.1 
2.3.1.0 
9.9.270 
seq( 180 .. 
Segments: 
2.3.2.1 
2.3.1.0 
9.9.270 
1.1.3.0 
2.3.1.0 
9.9.820 
2.3.1.0 
2.3.1.0 
2.3.2.1 
seq( 240 .. 
Segments: 
2.3.1.0 
2.3.2.1 
2.3.1.0 
2.3.1.0 
seq( 300 .. 
Segments: 
2.3.1.0 
9.9.726 
2.3.1.0 
2.3.1.0 
9.9.561 
2.3.1.0 
2.1.2.10 
2.1.2.3 
2.3.1.0 
seq( 360 .. 
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355 364 
419) 
355 364 
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382 391 
395 406 
410 420 
cagagtatggactttatttcccagaaagccttgaggcgtaactttctgtttccatagaac 
===C/EBP== 
=====Dl=== 
====PU.1== 
====Sp1=== 
=REV-ErbA= 
===ICSBP== 
tggtgggaaaatggcgtcgttgtttgtatccagggaccaataggaacagtgtataggcgg 
=PTF1-beta 
====YY1=== 
====USF=== 
====Sp1=== 
====TBP=== 
=====Sp1= 
gttctaaagaactttaaccaatccaaggtcgtctaagaggccatccgggaaagaggtagg 
====CP1=== 
====CP1=== 
=C/EBPalp= 
=embryo_D= 
====Sp1=== 
====SRF=== 
====REB1== 
ggagggggggaaaaaaaatctaggggaggggagaaagggggggaacctagagtcggtggg 
Krox-20= 
===Sp1==== 
===ETF=== 
=C/EBPalp= 
=====Sp1==== 
===TFIID== 
====Sp1=== 
=====Sp 
===Egr 
ggggaagcgatgtttgcccgtcagtcgagtccggagtgaggagctcggtcgccgaagcgg 
1=== 
-1== 
=====Sp1==== 
=====Sp 
agggagactcttgagcttcatcttgccgccgccacggccaccgcctggacctttgcccgg 
1==== 
=represso= 
=======Sp1===== 
====Sp1=== 
==NF-muE1= 
=====Sp1=== 
====COUP== 
=REV-ErbA= 
====S 
agggagctgcagagggtccatcgccgccgtcctctggagggcagcgcgattgggggcccg 
p1=== 
====YY1=== 
====Sp1=== 
=====Sp1==== 
=====Sp1== 
seq( 420 .. 479) 
/~ 
Segments: 
2.3.1.0 410 420 
2.3.1.0 428 439 
9.9.590 434 443 
2.3.2.1 451 460 
2.3.1.0 451 463 
2.3.3.0 454 463 
2.3.1.0 459 468 
2.3.1.0 465 474 
seq( 480 .. 539) 
Segments: 
9.9.539 481 490 
2.3.1.0 502 516 
9.9.726 504 513 
2.3.1.0 510 523 
2.3.1.0 517 526 
2.3.1.0 517 527 
2.3.1.0 524 533 
2.3.1.0 532 541 
1.1.1.1 535 544 
9.9.29 536 545 
9.9.31 536 545 
seq( 540 .. 599) 
Segments: 
2.3.1.0 532 541 
1.1.1.1 535 544 
9.9.29 536 545 
9.9.31 536 545 
3.5.1.2 543 552 
2.3.1.0 552 565 
1.6.1.0 555 564 
2.3.1.0 563 572 
~ 2.3.1.0 575 585 2.3.3.0 577 586 
1.6.1.0 578 587 
9.9.270 580 589 
2.3.1.0 582 591 
1.2.2.0 587 596 
2.3.1.0 599 609 
seq( 600 .. 659) 
Segments: 
2.3.1.0 599 609 
2.3.3.0 601 610 
2.3.1.0 616 625 
4.1.1.0 617 626 
9.9.539 631 640 
2.3.1.0 645 659 
9.9.726 647 656 
seq( 660 .. 719) 
Segments: 
9.9.539 705 714 
1.6.1.0 716 725 
2.3.1.0 717 731 
seq( 720 .. 779) 
Segments: 
1.6.1.0 716 725 
2.3.1.0 717 731 
9.9.539 724 733 
2.1.1.1 725 734 
4.1.1.0 737 746 
9.9.590 737 746 
1.6.1.0 759 768 
9.9.270 760 769 
(' 2.3.1.0 763 772 
2.3.1.0 774 787 
gacctccagtccgggggggatttttcgtcgtccccctccccccaaccagggagcccgagc 
=====Spl==== 
=NF-kappaB 
==Krox-20= 
======Spl==== 
=CPE bind= 
====Spl=== 
====YYl=== 
ggccgccaaacaaaggtaccagtcgccgccgcgggaggaggaggagccggagcctctgcc 
====NF-l== 
=======Spl===== 
=represso= 
======Spl===== 
====Spl=== 
=====spl=== 
====Spl=== 
====Spl= 
===c-
tcagcagccgctggacccgccgcccttcttccccatctctcccccgggcctgctggtttt 
Jun== 
AP-l== 
AP-l== 
===Adf-l== 
======Spl===== 
=AP-2alph= 
====Spl=== 
=====Spl=== 
=CPE bind= 
====AP-2== 
====ETF=== 
====Spl=== 
====MyoD== 
gggggggagaaggagagaggggactctggacgtgccagggtcagatctcgcctccgagga 
====Spl=== 
====MIGl== 
====Spl=== 
=NF-kappa= 
====NF-l== 
=======Spl===== 
=represso= 
aggtagggatattttctggggctttcgtggtctcctaagggggttcttttgggagtcgct 
====NF-l== 
gggcccggccaaggagcagaggaagatcgcggtggtggtccctgcggcgcccgaattcgg 
AP-2== 
====Spl===== 
====NF-l== 
=====GR=== 
=NF-kappa= 
=NF-kappaB 
=AP-2alph= 
====ETF=== 
====Sp1=== 
~ 
seq( 780 .. 839) 
Segments: 
2.3.1.0 774 787 
2.3.1.0 782 792 
1.6.1.0 794 803 
2.3.1.0 797 811 
9.9.77 798 807 
2.3.2.1 801 810 
2.3.2.3 803 812 
2.3.1.0 803 816 
1.6.1.0 808 817 
3.5.1.2 811 820 
9.9.726 824 833 
2.3.1.0 825 837 
2.3.1.0 838 847 
seq( 840 .. 899) 
Segments: 
2.3.1.0 838 847 
2.3.1.0 867 879 
2.3.1.0 873 884 
1.6.1.0 877 886 
2.3.1.0 879 891 
2.3.1.0 888 901 
9.9.77 890 899 
2.3.1.0 894 903 
seq( 900 .. 959) 
Segments: 
2.3.1.0 888 901 
2.3.1.0 894 903 
2.3.1.0 902 915 
2.3.1.0 913 927 
2.3.1.0 919 928 
2.3.3.0 924 933 
2.3.1.0 925 934 
1.3.1.2 927 936 
2.3.1.0 936 950 
1.6.1.0 938 947 
2.3.2.1 939 948 
2.3.1.0 942 952 
2.2.1.1 946 955 
seq( 960 .. 1019) 
Segments: 
2.3.1.0 
2.3.1.0 
1.6.1.0 
2.3.1.0 
2.3.1.0 
9.9.537 
2.3.1.0 
seq( 1020 .. 
Segments: 
2.3.1.0 
2.3.1.0 
2.3.1.0 
1.6.1.0 
2.3.1.0 
2.3.1.0 
2.3.1.0 
1.6.1.0 
2.3.2.1 
9.9.539 
2.3.1.0 
964 973 
989 998 
998 1007 
1000 1011 
1002 1011 
1002 1011 
1013 1026 
1079) 
1013 1026 
1020 1029 
1027 1041 
1032 1041 
1035 1048 
1049 1061 
1062 1076 
1065 1074 
1066 1075 
1066 1075 
1069 1079 
ggcctcggcctcccgggaacccccaccccccgcagccgctgtgtccgagccgccccctgg 
Sp1===== 
=====Sp1=== 
=AP-2alph= 
=======Sp1===== 
=CACCC-bi= 
==Krox-20= 
====WT1=== 
======Sp1===== 
=AP-2a1ph= 
===Adf-1== 
=represso= 
======Sp1==== 
ctgggcggccgcacactcagcggtttagcggccgcggtcgggggcccgggcagggtgggg 
==Sp1=== 
======Sp1==== 
=====Sp1==== 
=AP-2a1ph= 
======Sp1==== 
======Sp1=== 
=CACCC-bi= 
====Sp 
gccgttccgcctccggggccctcggccctcacgttgtccccgcggcggggccagatgttg 
1=== 
======Sp1===== 
=======Sp1===== 
====Sp1=== 
=CPE bind= 
====Sp1=== 
====USF=== 
=======Sp1===== 
=AP-2a1ph= 
==Krox-20= 
=====Sp1=== 
===GATA-1= 
atctcgctcccacttgtcgggtctgagcccggaacgggacgtgggcaggggctctgtggc 
====Sp1=== 
====Sp1=== 
=AP-2a1ph= 
=====Sp1==== 
====Sp1=== 
====NF-1== 
======Y 
gggccggtcctgcccgcggcccacaggccctcctggcccctcggtggcccccggccggcc 
Y1===== 
====Sp1=== 
=======Sp1===== 
=AP-2a1ph= 
======YY1===== 
======Sp1==== 
=======Sp1===== 
=AP-2a1ph= 
===Egr-1== 
====NF-1== 
=====Sp1=== 
~~' 
~ 
seq( 1080 .. 1139) 
Segments: 
2.3.1.0 1089 1101 
2.3.1.0 1098 1110 
2.3.2.1 1101 1110 
2.3.1.0 1113 1127 
2.3.1.0 1121 1130 
2.3.1.0 1127 1136 
2.3.1.0 1138 1147 
seq( 1140 .. 1199) 
Segments: 
2.3.1.0 
2.3.1.0 
9.9.537 
2.3.1.0 
2.3.1.0 
2.2.1.1 
seq( 1200 .. 
Segments: 
9.9.51 
4.1.1.0 
2.3.4.0 
9.9.590 
9.9.592 
9.9.594 
2.3.1.0 
seq( 1260 .. 
Segments: 
3.5.1.2 
3.5.1.2 
2.3.1.0 
1.3.1.2 
9.9.270 
2.3.1.0 
3.1.2.2 
2.3.1.0 
1138 1147 
1146 1159 
1152 1161 
1152 1163 
1162 1173 
1184 1193 
1259) 
1200 1209 
1220 1230 
1221 1230 
1221 1230 
1221 1230 
1221 1230 
1245 1256 
1319) 
1268 1277 
1274 1283 
1290 1304 
1294 1303 
1295 1304 
1296 1306 
1298 1307 
1304 1313 
tctcgctcggacgcggcgcgtgggggcgcggattcgctcggccgggcgccgaggccctag 
======Sp1==== 
======Sp1==== 
==Krox-20= 
=======Sp1===== 
====Sp1=== 
====Sp1=== 
gggagagcggccggccctgcgccggacgccgggcttgttgtgagtttcttctctgacaga 
==Sp1=== 
======Sp1===== 
====NF-1== 
=====Sp1==== 
=====Sp1==== 
===GATA-1= 
aatggcgtcattgtcgtagacgggaaactccgtcgggtctcgacaatggggacgggaagc 
====ATF=== 
=NF-kappaB2 
=MBP-1 (1) 
=NF-kappaB 
=NF-kappa= 
====RelA== 
=====Sp1==== 
tgccgagctgtgtaggtggttgggtttgcggggatggcggggccggagggagccccgagt 
====RAP1== 
====RAP1== 
=======Sp1===== 
====USF=== 
====ETF=== 
=====Sp1=== 
===Oct-1== 
====Sp1=== 
seq( 1320 .. 1379) cggcgtgtgatggttcgggggctggcgcctggttgcggctctttcttcggggttcggacg 
Segments: 
2.3.1.0 1335 1345 =====Sp1=== 
seq( 1380 .. 1439) 
Segments: 
2.3.1.0 1396 1409 
2.3.1.0 1415 1424 
1.3.1.2 1421 1430 
1431 1436 
3.5.1.2 1433 1442 
seq( 1440 .. 1499) 
Segments: 
3.5.1.2 1433 1442 
3.3.2.0 1443 1452 
1.1.3.0 1445 1454 
3.5.3.0 1445 1454 
2.3.1.0 1450 1462 
2.3.1.0 1492 1501 
seq( 1500 .. 1559) 
Segments: 
2.3.1.0 1492 1501 
1.1.1.1 1502 1511 
9.9.32 1502 1511 
9.9.29 1502 1512 
1.1.1.2 1503 1512 
tcgctcgcttctttccctccgcctccgccagtgcagaggggctcctgtggt~~actgg 
======Sp1===== 
====Sp1=== 
====USF=== 
HincII 
====RAP 
gtgtcttttgtttcccctccaggtgcagctgaacctggtgttttagaggataccttggtc 
1== 
===HNF-3== 
===C/EBP== 
===ICSBP== 
======Sp1==== 
ccagagtcatcatg 
===c-Jun== 
====AP-1== 
====AP-1=== 
===c-Fos== 
====Sp1= 
Figure A2: Putative transcription factor binding sites in BCAA promoter. 
135 
Position Mismatches Score Binding Factor Sequence 
-----------------------------------------------------------------------------------------
l1 (-) a 100.00 TCF-1 AATAAAGT 
13 (-) a 100.00 TBP ATAAA 
13 (-) a 100.00 TFIID ATAAA 
15 (+) a 100.00 HNF-3a1pha, HNF-3B TATTT 
17 (-) a 100.00 ISGF-3 GGAAA 
18 (+) 1 87.50 STAT1, STAT3 TTCCCGGAA 
18 (-) 1 87.50 STAT5B TTCTGAGAA 
19 (-) a 100.00 LUN-1 TGGGA 
19 (+) a 100.00 LUN-1 TCCCA 
28 (+) a 100.00 CP1, NF-E3 GCCTTG 
41 (-) a 100.00 GR GAAAGT 
47 (+) a 100.00 HNF-3a1pha, HNF-3B TGTTT 
49 (-) a 100.00 ISGF-3 GGAAA 
57 (-) a 100.00 c-Myb CAGTTC 
57 (-) a 100.00 c-Myb CAGTTC 
62 (+) a 100.00 Sp1 GGTGGG 
62 (-) a 100.00 CAC-binding protein CCACC 
64 (+) a 100.00 LUN-1 TGGGA 
66 (+) a 100.00 ISGF-3 GGAAA 
69 (-) a 100.00 YY1 CATTT 
81 (+) a 100.00 HNF-3a1pha, HNF-3B TGTTT 
94 (-) a 100.00 H4TF-2 GGTCC 
95 (+) a 100.00 CP1, GATA-1, NFE-6 GACCAAT 
95 (+) a 100.00 CDP2, Clox, CP1, CUTL1, GACCAAT 
Cutl1 
97 (-) a 100.00 NF-1 ATTGG 
97 (+) a 100.00 SRF CCAAT 
97 (-) a 100.00 CTF ATTGG 
97 (+) a 100.00 CP1 CCAAT 
97 (+) a 100.00 CP2 CCAAT 
97 (+) a 100.00 gammaCAAT CCAAT 
97 (+) a 100.00 CP1, NF-E3 CCAAT 
97 (+) a 100.00 NF-E CCAAT 
97 (+) a 100.00 H1TF2 CCAAT 
97 (-) a 100.00 CBAF, CBF-B, CP1A ATTGG 
~ 97 (+) a 100.00 CDP2, Clox, CP1, CUTL1, CCAAT 
Cutl1 
97 (-) a 100.00 CBTF, CP1, CTF ATTGG 
97 (+) a 100.00 alpha-CBF CCAAT 
97 (-) a 100.00 CP1 ATTGG 
l15 (+) a 100.00 Sp1 AGGCGG 
116 (+) a 100.00 SpI GGCGGG 
116 (-) a 100.00 SMAD-3, SMAD-4 CCCGCC 
129 (+) a 100.00 c-Myb GAACTT 
136 (+) a 100.00 CPl, NFE-6 AACCAAT 
138 (-) a 100.00 CTF ATTGG 
138 (+) a 100.00 CCAAT-binding factor CCAAT 
138 (-) a 100.00 CBTF, CP1, CTF ATTGG 
138 (-) a 100.00 CP1, CTF GATTGG 
138 (+) a 100.00 alpha-CBF CCAAT 
138 (+) a 100.00 CDP2, Clox, CP1, CUTL1, CCAAT 
Cutl1 
138 (+) a 100.00 NF-E CCAAT 
138 (+) a 100.00 gammaCAAT CCAAT 
138 (+) a 100.00 CP1 CCAAT 
138 (-) a 100.00 CBAF, CBF-B, CP1A ATTGG 
138 (+) a 100.00 CP2 CCAAT 
138 (+) a 100.00 H1TF2 CCAAT 
138 (+) a 100.00 CP1, NF-E3 CCAAT 
138 (-) a 100.00 NF-1 ATTGG 
138 (+) a 100.00 SRF CCAAT 
138 (-) a 100.00 H1TF1, HiNF-B GATTGG 
143 (+) a 100.00 AP-1, CCAAG 
CCAAT-binding factor 
159 (-) a 100.00 AP-2, AP-2alphaA, TGGCC 
AP-2alphaB, NF-1 
159 (+) a 100.00 AP-2, AP-2alphaA, GGCCA 
AP-2alphaB, NF-1 
162 (-) a 100.00 NIP, PEA3 GGATG 
163 (-) 1 87.50 STAT1, STAT3 TTCCCGGAA 
168 (+) a 100.00 ISGF-3 GGAAA 
173 (+) 1 87.50 MAZ, Sp1 GAGGGAGGG 
177 (-) 1 90.00 SpI CCCCTCCCCTC 
178 (+) 1 88.89 Sp1 GGGGGAGGGG 
179 (+) a 100.00 Sp1 GGGGAGGGG 
Position Mismatches Score Binding Factor Sequence 
-----------------------------------------------------------------------------------------
179 (-) 0 100.00 SpI CCCCTCCCC 
180 (-) 1 87.50 WT1 -KTS, WT1 1, CTCCCTCCC 
WT1 l -KTS, WT1 I-de12 
180 (-) 0 100.00 SpI, Sp3 CCCCTCCC 
181 (-) 0 100.00 SpI CCCCTCC 
182 (+) 1 87.50 MAZ, SpI GAGGGAGGG 
184 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
185 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
186 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
189 (+) 0 100.00 ISGF-3 GGAAA 
201 (-) 1 90.00 SpI CCCCTCCCCTC 
202 (+) 1 88.89 SpI GGGGGAGGGG 
203 (+) 0 100.00 SpI GGGGAGGGG 
203 (-) 0 100.00 SpI CCCCTCCCC 
204 (-) 0 100.00 SpI, Sp3 CCCCTCCC 
205 (-) 0 100.00 SpI CCCCTCC 
217 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
217 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
218 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
218 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
219 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
219 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
235 (-) 0 100.00 CAC-binding prote in CCACC 
235 (+) 0 100.00 SpI GGTGGG 
235 (+) 0 100.00 CAC-binding prote in GGTGGGG 
238 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
239 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
240 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
242 (+) 0 100.00 c-Ets-2 GGGAAG 
251 (+) 0 100.00 HNF-3a1pha, HNF-3B TGTTT 
255 (-) 0 100.00 LXR-a1pha, CGGGCA 
LXR-beta, mm-alpha 
255 (-) 0 100.00 ER-alpha, Sp1 GGGCA 
256 (+) 0 100.00 Sp1, Sp2, Sp3, Sp4 GCCCG 
259 (+) 0 100.00 c-Fos, c-Jun, CGTCA 
CRE-BP1, CREB 
259 (-) 0 100.00 CREB TGACG 
294 (-) 1 87.50 Sp1 CTCCGCCTC 
298 (-) 1 87.50 WT1 -KTS, WT1 1, CTCCCTCCC 
WT1 l -KTS, WT1 I-de12 
301 (+) 0 100.00 RXR-alpha, VDR AGGGAG 
301 (+) 0 100.00 T3R AGGGAG 
325 (-) 1 90.00 SpI GGGGCGGCGGC 
336 (+) 0 100.00 AP-2, AP-2alphaA, GGCCA 
AP-2alphaB, NF-1 
338 (+) 0 100.00 CAC-binding prote in CCACC 
341 (-) 0 100.00 SpI AGGCGG 
347 (-) 0 100.00 H4TF-2 GGTCC 
354 (-) 0 100.00 ER-alpha, SpI GGGCA 
354 (-) 0 100.00 LXR-alpha, CGGGCA 
LXR-beta, RXR-alpha 
355 (+) 0 100.00 SpI, Sp2, Sp3, Sp4 GCCCG 
358 (-) 1 87.50 WT1 -KTS, WT1 1, CTCCCTCCC 
WT1 l -KTS, WT1 I-de12 
361 (+) 0 100.00 RXR-alpha, VDR AGGGAG 
361 (+) 0 100.00 T3R AGGGAG 
366 (+) 0 100.00 CTCF GCTGC 
373 (-) 0 100.00 NF-Zc, NF-Zz GGACCCT 
375 (+) 0 100.00 H4TF-2 GGTCC 
396 (-) 1 88.89 SpI GCGGCCCTCC 
398 (+) 0 100.00 TR2-11 AGGGCA 
398 (-) 0 100.00 RXR-alpha, VDR TGCCCT 
399 (+) 0 100.00 ER-alpha, SpI GGGCA 
401 (-) 0 100.00 CTCF GCTGC 
408 (+) 0 100.00 H1TF1, HiNF-B GATTGG 
408 (+) 0 100.00 CP1, CTF GATTGG 
409 (-) 0 100.00 CCAAT-binding factor CCAAT 
CDP2, Clox, CUTL1, Cutll 
409 (-) 0 100.00 NF-E CCAAT 
~ .. 409 (-) 0 100.00 CP1, NF-E3 CCAAT 
409 (+) 0 100.00 CP1 ATTGG 
409 (-) 0 100.00 SRF CCAAT 
409 (-) 0 100.00 CDP2, Clox, CP1, CUTL1, CCAAT 
Cutl1 
409 (+) 0 100.00 CBAF, CBF-B, CP1A ATTGG 
Position Mismatches Score Binding Factor Sequence 
-----------------------------------------------------------------------------------------
409 (+) 0 100.00 NF-1 ATTGG 
409 (-) 0 100.00 alpha-CBF CCAAT 
409 (-) 0 100.00 H1TF2 CCAAT 
409 (+) 0 100.00 CTF ATTGG 
409 (+) 0 100.00 CBTF, CP1, CTF ATTGG 
409 (-) 0 100.00 garnrnaCAAT CCAAT 
412 (-) 0 100.00 Sp1, Sp2, Sp3, Sp4 CCCCC 
413 (+) 0 100.00 Sp1 GGGGCC 
416 (+) 0 100.00 SpI, Sp2, Sp3, Sp4 GCCCG 
420 (-) 0 100.00 H4TF-2 GGTCC 
433 (-) 0 100.00 Sp1, Sp2, Sp3, Sp4 CCCCC 
434 (-) 0 100.00 Sp1, Sp2, Sp3, Sp4 CCCCC 
435 (-) 0 100.00 Sp1, Sp2, Sp3, Sp4 CCCCC 
451 (+) 1 90.00 Sp1 GCCCCCTCCCC 
452 (+) 1 87.50 WT1 -KTS, WT1 l, CTCCCTCCC 
WT1 l -KTS, 
WT1 I-de12, 
452 (+) 1 88.89 Sp1 CCCCCGCCCC 
452 (+) 0 100.00 Sp1, Sp2, Sp3, Sp4 CCCCC 
453 (+) 0 100.00 Sp1 CCCCTCCCC 
453 (+) 0 100.00 Sp1, Sp3 CCC CT CCC 
453 (+) 1 88.89 AP-2alphaA, CCCCACCCCC 
AP-2alphaB, NF-1 
454 (-) 1 87.50 MAZ, Sp1 GAGGGAGGG 
458 (+) 1 87.50 LyF-1 CCTCCCAAC 
458 (+) 0 100.00 Sp1, Sp2, Sp3, Sp4 CCCCC 
458 (+) 0 100.00 Sp1, Sp2, Sp3, Sp4 CCCCC 
459 (+) 0 100.00 Sp1, Sp2, Sp3, Sp4 CCCCC 
459 (+) 0 100.00 Sp1, Sp2, Sp3, Sp4 CCCCC 
468 (+) 0 100.00 T3R AGGGAG 
468 (+) 0 100.00 mm-alpha, VDR AGGGAG 
470 (+) 0 100.00 NF-ATp GGAGCC 
473 (+) 0 100.00 Sp1, Sp2, Sp3, Sp4 GCCCG 
479 (+) 0 100.00 Sp1 GCGGCC 
480 (-) 1 90.00 DP-1, E2F TTTGGCGGGCG 
(~ 481 (-) 0 100.00 Sp1 GCGGCC 
483 (-) 0 100.00 E2F TTTGGCGG 
484 (-) 0 100.00 E2F TTTGGCG 
488 (-) 0 100.00 HNF-3alpha, HNF-3B TGTTT 
489 (+) 0 100.00 LEF-1 AACAAAG 
489 (+) 0 100.00 SRY AACAAAG 
489 (+) 0 100.00 LEF-1, mat1-Mc, AACAAAG 
Sox-13, Sox-5, SRY, 
TCF-1, TCF-1A, 
TCF-1B, TCF-1C, 
TCF-1E, TCF-1F, 
TCF-1G 
504 (+) 1 87.50 WT1 CGCCCCCGC 
508 (-) 1 87.50 AP-2, AP-2alphaA, GCCCGCGGC 
AP-2alphaB, 
AP-2beta, AP-2garnrna 
509 (+) 0 100.00 Sp1, Sp2, Sp3, Sp4 CCGCG 
511 (+) 1 91.67 MZF-1 GCGGGAGGGGGAG 
515 (-) 1 87.50 Sp1 CTCCGCCTC 
516 (+) 0 100.00 PPUR AGGAGGA 
516 (+) 0 100.00 ARP-1 AGGAGG 
518 (-) 1 88.89 Sp1 GCTCCGCCTC 
519 (+) 0 100.00 ARP-1 AGGAGG 
519 (+) 0 100.00 PPUR AGGAGGA 
523 (+) 0 100.00 NF-ATp GGAGCC 
524 (-) 1 88.89 Sp1 GCTCCGCCTC 
529 (+) 0 100.00 NF-ATp GGAGCC 
530 (+) 0 100.00 LF-A1 GAGCCT 
534 (+) 1 87.50 Sp1 CTCCGCCTC 
544 (-) 0 100.00 CTCF GCTGC 
553 (-) 0 100.00 H4TF-2 GGTCC 
554 (+) 1 88.89 Sp1 GACCCGCCCC 
556 (-) 0 100.00 Sp1 GGCGGG 
556 (+) 0 100.00 SMAD-3, SMAD-4 CCCGCC 
560 (+) 0 100.00 Sp1 CCGCCC 
560 (-) 0 100.00 CP1 GGGCGG 
561 (+) 0 100.00 VDR CGCCCT 
561 (+) 0 100.00 Sp1 CGCCC 
567 (-) 0 100.00 AP-2alphaA, GGGAAGA 
AP-2alphaB 
Position Mismatches Score Binding Factor Sequence 
-----------------------------------------------------------------------------------------
568 (-) 0 100.00 c-Ets-2 GGGAAG 
(~ 581 (+) a 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
585 (-) a 100.00 SpI, Sp2, Sp3, Sp4 GCCCG 
598 (-) 1 87.50 LyF-l CCTCCCAAA 
601 (-) a 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
601 (-) 1 87.50 WT1 -KTS, WT1 l, CTCCCTCCC 
WT1 l -KTS, WT1 I-de12 
602 (-) a 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
603 (-) a 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
613 (+) 1 87.50 MAZ, SpI GAGGGAGGG 
620 (-) a 100.00 RPF1, SpI GAGTCCC 
629 (+) a 100.00 HIF-1 GACGTG 
630 (-) a 100.00 HIF-1 GCACGT 
633 (-) a 100.00 NF-IlL TGGCA 
638 (+) a 100.00 LXR-alpha, GGGTCA 
LXR-beta, RXR-alpha 
638 (+) a 100.00 FOR1, FOR2, GGGTCA 
RXR-alpha 
638 (-) a 100.00 PXR-1, RXR-alpha TGACCC 
638 (+) a 100.00 AP-1 GGGTCA 
638 (+) a 100.00 T3R GGGTCA 
638 (+) a 100.00 RAR-alpha1, RAR-beta, GGGTCA 
RAR-garnrna, RXR-alpha 
638 (-) a 100.00 LF-A1 TGACCC 
638 (+) a 100.00 TR2-11 GGGTCA 
639 (-) 0 100.00 CAR, RAR-alpha1, TGACC 
RAR-beta, 
RXR-alpha 
670 (+) a 100.00 HNF-3alpha, HNF-3B TATTT 
699 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
708 (-) 1 87.50 LyF-l CCTCCCAAA 
710 (-) a 100.00 LUN-1 TCCCA 
710 (+) 0 100.00 AP-2alphaA, TGGGAG 
AP-2alphaB 
710 (+) a 100.00 LUN-1 TGGGA 
r-'. 722 (-) 1 88.89 SpI TGGGCGGGCC 
723 (+) a 100.00 SpI, Sp2, Sp3, Sp4 GCCCG 
727 (+) 0 100.00 AP-2, AP-2alphaA, GGCCA 
AP-2alphaB, NF-1 
729 (+) a 100.00 AP-1, CCAAG 
CCAAT-binding factor 
747 (+) a 100.00 E2F+p107 TCGCGG 
748 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCGCG 
751 (-) 0 100.00 CAC-binding protein CCACC 
754 (-) a 100.00 CAC-binding prote in CCACC 
757 (+) 0 100.00 H4TF-2 GGTCC 
763 (-) a 100.00 c-Ets-1, LEF-1, CCGCA 
PEBP2alphaAl 
768 (+) 0 100.00 SpI CGCCC 
769 (+) a 100.00 SpI, Sp2, Sp3, Sp4 GCCCG 
777 (-) a 100.00 ZFX AGGCCCCGA 
779 (+) 0 100.00 SpI GGGGCC 
784 (+) 1 87.50 SpI CTCCGCCTC 
791 (-) 1 87.50 STATl, STAT3 TTCCCGGAA 
795 (-) 1 88.89 NF-kappaB, GGGCGTTCCC 
NF-kappaBl 
795 (-) 1 88.89 SpI GGGCGTTCCC 
800 (+) a 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
801 (+) 1 87.50 SpI CACCACCCC 
801 (+) 1 87.50 CAC-binding protein CCCCACCTC 
801 (+) 1 87.50 SpI CCCCTCCCC 
801 (+) a 100.00 AP-2alphaA, CCCCACCCCC 
AP-2alphaB, NF-1 
803 (+) 0 100.00 CAC-binding protein CCACC 
803 (+) a 100.00 SpI CCACCC 
804 (+) 0 100.00 CACCC-binding factor, CACCC 
804 (+) 0 100.00 9 arnrna CAC 1 , CACCC 
garnrnaCAC2 
804 (+) a 100.00 SpI CACCC 
.~ 806 (+) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
807 (+) a 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
810 (+) a 100.00 c-Ets-1, LEF-1, CCGCA 
PEBP2alphaAl 
812 (-) 0 100.00 CTCF GCTGC 
827 (+) 1 88.89 SpI GACCCGCCCC 
Position Mismatches Score Binding Factor Sequence 
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830 (+) 0 100.00 SpI CCGCCCC 
/' 830 (-) 0 100.00 CP1 GGGCGG 
831 (+) 0 100.00 SpI CGCCC 
833 (+) 0 100.00 SpI, sp2, Sp3, Sp4 CCCCC 
836 (-) 1 87.50 E2F CCCGCCAGG 
838 (+) 0 100.00 HNF-1A, HNF-1B, TGGCTGG 
HNF-1C 
839 (+) 0 100.00 SpI GGCTGGG 
843 (+) 0 100.00 SpI GGGCGG 
843 (-) 0 100.00 SpI CGCCC 
845 (+) 0 100.00 SpI GCGGCC 
847 (-) 0 100.00 SpI GCGGCC 
849 (+) 0 100.00 c-Ets-l, LEF-1, CCGCA 
PEBP2alphaA1 
862 (+) 0 100.00 Crx GGTTTAG 
868 (+) 0 100.00 SpI GCGGCC 
870 (-) 0 100.00 SpI GCGGCC 
871 (-) 1 87.50 AP-2, AP-2alphaA, GCCCGCGGC 
AP-2alphaB, 
AP-2beta, 
AP-2gamma 
872 (+) 0 100.00 SpI, Sp2, Sp3, Sp4 CCGCG 
873 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCGCG 
880 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
881 (+) 0 100.00 SpI GGGGCC 
882 (+) 1 88.89 SpI GGGGCCGGGC 
884 (+) 0 100.00 SpI, Sp2, Sp3, Sp4 GCCCG 
887 (+) 0 100.00 LXR-alpha, CGGGCA 
LXR-beta, RXR-alpha 
887 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 GCCCG 
888 (+) 0 100.00 ER-alpha, SpI GGGCA 
889 (+) 1 90.91 SpI GGGAGGGTGGGG 
893 (-) 0 100.00 SpI CCCACCC 
893 (-) 0 100.00 CACCC-binding factor CACCC 
893 (-) 0 100.00 gammaCAC1, CACCC 
gammaCAC2 
897 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCCCC 
898 (+) 0 100.00 SpI GGGGCC 
904 (+) 1 88.89 SpI GCTCCGCCTC 
905 (+) 1 87.50 SpI CTCCGCCTC 
907 (-) 0 100.00 SpI AGGCGG 
914 (-) 1 87.50 ZFX AGGGCCCCA 
915 (+) 0 100.00 SpI GGGGCC 
918 (+) 1 87.50 AP-2, AP-2alphaA, GCCCGCGGC 
AP-2alphaB, 
AP-2beta, AP-2gamma 
938 (+) 1 87.50 AP-2, AP-2alphaA, GCCCGCGGC 
AP-2alphaB, 
AP-2beta, AP-2gamma 
940 (+) 0 100.00 SpI, sp2, Sp3, Sp4 CCGCG 
941 (-) 0 100.00 SpI, sp2, Sp3, Sp4 CCGCG 
942 (+) 1 87.50 SpI GGGGCGGGG 
944 (-) 0 100.00 SMAD-3, SMAD-4 CCCGCC 
947 (+) 0 100.00 SpI GGGGCC 
949 (-) 0 100.00 AP-2, AP-2alphaA, TGGCC 
AP-2alphaB, NF-1 
949 (+) 0 100.00 AP-2, AP-2alphaA, GGCCA 
AP-2alphaB, NF-1 
952 (-) 0 100.00 E12 CATCTG 
959 (-) 0 100.00 GR, GR-alpha, AGATCA 
GR-beta 
963 (+) 1 87.50 WTl -KTS, WT1 l, CTCCCTCCC 
WT1 l -KTS, 
WT1 I-de12, 
WTl-de12 
967 (-) 0 100.00 AP-2alphaA, TGGGAG 
AP-2alphaB 
968 (+) 0 100.00 LUN-1 TCCCA 
973 (-) 0 100.00 CPl, GATA-l, NFE-6 GACAAG (- 987 (+) 0 100.00 SpI, Sp2, Sp3, Sp4 GCCCG 
997 (+) 1 88.89 SpI GGGCGTGGGC 
998 (+) 0 100.00 HIF-1 GACGTG 
1002 (-) 1 90.00 SpI GCCCCTCCCCA 
1003 (+) 1 87.50 SpI GGGGAGGGG 
1003 (+) 0 100.00 ER-alpha, SpI GGGCA 
Position Mi smatches Score Binding Factor Sequence 
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1016 (+) 1 87.50 SpI GGGGCGGGC 
( 1018 (-) 0 100.00 SMAD-3, SMAD-4 CCCGCC 
1018 (+) 0 100.00 Sp1 GGCGGG 
1020 (-) 0 100.00 Sp1, Sp2, Sp3, Sp4 GCCCG 
1026 (+) 0 100.00 H4TF-2 GGTCC 
1031 (-) 0 100.00 ER-alpha, SpI GGGCA 
1031 (-) 0 100.00 LXR-a1pha, CGGGCA 
LXR-beta, RXR-alpha 
1032 (+) 0 100.00 AP-2, AP-2alphaA, GCCCGCGGC 
AP-2alphaB, 
AP-2beta, AP-2gamma 
1032 (+) 0 100.00 SpI, Sp2, Sp3, Sp4 GCCCG 
1034 (+) 0 100.00 SpI, Sp2, Sp3, Sp4 CCGCG 
1035 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 CCGCG 
1036 (+) 0 100.00 SpI GCGGCC 
1040 (-) a 100.00 AML1, AML1a, AMLlc TGTGGG 
1049 (-) a 100.00 ARP-1 AGGAGG 
1054 (+) a 100.00 AP-2, AP-2alphaA, TGGCC 
AP-2alphaB, NF-1 
1054 (-) a 100.00 AP-2, AP-2alphaA, GGCCA 
AP-2alphaB, NF-1 
1055 (-) 0 100.00 SpI GGGGCC 
1063 (-) 0 100.00 CAC-binding protein CCACC 
1065 (+) 0 100.00 AP-2, AP-2alphaA, TGGCC 
AP-2alphaB, NF-1 
1066 (-) a 100.00 Sp1 GGGGCC 
1067 (+) 1 87.50 AP-2, AP-2alphaA, GCCCGCGGC 
AP-2alphaB, 
AP-2beta, AP-2gamma 
1068 (+) a 100.00 Sp1, Sp2, Sp3, Sp4 CCCCC 
1076 (+) 1 87.50 WT1 CGCCCTCTC 
1092 (-) a 100.00 Sp1, Sp2, Sp3, Sp4 CCGCG 
1100 (+) 1 87.50 WT1 GCGGGGGCG 
1102 (-) a 100.00 Sp1, Sp2, Sp3, Sp4 CCCCC 
1104 (-) 0 100.00 Sp1 CGCCC 
r" 1107 (-) a 100.00 Sp1, Sp2, Sp3, Sp4 CCGCG 
1120 (+) 1 90.00 Sp1 GGCAGGGCGCC 
1123 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 GCCCG 
1124 (-) 0 100.00 SpI CGCCC 
1147 (+) a 100.00 Sp1 GCGGCC 
1154 (+) 1 88.89 Sp1 GCCCTGCCCC 
1170 (-) 0 100.00 SpI, Sp2, Sp3, Sp4 GCCCG 
1171 (-) 1 88.89 p53 CGACAAGCCC 
1194 (+) 0 100.00 Pbx-1a, Pbx-1b, TGACAG 
Pbx-2, PKNOX1, 
PKNOX2, UEF-3 
1194 (-) 0 100.00 Meis-2a, Meis-2b, CTGTCA 
Meis-2c, Meis-2d, 
TGIF 
1195 (-) 0 100.00 NF-E CTGTC 
1198 (+) a 100.00 Hi NF-A AGAAATG 
1200 (-) 0 100.00 YY1 CATTT 
1206 (-) 0 100.00 CREB TGACG 
1206 (+) a 100.00 c-Fos, c-Jun, CGTCA 
CRE-BP1, CREB 
1222 (+) 1 88.89 NF-kappaB2, NF-kappaB1 GGGAAATTCC 
NF-kappaB2 precursor 
1223 (+) a 100.00 ISGF-3 GGAAA 
1248 (+) 1 87.50 SpI GGGGAGGGG 
1254 (+) a 100.00 c-Ets-2 GGGAAG 
1259 (+) 0 100.00 CTCF GCTGC 
1275 (-) 0 100.00 CAC-binding prote in CCACC 
1287 (-) a 100.00 c-Ets-1, LEF-1, CCGCA 
PEBP2alphaA1 
1292 (+) a 100.00 NIP, PEA3 GGATG 
1293 (+) 1 88.89 HiNF-C GAGGGCGGGG 
1296 (+) a 100.00 Sp1 GGCGGGG 
1296 (-) 0 100.00 SMAD-3, SMAD-4 CCCGCC 
1296 (-) a 100.00 Sp1 CCCCGCC 
~ 1297 (+) 1 87.50 WT1 GCGGGGGCG 
1299 (+) 0 100.00 Sp1 GGGGCCGG 
1304 (-) 1 87.50 WT1 -KTS, WT1 1, CTCCCTCCC 
WTl l -KTS, 
WTl I-de12, WT1-de12 
1307 (+) a 100.00 T3R AGGGAG 
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1307 (+) 0 100.00 RXR-alpha, VDR AGGGAG 
r---.. 1309 (+) 0 100.00 NF-ATp GGAGCC 
1335 (-) 1 87.50 ZFX AGGCCCCGA 
1337 (-) 0 100.00 Sp1, Sp2, Sp3, Sp4 CCCCC 
1338 (+) 1 87.50 Sp1 GGGGCGGGC 
1354 (-) 0 100.00 c-Ets-1, LEF-1, CCGCA 
PEBP2a1phaA1 
1392 (-) 0 100.00 ISGF-3 GGAAA 
1396 (+) 1 88.89 Sp1 GCTCCGCCTC 
1397 (+) 0 100.00 Sp1 CTCCGCCTC 
1399 (-) 0 100.00 Sp1 AGGCGG 
1400 (+) 1 87.50 Egr-1 CGCCTACGC 
1400 (+) 1 87.50 WT1 CGCCCCCGC 
1420 (-) 0 100.00 NF-ATp GGAGCC 
1439 (-) 0 100.00 CACCC-binding factor CACCC 
1439 (-) 0 100.00 VDR ACACCC 
1439 (-) 0 100.00 Sp1 CACCC 
1439 (-) 0 100.00 garmnaCAC1, CACCC 
garmnaCAC2 
1446 (+) 0 100.00 TCF-4E TTTTGTT 
1449 (+) 0 100.00 HNF-3a1pha, HNF-3B TGTTT 
1451 (-) 0 100.00 ISGF-3 GGAAA 
1454 (+) 0 100.00 Sp1 CCCCTCC 
1455 (+) 1 87.50 E2F CCCGCCAGG 
1460 (-) 0 100.00 c-Myc, USF2 CACCTG 
1465 (-) 0 100.00 CTCF GCTGC 
1466 (-) 0 100.00 AP-4 CAGCTG 
1466 (+) 0 100.00 AP-4 CAGCTG 
1470 (+) 0 100.00 CAR, RAR-alphal, TGAAC 
RAR-beta, RXR-alpha 
1470 (-) 0 100.00 RXR-alpha, VDR GGTTCA 
1479 (+) 0 100.00 HNF-3alpha, HNF-3B TGTTT 
1479 (-) 0 100.00 GR AAAACA 
1494 (-) 0 100.00 AP-1, CCAAG 
CCAAT-binding factor 
~- 1497 (+) 0 100.00 H4TF-2 GGTCC 
1499 (+) 0 100.00 LUN-1 TCCCA 
1503 (-) 0 100.00 AP-1, c-Fos, c-Jun TGACTCT 
1504 (-) 0 100.00 VDR TGACTC 
Figure A3: BCAA RI SUMOylation. 
BCAA Ga14-Rl, K440R, and K429R/K440R were over-expressed in H1299 cells in the absence 
or presence of HA-SUMO 1. 
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Figure A4: SUMOylation of RBPI proteins by SUMO proteins. 
The results provided in this figure were generated as described in Figure 3.2D. (A) HA-SUMO-2 
was over-expressed. (B) HA-SUMO-3 was over-expressed. (C) HA-SUMO-4 was over-
expressed. 
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Figure AS: SAP30 knockdown. 
(A) Sequence information for the siRNAs used. (B) The siRNAs were transfected in HeLa ceIls 
using TransIT TKO reagent (Mirus). The ceIls were lysed 48 hours post-transfection and whole 
ceIl protein extracts resolved by SDS-P AGE, transferred to a PVDF membrane and analysed by 
irnrnunoblot using a rabbit polyclonal SAP30 specifie antibody (Abcam # ab15034). 
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SAP30 no. 1: UUCAUUUAUGUGAAUCCUCUA 
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SAP30 no. 2: UUCAAGCUUUGUCUUCUUUCU 
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SAP30 no. 3: UUUAUCAACCAACGGUGAAAU 
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SAP30 no. 4: UUCGCGUUCCGUAGAAAUGUA 
GCGCAAGGCAUCUUUACAUUU 
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